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ABSTRACT
Migraine is an episodic brain disorder characterised often by attacks of throbbing head 
pain and in many patients by sensitisation of the facial skin. Current research indicates 
that the dural blood vessels and their neural connectivity with the trigeminocervical 
complex play a fundamental role in the perception of these symptoms. As such, 
characterisation of this pathway may provide an insight into the pathological processes 
occurring during a migraine attack and offer new targets for the development of novel 
anti-migraine treatment strategies.
Utilising the techniques of in vivo electrophysiology, intravital microscopy and c-fos 
immunohistochemistry, the studies in this thesis have explored the consequences of 
trigeminal primary afferent neuronal activation during the following conditions:
-Exposure to glyceryl trinitrate, a nitric oxide releasing compound, known to 
induce migraine in susceptible individuals.
-Peripheral sensitisation following application of various mediators to the dural 
and facial receptive field.
-Following "wind-up" stimuli, known to hyper-excite spinal neurons 
The findings from these studies demonstrate that the behaviour of second order 
neurons in the spinal trigeminal nucleus is fundamentally different following input 
from the dura mater compared to input from facial cutaneous afferents. Furthermore, 
the time course of sensitisation seen following application of prostaglandin E2 to the 
dural receptive field correlates well to the allodynia and hyperalgesia reported during 
migraine. Sensitisation of dural afferents may thus underlie at least part of the 
pathophysiology associated with migraine.
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General Introduction
1.1 The history of headache
Recorded accounts of the disabling nature of head pain are first documented in 
transcribed ancient Egyptian medical papers, which are estimated to date back as far as 
3000BC. Hippocrates, 2460 years ago, clearly emphasised the visual disturbance, 
nausea, and vomiting associated with unilateral head-pain (Critchely, 1967) that was 
different in character to other forms of headache (Adams, 1939). Despite observations 
of migraine-like symptoms in these early times that are in extremely good agreement 
with the official current classification of the disease, few hypotheses of the origin of 
migraine pain are recorded until the 17th century.
Dr Willis' Practice o f Physicke published in 1684 and reproduced in 1963 (Knapp) 
states that "the source o f pain is not the brain, cerebellum or medulla" but rather 
"distension o f the vessels which pull the nervous fibres one from another and so brings 
to them painful corrugations or wrinklings". The theory that cranial vessels were the 
source of abnormality underlying migraine was further added to by the observation of 
Dubois-Reymond in 1859 that the pain of migraine "mounts synchronously with the 
pulse o f the temporal artery" but ceases on compression of the carotid artery (Schiller 
et al., 1975). The nineteenth century also saw suggestions of a central neuronal 
component of migraine with Living's analogy with epilepsy (1873) and Hughling 
Jackson’s (1880) description of migraine as "a form of sensory epilepsy with headache 
and vomiting as an epiphenomenon" (Schiller 1975). Over 100 years later, there is still 
considerable debate between researchers whether migraine results from a central or
- 13-
peripheral abnormality. This thesis thus explores the basis of the neuronal dysfunction 
in the trigeminal system that may account for the dural symptoms observed over many 
centuries.
1.2 Migraine
Headache is among the most common complaints in the western world. In many cases, 
headache symptoms represent primary headache syndromes such as migraine, tension- 
type headache and cluster headache. However, headache symptoms may also be an 
indication of a “secondary headache” resulting from underlying illness such as 
infection, cerebral haemorrhage, brain tumour and meningitis. Hence, accurate 
diagnosis of headache type is essential both in excluding serious illness and in 
determining treatment. Before the 1960’s, the definition of headache was not 
standardised and no internationally accepted classification system existed. In 1962, an 
Ad Hoc Committee of the National Institute of Health, published the first international 
classification system (The Ad Hoc Committee on the Classification of Headache; 
Friedman et al., 1962), however many felt that the classification required too much 
subjective interpretation. As a result, in 1985, a committee of world headache experts 
undertook the mammoth task of drawing a classification system based on clear 
operational criteria. The publication in 1988 of this classification system by the 
International Headache Society (IHS) not only provided a template for clinical 
diagnosis, but was a huge aid for researchers in the focusing of specific symptoms 
associated with headache types, allowing well defined patient populations for study 
(Headache classification Committee of the International Headache Society, 1988). The 
classification of the primary headaches, as defined by the IHS is summarised below,
- 14-
although some changes to this are expected soon following the first revision of the 
criteria.
Primary headache disorders___________________________________
1. Migraine
1.1 Migraine without aura (Common migraine)
1.2 Migraine with aura (Classical migraine)
1.3 Ophthalmoplegic
1.4 Retinal migraine
1.5 Childhood periodic syndromes that may be precursors to or associated 
with migraine
1.6 Complications of migraine
1.7 Migrainous disorder not fulfilling above criteria
2. Tension-type headache
2.1 Episodic
2.2 Chronic
2.3 Headache not fulfilling above criteria
3. Cluster headache and chronic paroxysmal hemicrania
3.1 Cluster headache
3.1.1 Periodicity undetermined
3.1.2 Episodic
3.1.3 Chronic
3.2 Chronic paroxysmal hemicrania
3.3 Cluster headache-like disorder not fulfilling above criteria
4. Miscellaneous headaches un-associated with structural lesions
4.1 Idiopathic stabbing headache
4.2 External compression headache
4.3 Cold stimulus headache
4.4 Benign cough headache
4.5 Benign exertional headache
 4.6 Headache associated with sexual activity_____________________
Table 1 Primary headache syndromes defined by IHS (1988)
This thesis is concerned with understanding dural and cranial neurovascular 
nociception that may be relevant to migraine. For the purpose of research, it is useful 
to consider migraine in the 3 phases commonly reported by sufferers of the disease:
-15-
1. Premonitory symptoms;
Some patients are able to predict the onset of an migraineous episode due to 
the presence of premonitory symptoms that occur up to 48 hours before an 
attack (Giffin et al.9 2003). These may include changes in mood such as 
irritability, depression, euphoria, increased food cravings for sweet foods or 
conversely anorexia, changes in motivation such as excessive sleepiness and 
difficulty in concentrating and in many subjects, repetitive yawning. 
Additionally some patients (less than a third) also report aura type symptoms.
2. The migrainous headache;
This is often the greatest source of disability in many patients and often occurs 
with associated nausea and sensitivity to external stimuli. In about two thirds 
of patients the headache is unilateral and bilateral in the remainder (Selby & 
Lance, 1960). The quality of the pain is often pulsating and largely involves 
the frontotemporal region. Pain is also commonly referred to the facial skin
3. “Postdrome”;
Resolution of the headache often leaves sufferers feeling exhausted for the 
following 24 hours and many experience similar symptoms to those of 
premonitory symptoms.
The separation of a migraine attack in to different phases along with the absence of 
migrainous symptoms between attacks is suggestive of a complex pathology. As 
attacks occur regularly and can sometimes be associated with premonitory symptoms
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such as alterations in appetite, wakefulness and mood, a role of the hypothalamus and 
a migraineous “brain” seems likely. However, some migraine attacks appear to be 
triggered in response to afferent stimulation such as flickering light, noise and some 
smells, whereas other migraine triggers, such as nitrates, appear to act primarily on 
cranial blood vessels. The potential role that higher brain centres, cranial blood vessels 
and a genetic susceptibility may play in initiating a migraine episode is discussed 
further in sections 1.3.5, 1.5 and 1.9.
There is considerable debate concerning whether the different forms of migraine, in 
particular migraine without aura and migraine with aura, are distinct clinical entities or 
whether the underlying pathology of both disorders is shared. Similarly, many 
clinicians think of tension-type headache and migraine as related diseases occupying 
different ends of a spectrum. In support of this, many patients tend to suffer from more 
than one type of primary headache syndrome.
The term cervicgenic headache was initially suggested by Sjaastad and colleagues 
(Fredrikson et al, 1987; Sjaasatd et al., 1990) and described episodic unilateral 
headaches lasting from 3 hours to a week and reoccurring at intervals from 2 days to 2 
months, considered to arise from the cervical spine. As with migraine, these headaches 
more frequently occurred in women than men and were accompanied by nausea, 
vomiting and photophobia, however unlike migraine they could be precipitated by 
neck movement. Headache patients often report pain that involves the front of the 
head, innervated by the ophthalmic division of the trigeminal nerve but also pain at the
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back of the head, resulting from the innervation of the greater occipital nerve 
(Anthony, 1992). This overlap of pain is suggestive of a convergence of afferent input 
from the meninges and upper cervical roots and it has now been shown in rat that 
stimulation of the greater occipital nerve induces increased central excitability of dural 
afferents (Bartsch & Goadsby, 2002, 2003). Hence, while the focus of this study is the 
head pain occurring during migraine without aura, due to the overlap of pathways 
postulated to be involved in different primary headache syndromes, many of the 
concepts discussed may also have relevance to the pathology of other headache types.
1.2.1 Migraine Prevalence
The prevalence of migraine (i.e. the proportion of a population affected over a defined 
period) has been extensively studied with considerable variation reported between 
populations. This variation in prevalence was examined following meta-analysis of 18 
published population-based studies (Scher et al., 1999), who found that when gender 
differences were not considered, age and geographical location were responsible for 
much of the variance seen between studies. However, methodological factors such as 
sampling method, response method and response rate also impacted on reported 
variance.
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Country Method Sample
size
Migraine prevalence 
<%)
Females Males
Reference
USA Posted
questionnaire
20,468 17.6 5.7 Stewart et 
a l , 1992
UK Clinical
interview
16,002 11.0 4.3 Cull et al., 
1992
Switzerland Clinical
interview
379 32.6 16.1 Merikangas 
etal., 1993
Hong Kong Telephone 7,356 1.5 0.6 Wong et 
al, 1995
Saudi
Arabia
Clinical
interview
22,630 6.8 3.2 Al-Rajeh et 
a l ,1997
Danish Posted
questionnaire
5360 19% 
migraine 
without 
aura 
8% 
migraine 
with aura
7% 
migraine 
without aura 
7% 
migraine 
with aura
Russell et 
al., 2002
Table 2 Summary o f some o f the studies examining migraine prevalence in different 
geographical populations
Despite the variance in these studies, two main factors with regards to migraine 
prevalence are obvious. Firstly, the greater incidence of migraine in females provides 
researchers with an immediate insight to the possible role of female hormones in 
generating susceptibility to attacks. However, episodic and chronic tension type 
headache prevalence also show a world wide higher incidence in females than males,
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although the gender difference is not as considerable as for migraine (for review see 
Lipton et al, 2001). In the second case, migraine is considerably more prevalent in 
Europe and America than in Asia and Africa, however possible reasons for this are 
much more complex and encompass a whole range of factors such as diet, stress, 
genetic and environmental influences as well as a possible cultural component.
1.2,2 Social impact of migraine
The direct costs associated with migraine such as physician consultation, prescriptions 
and laboratory procedures are relatively low in comparison with many illnesses, 
probably due to the low rate of hospitalisation among sufferers. The indirect costs 
though, are substantial and largely due to sickness related absenteeism and reduced 
productivity at work. However, the economic burden of the migraine is only one effect 
on society that this disease exerts. For the migraine sufferer, coping with a frequently 
occurring debilitating disease that influences mood, is likely to put great deal of 
pressure on family dynamics, especially as migraine incidence peaks during 
childbearing years, when sickness is likely to cause maximum disruption. In an 
attempt to validate the impact of migraine on patient’s lives, the use of the Headache 
Impact Test (HIT) and the Migraine Disability Assessment (MIDAS) and being 
increasingly recommended in providing individual coping strategies (for review see 
Dowson, 2001).
1.3 Anatomy of the trigeminovascular system
Despite the many theories of migraine pathophysiology, researchers agree that the 
trigeminovascular system, which encompasses the large intracranial arteries, dura
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mater and their neuronal innervation, plays a fundamental role in some manifestations 
of the disease. An understanding of the interconnections between these structures is 
hence crucial in understanding the mechanism of head pain and as such, the 
components of the trigeminovascular system are reviewed below.
Trigeminal ganglion
Cranial blood 
vessel
Trigeminal brainstem 
nuclear complex
Figure 1. The Trigeminovascular system
The key components o f the trigeminovascular system encompass the pain producing 
cranial vessels and dura mater, the peripheral branches o f the trigeminal nerve 
innervating the cranial vessels and dura mater and the central terminations o f the 
trigeminal nerve which synapse in the trigeminal brainstem nuclear complex.
1.3.1 The Trigeminal nerve
The trigeminal or fifth cranial nerve has motor (mastication, middle ear and throat 
muscles), proprioceptive (temporomandibular joint) and other sensory functions. 
Trigeminal means "three twins" and as such, the sensory distribution of the trigeminal 
nerve comprises three divisions, all arising from the trigeminal ganglion; the
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ophthalmic (Vi), the maxillary (V2) and the mandibular (V3) divisions. The trigeminal 
nerve is the only cranial nerve to be involved in sensory cutaneous innervation and 
provides the sole sensory innervation of facial skin and most of the innervation of the 
head, although some parts of the head also receive innervation from the upper cervical 
spinal nerves or other cranial nerves (Sessle, 2002).
Ophthalamic (VI)
maxilliary (V2) 
mandibular (V3)
Figure 2. The innervation territories of the trigeminal nerve
The sensory innervation o f the face occurs through the three divisions o f the 
trigeminal nerve; the ophthalmic (Vj), the maxillary (V2) and the mandibular (V3) 
divisions.
The terminations of trigeminal afferent fibres can be of several types. Some end in 
association with sensory organs and respond to light tactile stimuli, known as low 
threshold (LT) mechanoreceptors. Some respond to muscle stress and tension, the 
proprioceptors. Others, the nociceptors, terminate as free nerve endings and are 
activated by painful noxious stimulation. Nociceptors, under physiological conditions, 
are associated with two kinds of primary afferent fibres, the first are slow-conducting, 
small diameter, myelinated A-5 fibres and the second type, are even slower
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conducting, smaller diameter, unmyelinated C-fibres. These afferent fibres project into 
the central nervous system (CNS), where their first point of synapse occurs in either 
the trigeminal brainstem nuclear complex (VBNC) or upper cervical dorsal horn.
1.3.2 Morphology of nerve fibres innervating the dura mater
1.3.2.1 Sensory innervation
The majority of trigeminal nerve fibres terminate as free nerve endings and in the rat 
an estimated 800 A-5 and 250 C-fibres innervate each side of the supratentorial dura 
mater (Andres et al., 1987). The terminations of A-5 and C-fibres are commonly 
mixed in their final terminations into multi-axonal units, explaining the varied effects 
seen following their activation. The expression pattern of neurotransmitters and 
peptides has been well-studied in dural fibres and gives further information about their 
functional properties. Calcitonin gene related peptide (CGRP) and Substance P (SP) 
immunoreactivity are both extremely prominent along the meningeal arteries and 
venous sinuses and also show a strong association with dural mast cells (Dimitriadou 
et al., 1991). (For a comprehensive review of the projections of trigeminal afferents to 
the dura mater see Moskowitz et al., 1987).
1.3.2.2 Autonomic innervation o f dural and intracranial vessels
The major innervation of the tentorium, falx and venous sinus, occurs from the 
tentorial nerve, which arises from the cavernous plexus, which in turn, has been shown 
in the monkey, to be formed from fibres of the ophthalmic division of the trigeminal 
nerve and sympathetic fibres from the superior cervical ganglion (Ruskell, 1988).
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Perivascular sympathetic fibres accompany the middle meningeal artery (MMA) and 
build up a dense plexus around the sagittal sinus (Cavaollotti et al., 1998). Anteriorly, 
parasympathetic fibres from the pterygopalatine (sphenopalatine) ganglion, and fibres 
from the maxillary division of the trigeminal nerve join the cavernous plexus and are 
distributed along the middle cerebral artery (Cavanagh et al., 1990).
1.3.3 Primary afferent cell bodies in the trigeminal system
The cell bodies of trigeminal primary afferent neurons are located in the trigeminal 
ganglion in the peripheral nervous system. The presence of many classical peptide 
transmitters, such as glutamate, GABA, glycine, serotonin, noradrenaline, 
acetylcholine, cholecystokinin, somatostatin and opioids peptides, as well as 
neuroactive molecules like nitric oxide have been demonstrated within the trigeminal 
ganglion (for review see Lazarov, 2002). The co-existence of neuropeptides, such as 
SP and CGRP and transmitters in a single neuron is also evident. The discovery of 
such chemical heterogeneity has influenced the view that the trigeminal ganglion is at 
the centre of a complex plastic system that is highly susceptible to the environment of 
its primary afferent terminations (for review see Lazarov, 2002). However, there are 
currently no studies that have explored whether the activity of the trigeminal ganglion 
is altered in migraineurs, although recently, the technique of functional magnetic 
resonance imaging has been suggested as a means of such an investigation (Borsook et 
al., 2004).
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1.3.4 The Dura mater
The dura mater is the most superficial layer of the three connective tissue layers, the 
meninges, surrounding and protecting the brain and spinal cord. The dura mater 
surrounding the brain is tightly attached to and continuous with the periosteum of the 
cranial vault. Three dural folds extend into the main brain fissures to form the dural 
sinuses which collect most of the blood returning from the cranial circulation via the 
vein of Galen, the emissary and dipole vein. The dura mater itself, is richly supplied 
by meningeal arteries, veins and an extensive capillary network, especially in the 
parasagittal region (Kerber & Newton, 1973), which apart from a nutritive function, 
are thought to be involved in the regulation of intracranial pressure (Lang et ah, 1971).
1.3.5 The cerebral vasculature
The pivotal studies of Ray and Wolff (1940) on the perception of pain in conscious 
patients following stimulation of discrete regions of the dura mater identified the 
proximal regions of cerebral and dural arteries along with the large venous sinuses as 
important structures in the recognition of pain. Following the realisation, that 
stimulation of cranial vessels could evoke painful responses, much effort has been 
devoted to studying cranial blood flow abnormalities during migraine as a potential 
source of the pain (Martins et al., 1993; Nichols et ah, 1990).
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Stimulation site Area of pain perception
Middle meningeal artery distension back of the eye
Middle cerebral artery
-proximal section eye, forehead & temple
- middle section retro-orbital pain
-distal section above the eye
Intracranial segment of internal carotid lateral to the eye
artery
Vertebral artery occiput
Anterior cerebral arteries eye, forehead & temple
Superior sagittal sinus frontoparietal area
Table 3. Main cranial structures resulting in pain perception as identified by Ray and 
Wolff (1940)
1.3.5,1 Intracranial vessels
Reduced regional blood flow has been observed using transcranial Doppler 
sonography in the middle cerebral artery (MCA) on the headache side, during 
migraine attacks (Friberg et al., 1991), which is assumed to result from vasodilatation. 
In this study, following anti-migraine treatment, the headache was aborted and blood 
flow returned to normal, although the timing of the relief and the flow change were not 
related. These observations indicated that dilatation is at the very least, a reactive 
response during migraine in some patients, it does not necessarily follow however, that 
distended intracranial vessels are the primary source of pain during migraine. Further 
anecdotal evidence for abnormality of the intracranial arteries in migraine is the 
aggravation of symptoms by coughing, jolting or breath holding.
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13.5,2 Extracranial arteries
The innervation of extracranial arteries is separate from that of intracranial arteries 
with convergence of afferent fibres occurring only in the trigeminal brainstem nuclear 
complex (VBNC) (Borges & Moskowitz, 1983). The concept of abnormal extracranial 
artery dilatation during migraine is supported by the observations in some subjects that 
the throbbing nature of the headache appears to be synchronous with pulsations of the 
temporal artery. Indeed Blau and Dexter (1981) showed that the inflation of a 
sphygmomanometer cuff around a patient's head could relieve headache symptoms in 
about one third of those tested. However, the number of patients responding to 
compression of the temporal artery is small and many migraine patients do not even 
experience a throbbing component of their head pain. Hence, it is likely that 
extracranial vessel distension contributes to migraine pain in only a minority of 
subjects.
13.6 Trigeminal brainstem nuclear complex
The VBNC is a bilateral, multinucleated structure extending rostrally from the pons 
and caudally to the upper cervical spinal cord. Its main sub-divisions include the 
principal or main sensory nucleus (Vp) and the spinal trigeminal nucleus (Vsp) which 
consists of three subnuclei, namely the oralis (Vo), interpolaris (Vi) and caudalis (Vc). 
Unlike the organisation of the rest of the spinal cord, trigeminal collaterals ascend and 
descend in a trigeminal spinal tract, which runs throughout the VBNC, creating a 
convergent system (Lovick & Wolstencroft, 1983). In addition to spinal trigeminal 
tract neurons, lateral to each nucleus, groups or "islands" of neuronal elements known 
as the paratrigeminal nucleus are also apparent, which further facilitate transmission of 
neuronal signals throughout the VBNC.
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The structural organisation of the VBNC, with the exception of Vc is fairly uniform, 
with a somatotopic arrangement. The ventral part of each subnuclei or nuclei generally 
receives input from primary afferents from the Vi division, the dorsal part, from V3 
and the part in between from V2. An especially highly organised feature of the VBNC 
is vibrissal representation which runs in rostrocaudal columns and is conserved both in 
the thalamus and somatosensory cortex, indicating the importance of these structures 
in the exploration of the external environment.
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Vc
Vc/Vi
transition
zone
lUS
From Trigeminal 
ganglion
Rostral
Vc III-IV
Caudal
Vc
Cl
Figure 3. The Trigeminal Brainstem Nuclear Complex (VBNC)
The VBNC contains the principal sensory nucleus (Vp) and the spinal trigeminal 
nucleus (Vsp) which consists o f three subnuclei, namely the oralis (Vo), interpolaris 
(Vi) and caudalis (Vc). Like the spinal dorsal horn, the Sp5C has a laminated 
structure and contains in laminae I  and V numerous nociceptive neurones, many o f 
which project directly to higher brain centres involved in pain processing
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The Vc is the largest component of Vsp, at its caudal extremity, it merges with the 
spinal cord and rostrally it merges with Vi to form a distinctive transition zone. It's 
laminated structure resembles the spinal cord with laminae I-VI receiving sensory 
input, analogous to the dorsal horn, laminae VII-IX receiving motor input and laminae 
X receiving input similar to laminae I and II (For review see Gobel et al., 1981; 
Johnson et al, 1991; Henderson & Jacquin, 1995).
Due to the structural similarities of the trigeminal Vc with the spinal system and the 
similar behaviour of isolated trigeminal ganglion and dorsal root ganglion cells, many 
consider the dorsal hom and Vc to be analogous, despite awareness for many years of 
the complexity of trigeminal sensory system compared with spinal systems (Kruger & 
Young, 1981). Electrophysiological studies have also shown a differential response of 
trigeminal nucleus caudalis neurons compared to dorsal hom neurons to the effects of 
naratriptan indicating different receptor pharmacology between the two areas 
(Cumberbatch et al., 1998). Analysis of the type of input the Vc receives in 
comparison to the dorsal hom has been gained from exploration of the presence of the 
neuropeptide nociceptive markers, CGRP and SP and the expression of the cell surface 
marker isolectin I-B4 (IB4) (Snider & McMahon, 1998). CGRP and SP-positive fibres 
project mainly to laminae I and IIo of the dorsal hom, which shows little IB4 
immunoreactivity, where as in Vc, a significant immunoreactivity is seen for both 
fibre types across I, IIo and Iii as well as I-B4 (Sugimoto et al., 1997).
The Vi /Vc transition zone however tends to resemble the dorsal hom, indicating that 
the caudal Vc and Vi /Vc border receive a different compliment of afferent
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nociceptive input (Bereiter et al., 2000). An elegant study by Meng and colleagues 
showed that electrical comeal stimulation, activated cells in both the Vi /Vc transition 
zone and Vc/ Ci border, however the cell populations (based on receptive field 
properties, activation by algesic substances and their supraspinal projections) were 
significantly different (Meng et al., 1997),. The authors suggested that the Vc /Ci 
population was more likely to be involved in motor reflexes and the recruitment of 
descending pathways, while neurons at the Vi /Vc border were likely to be involved in 
the conscious perception and reaction to pain.
While several studies have focused on the characterisation of the Vc, relatively little is 
known about the role of Vo and even less about Vi in the processing of nociceptive 
pain. Lesioning of these areas suggests a significant dismption to the transmission of 
craniofacial pain, hence electrophysiological and immunocytochemical investigations 
would prove useful in relating the different VBNC components to behaviour, 
autonomic and motor effects seen clinically.
In the spinal cord, afferent nerves project to a single segment, where as the VBNC has 
a unique feature of dual representation, where afferents projecting from the same 
craniofacial structures synapse in different areas of the VBNC. At present, there is 
only evidence for this phenomenon in structures innervated by V i and the functional 
relevance is not clear. It may facilitate different responses to nociceptive stimuli by 
projection to different supraspinal structures or purely represent a redundant pathway.
-31  -
1.3.6.1 Characterisation of second order neurons in the trigeminal 
brainstem nuclear complex
The result of numerous electrophysiological studies on the response of second order 
neurons within the spinal cord and VBNC has led to a widely accepted classification 
into three basic classes of sensory neuron (Sessle, 2000):
i.) Nociceptive specific (NS); responding only to noxious stimulation (e.g. 
pinch) of the receptive field and activated by A-5 and C-fibres.
ii.) Wide dynamic range (WDR); responding with a graded intensity to both 
tactile and noxious stimulation, activated by A-|3, A-5 and C-fibres.
iii.) Low threshold (LT); responding only to tactile stimuli and activated by A- 
(3 primary afferents only.
NS and WDR cells are typically located in the superficial (I / II) and deep laminae (V / 
VI) of Vc. The NS cells tend to have a small receptive field, where as the receptive 
fields of WDR cells are much larger. This classification applies to cells throughout 
VBNC (for review see Dunber et al., 1978), although examination of cells in the 
rostral VBNC is limited, with only a few studies of neuronal properties carried out on 
Vo cells (Dallel et al., 1990, 1999). The studies in this thesis, largely involve 
examination of WDR cells in the VBNC, activated by noxious electrical stimulation of 
the dura. In most cases, these second-order neurons could also be activated by 
stimulation of the facial receptive field (FRF).
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Electrical stimulation of the dura mater is assumed to be nociceptive in character as 
the dura mater is almost exclusively innervated by A-5 and C-fibres (Andres et al, 
1987). This is further supported by studies showing that dural stimulation results in c- 
fos expression in the Vc, which has been previously shown to be well correlated to the 
magnitude of nociceptive insult (Munglani & Hunt, 1995).
1.4 Transmitters in the Trigeminovascular system
Immunocytochemical studies have reported a wide variety of neurochemicals or their 
cellular receptors in the VBNC, all of these may play a significant role in the 
modulation of VBNC activity. However, headache research in the last decade has very 
largely focused on CGRP, SP and 5-HT for their possible involvement in migraine.
1.4.1 Calcitonin gene related peptide (CGRP)
Calcitonin gene related peptide (CGRP) is the most abundant peptide transmitter 
found in perivascular sensory trigeminal nerve fibres, where it is colocalized with 
substance P and other neurotransmitters (Uddman et al., 1985). Evidence for a role of 
CGRP in the pathophysiology of migraine, comes from the observation that the levels 
of CGRP in blood from the external jugular vein, which drains blood from extracranial 
tissue including the dura and the trigeminal ganglion, is increased during spontaneous 
migraine attacks (Goadsby et al., 1990). Furthermore, this increased CGRP level is 
normalised following administration of the anti-migraine treatment, sumatriptan 
(Goadsby et a l, 1993).
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A recent study provided evidence that as well as an involvement in the pain phase of 
migraine, CGRP may also play a role in the generation of attacks. In this study, CGRP 
infusion into patients suffering from episodic migraine, outside of an attack resulted in 
an immediate headache during the infusion in all subjects studied. Furthermore, all 
subjects developed a delayed headache approximately 5 hours after the infusion, 
which in 3 out of 9 subjects was of sufficient magnitude to fulfil the IHS diagnostic 
criteria of migraine (Lassen et al., 2002).
In animals, stimulation of trigeminal sensory nerve fibres causes antidromic release of 
CGRP with subsequent vasodilatation of the cerebral vasculature (Beattie & Connor, 
1994; Escott et al., 1995). Furthermore, CGRP infusion in addition to generating 
dilatation of the MMA also increased firing of Vc neurons (Cumberbatch et al., 1999). 
However, this increase in Vc neuronal activity was short lived (approximately 6 
minutes) and hence unlikely to be directly responsible for long term sensitisation, 
however, identification of the downstream processing following CGRP infusion is 
likely to further understanding of the molecular processes involved in the generation 
of headache. Indeed, a causative role of CGRP has now been confirmed following the 
recently described efficacy of CGRP antagonists in the treatment of acute migraine 
(Brain et al., 2002; Doods et al., 2000; Olesen et al., 2004).
1.4.2 Substance P
SP is a potent neurochemical involved in the transmission of pain signalling and is 
released from both peripheral and central terminals of primary afferent fibres 
following nociceptive stimuli in both the spinal and trigeminal systems (for review see
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Harrison & Geppetti, 2001). The co-localisation of SP with CGRP in the trigeminal 
system and its nociceptive character, led to exploration of SP antagonists as potential 
anti-migraine drugs. Pre-clinically, SP antagonists are highly potent in blocking both 
plasma protein extravasation in a model of neurogenic inflammation (Cutrer et al., 
1995; O'Shaughnessy et al., 1994) and c-fos expression in the VBNC following 
trigeminal ganglion and meningeal stimulation (Clayton et al., 1997; Cutrer et al., 
1995; Shepheard et al., 1993). However, they have no effect on Vc firing elicited by 
superior sagittal sinus (SSS) stimulation in the anaesthetised cat (Goadsby et al.,
1998).
Clinically, SP antagonists have been reported to have no significant effect over 
placebo either in the acute (Connor et al., 1998; Diener, 2003) or prophylactic 
(Goldstein et al., 1997) treatment of migraine, indicating that the blockade of 
neurogenic inflammation, at least in the species tested, is not sufficient in predicting 
anti-migraine activity of compounds.
1.4.3 Serotonin
Serotonin or 5-hydroxytriptamine (5-HT) is widely distributed throughout the body 
and in particular in the gastrointestinal tract, platelets and the brain with seven major 
classes of receptor (5-HT1.7) and further subclasses in each division. There is 
considerable circumstantial evidence, which suggests the involvement of serotonin (5- 
HT) in the pathophysiology of migraine (for a detailed review see Silberstein et al., 
2001). Decreases in platelet 5-HT concentration, increase in urinary 5-HT and increase 
in 5-HIAA, the major metabolite of 5-HT (Ferrari et al., 1989) have been reported 
during attacks. Furthermore, headache can be aborted by 5-HTi agonists (Humphrey
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& Feniuk, 1991; Silberstein, 1994) and induced such as reserpine, which causes an 
increase in endogenous 5-HT concentrations, an effect that can be prevented by pre- 
treatment with methysergide, a 5-HT2 antagonist. Centrally penetrating 5-HT 1 agonists 
such as naratriptan and zolmitriptan, also inhibit the activity of Vc neurons responding 
to noxious dural stimulation (Goadsby & Hoskin, 1996) as well as constricting 
meningeal, dural and pial blood vessels (Ferrari & Saxena, 1993; Longmore et al., 
1997; Humphrey & Feniuk, 1991) and this is discussed further in section 1.8.3.2.
1.4.4 Other transmitters modulating VBNC activity
GABA is an inhibitory neurotransmitter released from local intemeurons within the 
substantia gelatinosa of the VBNC. Agonists acting both through the GABAa and 
GABAb receptor subtype appear to inhibit Vc neurons following noxious electrical 
stimulation of the SSS (Storer et al., 2001). This GABA mediated inhibition appears 
dependant on C-fibre activation, as neonatal capsaicin disrupts the modulation (Chiang 
et al., 1999). Exogenous opioids are also capable of decreasing Vc neuronal activity 
when administrated directly to the VBNC or into the supraspinal structures influencing 
the activity of the VBNC, indicating wide spread distribution of opiate receptors in the 
trigeminal system. There is also significant evidence to support a role of nitric oxide in 
modulation of the trigeminovascular system and this is discussed in detail in Chapter 
3.
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1.5 Modulation of neuronal processing in the Trigeminal brainstem nuclear
complex
As discussed in section 1.2, migraine is not only characterised by headache that has a 
component of referred pain in the head and face, but also by distinct behavioural 
changes (e.g. loss of appetite, mood changes). The presence of premonitory symptoms 
that allows some migraineurs to predict the onset of an attack (Giffin et al, 2003; 
Jacome, 2001; Santoro et al., 1990) and the susceptibility to "ice cream-headache" that 
migraineurs exhibit (Drummond & Lance, 1984) indicates the involvement of central 
brain regions in the generation of an attack. While the studies in this thesis have not 
directly examined the activity of these higher centre structures, it is of relevance to 
discuss the ascending and descending connections with the VBNC as well as the 
control systems within the VBNC, for an understanding of how the responses of the 
trigeminovascular system may be altered during migraine.
1.5.1 Neuronal modulation within the Trigeminal brainstem nuclear complex
The gate control theory of pain was first proposed by Wall & Melzack in the 1960's 
and suggested that the relay of pain signalling between the primary afferent neurons 
entering the dorsal hom and VBNC could be significantly modulated before 
transmission to the brain (Wall & Melzack, 1994). The theory suggests that following 
activation of fast conducting primary afferents, the dorsal hom becomes a “locked 
gate” and prevents further afferent input synapsing with ascending pathways. This 
theory is now widely accepted, although the precise contribution of these inhibitory 
circuits to specific pathways is unknown.
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Figure 4. Schematic representation of ’’gate control”
The gate control hypothesis suggests that the pathway o f impulses from the primary 
afferent neurons to the thalamus are regulated by inhibitory interneurons originating 
in the substantia gelatinosa o f the dorsal horn. The interneurons are activated by 
descending inhibitory neurons or non-nociceptive afferent input and inhibited by C - 
ffbre input.
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1.5.2 Higher centre connections with the trigeminal nuclear brainstem
complex
1.5.2.1 Ascending Spinal and Trigeminal tracts
From the spinal cord and Vc, pain sensation is relayed to the thalamus and brainstem 
via the spinothalamic and spinomesencephalic tracts. At the level of the thalamus, the 
pain system is believed to separate into a lateral system, involved in the perception of 
sensory and discriminative pain and a medial system involved in the affect and 
motivation responses to pain (Bushnell & Duncan, 1989; Rainville et al., 2000). 
Spinothalamic fibres originate mainly in laminae I, IV, V and VI of the dorsal hom 
and Vc, where they synapse with second order neurons and send axonal projections 
across the anterior commissure of the cord to the opposite anterior and lateral white 
columns These fibres then ascend to the brain in both the anterior spinothalamic tract 
and lateral spinothalamic tract. The anterior spinothalamic tract is located in the 
anterior funiculus of the spinal cord and is intermingled with ascending spinoreticular 
and spinomesencephalic tract fibres. Laterally the tracts are continuous with the lateral 
spinothalamic tract, located in the lateral funiculus. At the level of the lower 
brainstem, spinothalamic tract axons separate and those of the anterior tract join the 
medial lemniscus, while the axons of the lateral tract continue as the spinal lemniscus, 
with both lemnisci ascending to the thalamus. Specific ascending tracts from the 
trigeminal system are shown in the figure 5 and are essentially synonymous with those 
from the spinal system, with axons from the spinal trigeminal nucleus, joining the 
spinothalamic, spinomesencephalic and spinoreticular tracts to form the 
trigeminothalamic tract (Grays anatomy, 1995).
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Figure 5. Ascending spinal trigeminal tracts conveying pain information
The spinothalamic tract (green) projects to the somatosensory nucleus o f the 
thalamus, which in turn projects to the somatosensory cortex for the perception o f 
pain. The spinothalamic tract also projects to other thalamic nuclei, which in turn are 
thought to project to the anterior cingulated cortex to modulate the emotional aspects 
o f pain (blue). Spinomesencephalic tract neurons (orange) ascend in association with 
the spinothalamic tract and project to various midbrain structures, where they are 
thought to be involved in the motivational-affective component o f pain. Pain, thermal 
and tactile fibres, originating from the spinal trigeminal nucleus (red), cross at 
various locations in the lower brainstem and ascend in the ventral trigeminothalamic 
tract in association with the contralateral medial lemniscus. Fibres conveying touch 
and pressure (blue) ascend by two separate pathways; 1.) Fibres from the ventral 
portion o f the spinal trigeminal nucleus cross and ascend with the contralateral 
medial lemniscus. 2.) Fibres from the dorsomedial part o f the spinal trigeminal 
nucleus ascend, uncrossed as the dorsal trigeminal tract. Both dorsal and ventral 
trigeminal tracts project to the ventral posteromedial nucleus o f the thalamus. 
(Adapted from Grays Anatomy, 1995).
1.5.2.2 Descending Spinal and Trigeminal tracts
Pre-clinically the involvement of descending pathways in modulating the activity of 
VBNC neurons has been well documented and further indicates that an imbalance in 
these systems may underlie migraine pathology. Both direct and indirect pathways 
originating in the hypothalamus, PAG, nucleus raphe magnus, LC and nucleus 
paragigantocellularis lateralis are all of potential relevance. Clinically PET studies 
have shown an increase in blood flow (which may represent either an increase in 
excitatory or inhibitory activity) occurs in the midbrain during migraine, which may 
be indicative of activity in the nucleus raphe dorsalis, PAG and pons (Bahra et al., 
2001; Weiller etal., 1995).
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The above schematic diagram is an extremely simplified version o f how descending 
pathways act to dampen the activity in the dorsal horn and Vc. For example, opioids 
may excite neurons in the PAG, which in turn activates neurons in the NRM, which 
result in activation o f inhibitory 5-HT and enkephalin-containing neurons, which 
project to the substantia gelatinosa. (Diagram adapted from Rang et al., 1995). PAG, 
periaqueductal grey: LC, locus ceruleus: NRM, nucleus raphe magnus: NRPG, 
nucleus reticularis paracellularis.
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1.5.2.3 Thalamus
Thalamic neurons are predominantly activated in the ventral periphery of the ventral 
posteromedial nucleus and interlaminar complex following electrical stimulation of 
the MMA and SSS (Zagami & Lambert, 1990). Furthermore, single thalamic neurons 
have been found to respond to both SSS and tooth pulp stimulation (Angus-Leppan et 
al., 1995). This convergence of inputs from cutaneous and craniovascular structures 
offers a possible explanation for some of the pain referral patterns seen during 
migraine.
1.5.2.4 Hypothalamus
Until recently, ascending connections of VBNC with the hypothalamus were assumed 
to be via polysynaptic pathways involving other brainstem structures (Malick et al.,
2000). However, in an elegant series of experiments using antidromic stimulation and 
single unit recordings, a population of cells at the level of Vc and Cl, with trigeminal 
receptive fields, were identified with direct ascending connections through the 
contralateral brainstem to the supraoptic decussation in the lateral hypothalamus. At 
the level of the hypothalamus, almost half of the fibres again crossed the midline to the 
ipsilateral side with collateral projections found in many hypothalamic nuclei such as 
suprachiasmatic and supraoptic nuclei and structures rostral to the hypothalamus such 
as the caudate-putamen, globus pallidus and substantia innominata.
The functional relevance of these direct VBNC-hypothalamic connections merit 
further investigation, for example, the current understanding of the function of the 
suprachiasmatic nucleus, makes it ideally placed for an involvement in migraine. As
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well as showing sexual dimorphism (in females it is elongated, whereas in males it is 
spherical in shape), it is considered to be important in the control of circadian rhythm 
in humans and neuronal activity within it is directly regulated by photic stimuli. The 
suprachiasmatic nucleus is also thought to be involved in regulating the serotonin 
system and melatonin concentrations, which are known to be altered in migraineurs 
e.g. significant seasonal variations in hypothalamic 5-HT content, cerbro-spinal fluid 
5-HIAA, platelet 5-HT uptake and platelet 5-HT content have been found in migraine 
patients (Ferrari et al., 1993) and a low melatonin concentration has been reported in 
both episodic and chronic migraine sufferers (Peres et al., 2001).
Activation of the preoptic nucleus results in profound inhibition of the activity of the 
Vc. This effect is mediated, at least in part, by pathways directed via the ventrolateral 
PAG, the nucleus raphe magnus or the nucleus paragigantocellularis, since lesions in 
these pathways reduce hypothalamic mediated inhibition of Vc activity (Mokha et al, 
1987). The extent to which inhibition of Vc activity is mediated via projections from 
the hypothalamus to the nucleus raphe magnus or the nucleus paragigantocellularis, or 
via projections routed through the periaqueductal gray matter is not known.
/.5.2.5 Periaqueductal grey
The periaqueductal grey (PAG) is the grey matter surrounding the midbrain aqueduct. 
Its anatomical organisation involves functional neuronal columns, the dorsolateral, 
dorsomedial, lateral and ventrolateral columns of which, the lateral and ventrolateral 
columns receive a dense afferent projection from Vc and Vo (Wiberg et al., 1986). 
Activation of these ascending trigeminal projections results in a wide range of
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behavioural (Fields & Basbaum, 1999) and cardiovascular responses (Carrive & 
Bandler, 1991). There is also significant evidence that stimulation of the 
periaqueductal grey (PAG) can produce migraine like headaches in humans (Raskin et 
al., 1987; Veloso et al, 1998). A role of the PAG in the generation of migraine is 
supported by a recent clinical communication regarding a patient with a cavemoma in 
the midbrain that bled. The patient previously had no history of headache and now 
suffers from frequent migraine (Goadsby, 2002).
There are a considerable number of direct projections from the PAG to the VBNC 
(Blomqvist & Craig, 1991) as well as indirect connections via the NRM. The ability of 
the PAG to modulate VBNC activity has been determined in animal models where 
stimulation of the ventrolateral PAG produces analgesia and reduces neuronal activity 
(Levine et al, 1991; Knight & Goadsby, 2001). A dysfunction of PAG descending 
pathways has been suggested to underlie neuronal hypersensitivity of the VBNC that 
may occur during a migraine attack (Knight & Goadsby, 2001; Knight et al, 2002). In 
support of the theory of the PAG as a source of abnormality in headache, are the 
results of a clinical study examining iron homeostasis, thought to be representative of 
cellular function in both episodic migraine and chronic daily headache patients. In 
both groups of patients, iron homeostasis was found to be selectively impaired in the 
PAG, indicating the possible role of the PAG in the generation of headache (Welch et 
al., 2002).
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L5.2.6 Nucleus raphe magnus
The raphe nuclei are located along the midline in the lower pons and upper medulla. 
Of these nuclei, the nucleus raphe magnus is implicated in both the control of VBNC 
neurons and the processing of trigeminal sensory information to the cortex. It receives 
its main input from sensory spinothalamic tract neurons via the adjacent nucleus 
reicularis paragigantocellularis, however a sparse direct projection from the VBNC 
has also been identified. Neurons in the nucleus raphe magnus and adjacent structures 
of the rostral ventromedial medulla (RVM) are involved in the control of nociceptive 
transmission. In the RVM the so-called on-cells are excited, and the so-called off-cells 
are inhibited, by noxious stimuli applied almost anywhere on the body surface, thus 
showing that they receive information from spinal and trigeminal nociceptive neurons 
(Hernandez & Vanegas, 2001). Indeed, the RVM has been shown to possess on- and 
off-cells can encode the stimulus intensity in terms of response latency and discharge 
rate and closely reflects spinal neuronal encoding suggesting a role in the modulation 
of pain information by RVM neurons.
Single unit electrophysiological recordings of cells in the raphe nuclei have indicated 
the presence of "pacemaker cells" which exhibit tonic discharge (Mosko & Jacobs, 
1976). When this is considered with the reported functional organisation of raphe 
nuclei cells according to the afferent input they receive (Kirifides et al., 2001), it 
provides weight to the theory of Eggers, that abnormally functioning cells in the raphe 
nuclei might underlie an excitotoxic cortical response linked to the initiation of 
migraine (Eggers, 2001).
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The nucleus raphe magnus is an essential part of the descending analgesia system and 
a specific role in migraine is implicated by the discovery that naratriptan, an effective 
anti-migraine drug, is able to decrease activity in on-cells and increase activity in off 
cells in the nucleus raphe magnus (Ellrich et al., 2001a). However, an indirect action 
of naratriptan on structures such as the PAG, which influence the activity of the 
nucleus raphe magnus, rather than a direct action on the nucleus raphe magnus cannot 
be ruled out. However, retrograde tracing studies using horseradish peroxidase have 
demonstrated the existence of descending pathways from the nucleus raphe magnus 
and nucleus paragigantocellularis to both the Vc and Vo. Furthermore, antidromic 
stimulation in the VBNC has been shown to activate cells in the nucleus raphe magnus 
(Lovick & Wolstencroft, 1983).
7.5.2.7 Gigantocellular neurons of the reticular area
The gigantocellularis neurons (or Betz cells) are located in the reticular area of the 
pons and mesencephalon and use acetylcholine as their neurotransmitter. The reticular 
formation is representative of an old neural system where neurons lie among 
ascending and descending tracts of all types with the ability to exert a wide range of 
effects on both the spinal cord and brain. There are 6 main nuclei of the reticular 
formation, namely the nucleus reticularis gigantocellularis, the nucleus reticularis 
magnocellularis, the nucleus reticularis parvocellularis, the nucleus reticularis 
paragigantocellularis lateralis, the nucleus reticularis paragigantocellularis and the 
infratrigeminal nucleus, although the term nuclei is used loosely as all have 
overlapping distributions. The connections of the VBNC and the brain with these 
nuclei have been previously reviewed (Abols & Basbaum, 1981; Newman, 1985; Van
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Bockstaele, 1989). Because of their wide distribution, it is likely that these nuclei play 
many roles in the processing of sensory and motor function. Of particular importance 
in trigeminal sensitisation studies is the integration of nociceptive trigeminal input and 
cardiovascular responses by a regulation centre located in the most caudal portion of 
the reticular formation.
1.5.2.8 Locus ceruleus
The locus ceruleus (LC) is the most prominent cluster of noradrenergic neurons in the 
brain and is located in the grey matter of the pons. Collaterals of these neurons give 
rise to millions of noradrenergic terminals throughout the cortex as well as other brain 
regions. The nerve terminals of this system, instead of forming discrete terminals are 
located away from their target cells, hence central noradrenergic effects tend to be 
diffuse. A malfunction in the activity of the LC has been suggested to underlie both 
the extracranial vascular changes occurring during migraine and the process of cortical 
spreading depression (Lance et al., 1983). More recently, a parasympathetic role in 
migraine has been suggested to underlie exaggerated facial flushing, lacrimation and 
rhinorrhea, which is supported by the increased levels of cranial venous vasoactive 
intestinal peptide in migraineurs during attacks. As a result of these studies, a within- 
brainstem interaction between the two locus coeruleus nuclei which are involved in 
control of pain and cranial parasympathetic outflow has been suggested to be involved 
in the initiation of migraine (Avnon et al., 2003).
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1.5.2.9 Parabrachial area
The parabrachial area, including the Kolliker-Fuse nucleus and the nucleus 
cuneiformis have also been implicated in the modulation of trigeminal nociception 
(Hayashi, 1992). Studies examining c-Fos expression following intra-plantar 
carraggeenan at both the spinal and PB levels and inflammatory edema have provided 
evidence for the involvement of spinoparabrachial pathway in inflammatory 
nociceptive processes (Buritova et al., 1998). This is supported by other studies that 
show one of the major supraspinal targets for lamina I projection neurons is lateral 
parabrachial area (Spike et al, 2003). Activation of the parabrachial area has also been 
shown to inhibit Vc neuronal responses evoked by both cutaneous and deep tissue 
stimulation (Chiang et al., 1995).
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Figure 7. Brainstem structures with trigeminal brainstem nuclear complex 
connections
Ascending projections from the trigeminal nuclear brainstem complex reportedly have 
many targets
POA, Pre-optic area: SON, supra-optic nucleus: DMN, dorsomedial nucleus: PN, 
posterior nucleus: VMN, ventromedial nucleus: PAG, periaqueductal grey: ARF: 
anterior reticular formation: LC, locus ceruleus: NRM, nucleus raphe magnus: SSN, 
superior salivitory nucleus: NTS, nucleus tractus solitarius: RF, reticular formation.
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1.5.3 Diffuse noxious inhibitory controls
The ability of diffuse noxious inhibitory controls (DNICs) to inhibit activity in the Vc 
has been long established (Villanueva, 1984) and can be defined as inhibition of WDR 
neurons produced by noxious stimulation applied to remote widespread areas of the 
body. Such DNICs indicate that although the trigeminal system may receive specific 
modulation in relation to orofacial and cranial pain, it is also substantially regulated by 
a generalised analgesia system.
1.5.4 Autonomic connections with the trigeminovascular system
The presence of systemic visceral autonomic symptoms in migraine, such as nausea 
and vomiting are well known and are likely to result from a connection between the 
trigeminal nerve and the nucleus tractus solitarius (Goadsby & Kaube, 2000). Studies 
examining the involvement of autonomic symptoms in migraine are limited, although 
there are know connections between the trigeminovascular system and the superior 
salivatory nucleus, the sphenopalatine ganglion and the nucleus tractus solitarius.
The superior salivatory nucleus receives an ipsilateral afferent input from Vc, Vo and 
Vp (Spencer et al., 1990) as well as other brainstem structures. The pre-ganglionic 
parasympathetic cells in the superior salivatory nucleus then send axons to join with 
fibres from the superior cervical ganglion to the sphenopalatine ganglion. The 
sphenopalatine ganglion provides a source of vasoactive intestinal peptide and 
cholinergic fibres to the anterior cerebral vessels (Uddman et al., 1980). However, the 
physiological function of the cerebrovascular vasoactive intestinal peptide innervation 
is currently unknown.
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c-fos expression in the caudal nucleus tractus solitarius and its caudal extension in 
lamina X of the spinal cord was seen bilaterally in response to MMA stimulation 
(Hoskin et al., 1999). Autoradiography studies have also confirmed that intravenously
i n
injected zolmitriptan labels a discrete population of cells in the nucleus tractus 
solitarius (Martin, 1997) suggesting a possible role of this structure in the reactive 
response to trigeminovascular activation.
1.6 Visceral pain
The sensory pain systems described above are likely to be of central importance in 
many aspects of head pain. However, it is also worth considering that the dura mater 
may be considered as a visceral structure and as such, attention to the processing in 
visceral pain pathways is required for a full understanding of migraine 
pathophysiology. The following summary is adapted from recent reviews; (Cervero & 
Laird, 1999; Gebhart, 1995; McMahon et al., 1995).
Characteristically, sensation of visceral pain is diffuse and poorly localised, pain is 
also commonly referred to skin and other areas and accompanied by autonomic and 
motor disturbances. While the neural mechanisms underlying visceral pain are 
relatively unexplored, current research suggests there are essentially two classes of 
visceral nociceptor responsible for the transmission of pain signals to the central 
nervous system. The first can be considered to be NS, responding to high threshold 
stimuli in the noxious range only and the second, an intensity coding type with a low 
threshold to natural stimuli. A further group of "silent receptors" that only respond to
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stimuli in the presence of inflammation have also been proposed. The role of these 
“silent receptors” remains speculative, however, their function under sensitised 
conditions may purely aid the adaptation to normal processing.
1.7 Migraine Models
Experimental models of disease are invaluable in furthering scientific understanding 
and detecting pharmacological properties of new compounds that will determine their 
usefulness as a treatment. The basis of model development depends on clinical 
observations of the disease, which in primary headache syndromes such as migraine 
can be problematic due to the difficulty in getting patients to present at the onset of 
spontaneous attacks. Hence, it is useful to be able to induce attacks of migraine in 
patients that already suffer from the disorder, an example of which was the use of red 
wine. The most widely used and best characterised is the glyceryl trinitrate (GTN) 
model (Iversen et al, 1989). The GTN model has provided considerable information 
on the changes in regional cerebral blood flow, cranial arterial dilatation and CGRP 
efflux occurring during a migraine attack. Human experimental data has made it 
possible to develop a number of animal models of components of migraine. No animal 
models are currently available that reflect the clinical picture of a full migraine attack 
and it is unlikely that it will ever be possible to develop such a model due to the 
varying pharmacology between species. However, pre-clinical research into different 
phases of the attack, such as aura and pain, are continually increasing knowledge of 
pathological events that may underlie each stage.
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1.7.1 Neuronal sensitisation as a model o f migraine pain
The development of models which reflect the pain phase of migraine have focused on 
the sensitivity seen clinically, where patients frequently report pain to normally 
innocuous stimuli such as head movement and light touch of areas innervated by the 
trigeminal nerve including large areas of the face on the side of the headache. This 
increased sensation is known as allodynia and is often accompanied by hyperalgesia, 
defined as an amplified response to noxious stimulation. Both phenomena are present 
in most forms of clinical pain, hence there has been a huge research effort to more 
fully characterise their underlying cellular mechanisms in the spinal cord, although 
similar investigations in the VBNC have only been evident in the last few years.
At present, it is thought the processes of peripheral and central sensitization account in 
some part for clinical pain sensitivity. Peripheral sensitization describes how 
peripheral sensory receptors may respond following exposure to algesic mediators 
such as might be released during times of inflammation or tissue injury. Central 
sensitization describes an alteration of the behavior of second order neurons within the 
central nervous system. The concept that CNS changes occur following noxious 
stimulation has now been unequivocally shown. It has been demonstrated that noxious 
peripheral stimuli produce changes in the sensitivity of dorsal horn neurons to further 
stimulation (Kenshalo et al., 1982) and that a primary afferent input triggers sustained 
increases in central excitability (Woolf and Wall, 1983, 1986). Noxious stimulation or 
injury has also been shown to produce dramatic alterations in spinal cord function, 
including sensitization, wind-up, or the expansion of the receptive fields of spinal 
neurons. In addition to a neuronal hyperactivity, a variety of cellular and molecular
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changes that affect membrane excitability and induce new gene expression have been 
proposed to occur (for review see Coderre et al, 1993, 1997).
A common model to study sensitization at the single cell level is the "windup” 
phenomenon (Woolf, 1983; Woolf & Wall, 1986; Thompson et al., 1990). Action 
potential windup (or windup) is an increase in the number of spikes generated by a 
neurone after each successive stimulus (of appropriate strength) during a pulse train 
following activation of dorsal root thin fibres (Mendell & Wall, 1965, McMahon et 
al., 1993; Urban et al., 1994). Although sensitization can be induced by stimuli other 
than the one used in windup, the sensitivity to receptor blockers and the time course 
remain very similar, thus suggesting common underlying mechanisms.
The investigation of receptor mechanisms involved in sensitization and wind-up 
initially focused on the NMDA glutamate receptors (Wigstrom & Gustafsson, 1986; 
Faden et al., 1988; Davies & Lodge, 1987; Dickenson & Sullivan, 1990; Thompson et 
al., 1990). The voltage-dependence of NMDA receptors (where by membrane 
depolarization removes their Mg -dependent block; Mayer et al., 1984; Nowak et al., 
1984) places NMDA receptors in an ideal position to generate sensitization since the 
cumulative depolarization would trigger a self-reinforcing excitatory phenomenon. 
However, windup in dorsal horn superficial neurons has been suggested to be 
mediated by an NMDA receptor independent mechanism (Dickenson & Sullivan,
1999) suggesting that the role of NMDA receptors in windup might depend on the 
particular cell type examined or its functional conditions (Dickenson & Sullivan, 
1990).
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Substance P, has also been shown to have a role in wind-up and sensitization as 
tachykinin antagonist SR 140333 (selective for NKi receptors) produced a significant 
reduction in the rate of rise of cumulative depolarization and abolished action potential 
windup (Baranauskas et al., 1995, 1996). However, the exact role of substance P 
remains is unknown, a major function of substance P in sensitization (Wiesenfeld- 
Hallin et al, 1991) and a requirement for NMDA and NK receptor co-activation (Xu 
et a l , 1992; Thompson et al., 1993) have both been suggested.
Other receptor systems suggested to have a role in wind-up and sensitization include 
serotonin 5-HTia receptors (Gjerstad et a l , 1996), adrenoceptors (Reeve & 
Dickenson, 1995), metabotropic glutamate receptors (Boxall et al., 1996), opioid 
receptors (Stanfa et a l, 1992; Chapman et a l, 1994), TRH receptors (Chizh & 
Headley, 1996) and muscarinic cholinoceptors (Bleazard & Morris, 1993). Excitatory 
responses induced by dorsal root stimulation in the spinal cord are also under 
inhibitory control by both GABA and glycine receptors (Sivilotti & Woolf, 1994; 
Wilcox et al., 1996) although it is unclear how much these inhibitory mechanisms 
contribute to windup.
A further possible origin of central sensitisation is an imbalance in the descending 
influences from the brainstem, either an increased facilitatory pathway or a decreased 
inhibitory tone following a pathological event such as might occur to initiate a 
migraine attack. Alternatively, the degree of descending inhibitory tone might be 
genetically set to a lower level in migraineurs, explaining why some environmental
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factors, certain food types and emotional stress can trigger attacks in susceptible 
individuals.
The theory of peripheral sensitisation within the dura mater as a generator of central 
sensitisation in migraine pathology has also been investigated (for review see Burstein,
2001). One hypothesis suggests that following a cortical disturbance, as some believe 
to be the "trigger" phase of migraine, potassium and hydrogen ions are released into 
the extracellular space (Bolay et al, 2002). These ions may then induce activation of 
peripheral nociceptors with subsequent release of mediators such as CGRP, 
prostanoids, bradykinin, serotonin and histamine, which further sensitise the peripheral 
receptors, resulting in a lowered threshold of activation. In regions where these 
receptors are associated with blood vessels, the pulsatile flow of blood under these 
sensitised conditions may then be sufficient to activate these receptors, providing one 
explanation for the throbbing nature of migraine pain.
Peripheral dural sensitisation has been explored in the anaesthetised rat, where an 
inflammatory cocktail was applied to the dura mater and the response of second-order 
neurons in laminae IV and V of the Vc to dural and facial stimulation examined. 
Profound sensitisation of both the dural and FRF was seen to thermal, mechanical and 
electrical sensitisation that lasted for up to 10 hours (Burstein et al., 1998). This 
corresponded well with data from a later clinical study that assessed pain thresholds 
during a migraine attack with the finding that more than 70% of patients developed 
cutaneous allodynia ipsilateral to the headache (Burstein et al., 2000). The study also 
found that at later time points, allodynia could also be detected in the contralateral 
head and forearms, which led the authors to suggest that not only did peripheral
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sensitisation in the dura result in central sensitisation of Vc neurons but also of 
brainstem neurons such as third order neurons in the thalamus. Another significant 
finding of the study was the time-dependence (i.e. the duration that individuals had 
suffered from migraine) in the development of cutaneous allodynia implicating that 
the strength of the synapses that facilitate central sensitisation increases after repetitive 
use.
1.7.2 Electrophysiology
1.7.2,1 Human studies
Electrophysiology has been used in humans to determine the role of the VBNC in 
trigeminal function during a migraine attack by the use of a technique known as the 
blink reflex. In this reflex, electrical pulses or radiant heat is used to stimulate the 
supraorbital nerve, which activates primary afferents, synapsing in the Vc to exert the 
efferent blink effect via the facial nerve. The resulting electromyogram response 
determined by non-invasive surface electrodes, has three components named Rl, R2 
and R3. Both Rl and R3 can be triggered by stimuli in the innocuous range (Ellrich et 
al., 2001b), where as R2 can by elicited by selective activation of nociceptors by the 
use of a newly developed concentric stimulating electrode which only stimulates the 
superficial A-5 and C-fibres (Kaube et al., 2000). Several studies have now 
demonstrated a facilitation of this nociceptive-specific component of the blink reflex 
during migraine attacks, indicating central sensitisation of nociceptive circuitry during 
migraine (Katsarava et al., 2002; de Tommaso et al., 2002).
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1.7.2.2 Animal studies
Electrophysiological recordings in anaesthetised animals are an extremely useful tool 
for assessing how either a single neurone or a population of neurones may respond to a 
specific stimulus. With relevance to migraine pathophysiology, this has been carried 
out in both trigeminal ganglion and VBNC neurons and more recently on brainstem 
neurons. Further details of methodology are provided in Chapter 2.
1.7.3 Neuropeptide release
In human studies, CGRP levels are elevated in the jugular vein during a migraine 
attack (Goadsby, 1990). This corresponds well with animal data, where stimulation of 
the superior sagittal sinus results in the release of CGRP in both cat and rat (Zagami et 
al., 1990). Stimulation of the trigeminal ganglion increases both CGRP and SP levels 
in humans and cats (Goadsby et al., 1988), which given the failure of SP antagonists in 
migraine, may indicate better predictability in pre-clinical models could be obtained 
by specific stimulation of the durovascular afferents rather than the trigeminal 
ganglion.
Recently, an in vitro method of examining the release of neuropeptides and other 
mediators in the dura mater has been described (Ebersberger et al., 1999). In these 
studies, a rat skull was divided in two and bathed in a synthetic interstitial fluid 
allowing the effects of trigeminal ganglion stimulation to be assessed by use of 
enzyme immunoassays on the superfusate collected. It is also possible in this model to 
introduce drugs and chemical mediators into the synthetic interstitial fluid and assess 
effects.
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1.7.4 Plasma protein extravasation (PPE) and neurogenic inflammation
The possible involvement of a neurogenic inflammation within the dura mater during 
the pain phase of migraine was first suggested by Moskowitz (1984). This group 
showed that following electrical stimulation of the trigeminal ganglion, leakage of 
plasma proteins could be detected in the rat dura and retina, as measured by iodine- 
radiolabelled albumin. However, there is currently no evidence of plasma protein 
extravasation occurring clinically during acute attacks of migraine or cluster headache 
when MRI scanning of patients (Nissila et al., 1996) or retinal angiography (May et 
al, 1998) has been carried out. Stimulation of the trigeminal ganglion, also results in a 
neurogenic vasodilatation, with resultant increases in cerebral and extracerebral blood 
flow observed in several species, including human (Goadsby, 1997). In rats and cats, 
this effect can be blocked by the CGRP antagonist, CGRP8-37, indicating it is the result 
of CGRP release from trigeminal sensory nerves (O'Shaughnessy & Connor, 1994; 
Wei etal., 1992).
Interestingly in rat models of neurogenic inflammation induced by trigeminal ganglion 
stimulation, neurogenic vasodilatation and plasma protein extravasation have been 
shown to be differentially affected by 5-HTib/id agonists (Shepheard et al., 1997). It 
appeared that inhibition of plasma protein extravasation was due to an action through 
the 5-HTid receptor where as inhibition of dural vasodilatation was due to an action at 
the 5-HTib receptor. Furthermore, the stimulation parameters required to elicit a 
neurogenic vasodilatation were much lower than stimulation parameters required to 
elicit plasma protein extravasation indicating that activation of different trigeminal
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obtained by using laser Doppler studies. Details of this technique are discussed further 
in Chapter 2.
L 7.6 Molecular markers
The investigation of molecular events underlying the neuroplastic response to nerve 
stimulation and injury has provided significant advances in the understanding of 
various pain states in recent years. In particular, expression of the c-fos gene following 
noxious but not innocuous stimulation has been observed in the spinal cord and is 
considered a useful marker of neuron activation (Hunt et al., 1987; Munglani & Hunt, 
1995; Naranjo et al., 1991; Sagar et al., 1988). Fos is an acronym of the words: Finkel, 
Osteogenic and Sarcoma, used to describe the gene encoded by the Finkel-Bislis- 
Jinkins murine osteogenic sarcoma retrovirus. This ‘Viral-fos” and other immediate 
early genes were shown to be capable of inducing cellular proliferation and as such, 
are now known as proto-oncogenes. Many of these proto-oncogenes have now been 
identified in cells and share the property of rapid induction following stimulation 
without the need for protein synthesis (Evans, 1995). They are thought to regulate 
long-term cellular function by altering the downstream expression of target genes, 
through interaction with several second messenger systems, following an increased 
intracellular calcium concentration induced by the action of various neurotransmitters 
(Armstrong & Montminy, 1993; Lerea & McNamara, 1993; Peunova & Enikolopov, 
1993).
The induction of cellular fos {c-fos) has proved to be an extremely useful marker of
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those cells in the spinal cord that are activated by peripheral noxious stimulation 
(Sagar et al, 1988). This is supported by the observation that ybs-expression is 
restricted to laminae, I, II and V of the spinal cord, which receives input from A5 and 
C-fibres associated with the transmission of noxious signalling, c-fos mRNA can be 
observed minutes after a stimulus and the c-fos protein, 1-2 hours after stimulation, 
allowing large sections of brain and spinal cord to be analysed for either fos mRNA or 
protein and correlated with anatomical pathways known to be activated by a particular 
stimulus.
The long-term cellular effects of c-fos activation are thought to be mediated through 
the formation of a complex between c-fos protein and c-jun protein (a product of 
another immediate early gene). This protein complex, in turn, forms part of the API 
transcription factor complex, which is able to alter the expression of various 
transcription genes, ultimately resulting in a modification of cellular behaviour (Chiu 
et al., 1988; Halzonetis et al., 1988). Hence, in addition to providing a marker of 
neuronal activation, c-^bs-expression is likely to provide an indication of the location 
of a neuroplastic response to noxious stimulation.
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Kinase
cascade
Nucleus
Neurotransmitters 
Depolarisation- 
Neurotrophic factors
Figure 8 c-Fos expression
Factors such as neurotransmitters and hormones lead to an influx o f intracellular 
calcium which activates kinase cascades which ultimately result in the 
phosphorylation o f transcription factors such as fos and jun. Fos is then able to form a 
heterodimeric complex with other nuclear proteins o f the Jun family. This complex 
then binds to DNA, where it exerts its effects on expression o f target genes, resulting 
in long-term cellular changes. The action o f the fos-jun complex is then eventually 
terminated by the action o f phosphoprotein phosphatases.
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The expression of c-fos has been studied in several experimental models of migraine 
and headache. In particular, c-fos expression has been observed in lamina 1 and 2 of 
the Vc after stimulation at various sites in the trigeminovascular system, including the 
meninges (Nozaki et al., 1992), the trigeminal ganglion (Markowitz et al., 1988) and 
the SSS (Kaube et al., 1993b). Furthermore, c-fos expression in the Vc has been 
shown to be modulated through an action at 5-HTiB/id, NMDA and glutamate receptor 
(for review see Mitsikostas & Sanchez, 2001) and is such, an extremely useful tool for 
identifying the nature of the nociceptive input peripheral trigeminal structures.
1.7.7 Brainstem manipulations
This is a relatively unexplored area of migraine research but has huge potential in the 
development of models with relevance to the pain phase, the trigger phase and 
premonitory phase of migraine. Recent exciting new data showed the activity of Vc 
neurons as assessed by electrophysiology could be modified by selective blockade of 
P/Q type calcium channels in the PAG using a micro-injection system (Knight et al.,
2002). Further exploration of this area is possible using the technique of ionophoresis, 
where an electrode containing micropipettes of drug solutions can be inserted into the 
area of interest and the required drug solution expelled (Storer & Goadsby, 1997).
1.7.8 Models of aura- cortical spreading depression (CSD)
The phenomenon of cortical spreading depression (CSD) has developed from the 
observations of Lashley (1941) who estimated that his own visual symptoms
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preceding migraine were spreading over the cortex at rate of about 3mm each minute. 
These observation correlated well to the description by Leao (1944) of a progressive 
shutdown of cortical function with inhibitory waves moving slowly over the cortex at 
a speed of 2-3mm each minute and suppressing normal neuronal activity in the animal 
brain (Leao, 1944).
Subsequent blood flow studies in migraine patients have shown that a "wave" of 
oligaemia spreads over the cortex at a similar speed (Lauritzen, 1983), which led to the 
conclusion that spreading oligaemia was responsible for the spread of fortification 
spectra and other neurological symptoms described as aura (Lauritzen, 1994). 
Extensive animal studies have since ensued, with reports of models of progressive 
inhibitory neuronal waves passing over the cerebral cortex, preceded by a transient 
excitation, following a stimulus such as application of potassium chloride to the 
cortex. However, correlation of CSD in animals with aura phenomena observed in 
patients is only speculative. The importance of studying aura, given that only a small 
number of patients report aura like symptoms is uncertain. However, it is possible that 
the manifestation of visual symptoms is related to a threshold and these cortical waves 
are the trigger for both migraine with aura and migraine without aura but do not reach 
a sufficient level to trigger visual symptoms in migraine without aura patients.
1.7.9 Functional imaging
The technique of positron emission tomography (PET) provided evidence for the 
involvement of the rostral brainstem during spontaneous migraine attacks in migraine 
without aura sufferers (Wellier et al., 1995). The study also showed that the activation
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persisted after treatment aborting the head pain, indicating a fundamental role of the 
area in migraine pathophysiology, rather than simply a response to pain. Further 
functional imaging studies would be extremely useful in migraine research, however 
the expense and limitation of equipment severely limits the technique.
1.8 Drug treatments for migraine
An accurate diagnosis is crucial in the treatment of migraine, however given the large 
array of headache disorders and the varied symptoms associated with each, migraine is 
estimated to highly under-diagnosed. When a patient presents with migraine 
symptoms, other co-morbid illness should be investigated to ensure drug interactions 
are not underlying the onset of headache symptoms. Factors such as pregnancy, 
menopause and the use of oral contraceptives, also have significant implications for 
migraine and care needs to be taken to consider this. Once a diagnosis of migraine has 
been established, patients need to be educated about their condition and the avoidance 
of triggers, in order to maximise the efficacy of pharmacotherapy. In general, migraine 
pharmacotherapy involves either or both prophylactic and acute medication depending 
on the frequency and severity of attacks.
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Migraine triggers
Diet
Sleep
hormonal changes
environment
stress
Alcohol
Alteration in pattern 
Menstruation, Oral 
contraceptives 
Climate changes 
Anxiety__________
Table 4 Migraine triggers
1.8.1 Pre-emptive treatment
In those patients who can predict the onset of a migraine attack by the presence of 
premonitory symptoms, administration of 30-40mg domperidone has been found to be 
effective in preventing development of the headache in some patients (Waelkens,
1.8.2 Anti-Emetics
Many migraine patients suffer nausea and vomiting, which they may find more 
distressing than the associated head pain; hence, anti-emetics should be a 
consideration in the drug treatment for migraine. Both the chemoreceptor trigger zone 
(CTZ), located in the fourth ventricle and the vomiting centre, which receives input 
from the CTZ, as well as other higher centres and the upper gastrointestinal tract are 
the site of action for anti-emetics. The CTZ lies outside the brain-barrier and hence is 
subject to activation by many toxins. It is the site of action of anti-emetics such as 
domperidone, metoclopramide and the phenothiazines, which all have dopamine 
antagonist properties. The vomiting centre is also rich in muscarinic, cholinergic and 
histamine receptors that are also the site of action of anti-emetics, such as
1981).
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butyrophenones and phenothiazines. There is limited clinical data concerning the 
efficacy of anti-emetics in the treatment of migraine but as gastric stasis and delayed 
gastric emptying are commonly associated with migraine (Boyle et al., 1990), pro- 
kinetic anti-emetics, which promote gastric emptying, are the first choice treatment.
1.8.3 Acute treatment
1.8.3.1 Ergot Alkaloids
For over a century, ergot alkaloids were the drug of choice for the treatment of head 
pain with medical reports of their efficacy as early as 1883 (Eulenburg, 1883). Ergots 
are powerful vasoconstrictors; however, their effects are long lasting and not specific 
to cranial vessels. Their wide action on adrenergic and dopaminergic systems results 
in a side effect profile of dysphoria, nausea, emesis and cardiovascular effects, which 
limits their therapeutic use. However, they are still used sparingly in migraine, in 
certain specific settings (Tfelt-Hansen et al., 2000).
It is largely due to the potent vasoconstrictor action of the ergot derivatives that the 
vascular theory of migraine was formulated by Graham & Wolff in 1938. Further 
study of ergot derivatives identified other mechanisms of actions, such as the 
inhibition of neurogenic inflammation (Saito et al., 1991) and central inhibition of 
trigeminal pain pathways (Goadsby, 1991; Hoskin et al., 1996), all of which has 
significantly advanced our understanding of migraine pathophysiology. However it 
was the studies of Saxena (1972), using methysergide, an ergot derivative and 5-HT 
antagonist that generated a significant advance during the last decade in acute 
migraine therapy, by providing the rationale for the development of the triptans.
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1.8.3.2 Triptans
The late eighties saw the development and marketing of the first 5-HT ib / i d  agonist, 
sumatriptan for the specific treatment of migraine (Humphrey et al., 1990). 
Sumatriptan was not only a breakthrough treatment but it also altered clinical and 
scientific opinion on the characterisation of migraine as a recognised disease. 
However, there were significant problems with oral bioavailability, slow onset of 
action, brain penetration and headache recurrence. The availability of a subcutaneous 
injectable form of the drug, and later as a suppository and intranasal spray, removed 
many of these problems. However, a significant number of patients still do not 
respond to sumatriptan and many are left with some residual head pain. A further 
problem with sumatriptan is the constriction of peripheral vessels and the contra­
indication in-patients with history of ischemic heart disease. As a result many so- 
called "second-generation triptans" have been developed, notably naratriptan, 
rizatriptan, zolmatriptan, eletriptan, almotriptan and frovatriptan each with a literature 
suggesting benefits in onset of action, recurrence rate or adverse event profile, placing 
the responsibility on the physician to determine the right triptan for the patient.
Much work has been carried out to determine the mechanism of the anti-migraine 
activity of the triptans. However, until recently, work has been hampered by the lack 
of highly selective 5-HTi agonists. The development of highly specific polyclonal 
antibodies to both the 5-HTjb and the 5-HT id receptors has allowed determination of 
their anatomical distribution. In the human, a rich density of 5-HTib but not 5-HTid 
receptors has been identified in the medial layer of the MMA (Nilsson et al., 1999).
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Both 5-HTib and 5-HTjd receptors have been identified on human trigeminal 
ganglion, although in studies on trigeminal nerve fibres, only 5-HTid 
immunoreactivity was observed, with immunoreactivity observed on both peripheral 
projections to the dura mater and central projections to the Vc (Longmore et al., 
1997). However, in the rat, autoradiographic receptor mapping studies have identified 
5-HTib receptors in the spinal trigeminal tract (Bruinvels et al., 1994) and 5-HTib / id  
receptors on cell bodies of trigeminal neurons, Vc and in the spinal cord at the level of 
C , / C 2.
Several possible sites of action for the triptans have been identified and an effect at all 
sites is likely to contribute to the overall anti-migraine activity. In the first instance, a 
selective cranial vasoconstrictor effect has been demonstrated for all available triptans, 
lending weight to the theory developed by Wolff in the 1940's that during an attack, 
cranial vessels become excessively distended resulting in activation of the trigeminal 
sensory fibres innervating them. Of the triptans, sumatriptan has been studied most 
extensively for it's vasoconstrictor effect, which is now generally accepted to be 
mediated through the 5-HTib receptor, and hence it is likely that the observed 
craniovascular selectivity seen over coronary arteries may be explained by the relative 
density of 5-HTib on cranial and coronary vessels (Villalon et al., 1999).
Activation of the trigeminal nerve has been extensively studied in animal models as 
detailed earlier, with the aim of further understanding how this system may 
dysfunction in migraineurs. The triptans have been tested for efficacy in peripheral 
models such as PPE, intravital microscopy and neurogenic inflammation and in all 
cases have inhibited trigeminal nerve activity. However, it should be remembered that
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other classes of drugs such as the neurokinin-receptor antagonists, are also able to 
inhibit PPE but are not effective in the treatment of migraine. Naratriptan and 
Zolmitriptan are also able to block electrophysiological recordings and c-fos 
expression in the Vc following stimulation of the dural receptive field (Goadsby & 
Hoskin, 1996; Goadsby & Knight, 1997). This effect appears specific to the 
trigeminal system as no effect on lumbar dorsal horn responses linked to sciatic nerve 
stimulation is seen following triptan administration (Cumberbatch et al., 1997).
Further to an action through the 5-HTib / id  receptors, many of the triptans also have 
affinity for the 5-HT if receptor. The selective 5-HTif receptor agonist, LY334370 (Eli 
Lilly) has recently been developed and has been found to be effective at inhibiting 
both neurogenic vasodilatation and firing of second order neurons within the Vc, 
without any vasoconstrictor effects on cerebral arteries in vitro (Shepheard et al., 
1999). It has also proved successful in the treatment of acute migraine in a randomised 
controlled trial (Goldstein et al., 2001).
1.8.3.3 Non-steroidal anti-inflammatory drugs
Non-steroidal anti-inflammatory compounds have been used since the time of the 
Hippocrates, 2000 years ago for the treatment of pain (Butler, 1998; Levesque & 
Lafont, 2000). Since the isolation of acetylsalicylic acid from extracts of willow bark, 
many other non-steroidal anti-inflammatory drugs’ (NSAID’s) have been synthesised 
with different properties. However, all NSAIDs are weak organic acids, with the main 
mechanism of action being prevention of the prostaglandin synthesis from arachidonic 
acid with anti-inflammatory, analgesic and anti-pyretic activity. The mechanism of
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action of NSAIDs in headache is not fully understood but in animal models, they are 
effective they have been reported to inhibit both neurogenic inflammation and firing of 
Vc neurons, suggesting a combination of central and peripheral mechanisms (Buzzi et 
al, 1989; Kaube et a l, 1993a).
Initial trials using NSAID's for the treatment of migraine were limited in success, 
however this was later discovered to be due to the lack of absorption due to the 
delayed gastric emptying seen during migraine. Recent trials where NSAIDs have 
been co-administered with anti-emetics, have shown the combination to be as effective 
as the triptans (Diener, 1999), warranting further investigation to the mechanism of 
action of NSAIDs and the role of prostanoids in migraine. There has also been recent 
interest in the new class of NSAIDs, which selectively inhibits the COX-2 enzyme and 
are associated with a lower risk of gastrointestinal side-effects. Preliminary trials for 
migraine with rofecoxib (a COX-2 inhibitor) have indicated that while it is effective in 
long-lasting reduction of headache and in reducing photophobia, phonophobia and 
nausea (Silberstein et al, 2004), it offers no superiority over ibuprofen (Misra et al, 
2004). However, a combination of rizatriptan and rofecoxib reduced headache 
recurrence rates, was well tolerated and was suggested to be more effective than the 
use of rizatriptan alone (Krymchantowski & Barbosa, 2002).
1.8,3.4 Opioids
Opioids describe a group compounds with morphine like activity. Analgesia induced 
by this class of compounds occurs at several spinal and supraspinal sites. Agonists 
acting at post-synaptic mu receptor sub-type can selectively inhibit nociceptive
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transmission and agonists acting at pre-synaptic kappa, delta as well as the mu 
receptors inhibit the release of transmitters involved in pain transmission (such as 
glutamate and substance P). Opioids are also able to cause direct hyperpolarization of 
post-synaptic cells in the trigeminal nucleus caudalis and dorsal hom, hence reducing 
pain transmission into the brainstem (Storer et al, 2003; Williamson et al, 2001). The 
use of opioids to treat migraine is controversial and due to their addictive properties, it 
is recommended that use by restricted to patients not responding to other medication, 
pregnant patients or patients who are unable to take headache medication due to drug 
interaction with other treatment regimens (Silberstein & McCrory, 2000).
1.8,3.5 Miscellaneous drugs
A wide range of drugs other than triptans, ergots or NSAIDs are currently used for the 
acute treatment of migraine however, there is not significant evidence from controlled 
trials to indicate superiority over placebo for many of them. Isometheptene, a 
sympathomimetic amine, is widely used in countries such as the United States of 
America for the treatment of mild migraine, largely due to its safer cardiovascular 
profile than the triptans. Intranasal lidocaine, corticosteroids, magnesium, calcium 
antagonists, nitric oxide synthase inhibitors (Blanda et al, 2001; Lassen et al., 1998,
2003) and beta-blockers have also been explored as acute treatments with little success 
to date.
Despite the lack of success in the generation of a safer, efficacious migraine treatment, 
clinical trials have aided in the development of understanding in migraine. The failure 
of the NK-1 receptor antagonists (Diener et al, 1995, 2003; Connor et al., 1998;
-74-
Goldstein et al., 1997) and similarly the endothelin antagonists (Brandli et al., 1996; 
Clozel et al., 1994) to work in acute migraine, despite efficacy in some pre-clinical 
models, has necessitated the development of new animal models.
1.8.4 Prophylactics
The use of preventive treatment in migraine is usually considered for patients where 
attacks are occurring three times a month or more, or for patients suffering less 
frequent but more severe attacks, or where a specific trigger exists for attack, e.g. 
indomethacin is effective in preventing an attack if taken before exercise in those 
patients where exercise is a trigger factor. The advances in prophylactic treatment are 
significantly behind those made in acute treatment and no pattern has been established 
of how patients respond to the available medications, emphasising the likelihood that 
migraine is indeed a multifactoral disease. Hence, migraine prophylaxis is largely a 
case of trial and error.
1.8.4.1 P-blockers
Following the introduction of P-blockers for cardiac disorders in the 1960's, their 
effectiveness in reducing migraine frequency was serendipitously discovered shortly 
after (Rabkin et al., 1966). They are currently the first choice for migraine prophylaxis 
and between 60 and 80% effective in reducing the frequency of attacks by half. The 
mechanism of action of p-blockers is unknown and despite distinctive 
pharmacological profiles of the different drugs in this class such as blood brain-barrier 
penetration and receptor selectivity, (at least three types of P-adrenergic receptor sub- 
types are known to exist), no advances have been made in this area. Discovery of the
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mechanism of action is further hampered by the lack of animal models of prophylaxis.
1.8.4.2 Anti-convulsants
The use of anti-convulsant medication for migraine prophylaxis is becoming 
increasingly common due their proved effectiveness in clinical trials. The anti­
convulsant activity of most of the drugs in this class is thought to be due to a state- 
dependant blockade of voltage dependant sodium or calcium channels or an ability to 
enhance the activity of GABA at GABAa receptors through a chloride conductance 
(Rogawski & Porter, 1990; MacDonald & McLean, 1986).
1.8.4.3 Serotonin antagonists
The ergot derivative, methysergide, was the first available treatment for migraine 
prophylaxis with reasonable efficacy in reducing migraine frequency, however its 
significant side effect profile restricts its use. Methysergide is a potent 5-HT2 
antagonist at the 5-HT2B and 5-HT2C receptor but also acts at an agonist at the 5-HTjb 
receptor. Its mechanism of action is still debatable and theories include a 
vasoconstrictor activity within the carotid vascular bed (Saxena & Verdouw, 1984) 
and pre-synaptic inhibition of CGRP release from perivascular sensory nerves 
(Moskowitz, 1992).
1.8.4.4 Antidepressants
Anti-depressants of all classes (monoamine oxidase inhibitors, tricyclics and selective 
serotonin re-uptake inhibitors) have been assessed in both migraine and headache
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prophylaxis. Due to the wide range of actions throughout the different classes of anti­
depressant drugs, their mechanism of headache prophylaxis is uncertain but it does not 
result from treating masked depression as the response to treatment is considerably 
more rapid than the expected onset of any anti-depressant effect (Couch et al., 1976). 
However most antidepressants that are clinically effective for headache prophylaxis 
can either inhibit 5-HT reuptake or are antagonists at the 5-HT2 receptor (Richelson, 
1990).
1.8.4.5 Botulinum toxin A
Clinical data has demonstrated that Botulinum toxin A (BTX-A) is an effective and 
well-tolerated therapy for the prevention of migraine and other headache disorders 
(Blumenfeld et ah, 2004) Injection of BTX-A directly affects neuromuscular 
signalling processes by inhibiting the vesicular release of the acetylcholine (ACh) 
neurotransmitter at the neuromuscular junction. Although inhibition of neuromuscular 
activity may alleviate a portion of the pain associated with headache disorders, it does 
not fully explain the pain-relief mechanisms mediated by BTX-A. It has now been 
suggested that BTX-A may interact with several other neuronal-signalling pathways, 
although the exact mechanisms remain elusive. Current data suggests that BTX-A 
modifies the sensory feedback loop to the central nervous system by blocking 
intrafusal fibres, resulting in decreased activation of muscle spindles. This effectively 
alters the sensory afferent system by reducing the traffic along la spindle afferent 
fibres (Rosales et al., 1996). BTX-A also appears to inhibit the release of glutamate 
and CGRP from primary afferent nociceptive fibres, reduce the firing of wide- 
dynamic-range neurons within the dorsal horn of the spinal cord, and reduce the 
activity of central nociceptive neurons, as demonstrated by decreased expression of
-77-
immediate early genes (<c-Fos) after nociceptor stimulation (Aoki, 2002). A reduction 
in afferent sensory activity coming from pericranial and cervical muscles, and 
inhibition of peripheral and central trigeminal sensitization, may be the potential 
mechanisms by which BTX-A exerts its therapeutic effect in migraine, tension-type 
headache, and other primary headache disorders (Burstein et al, 2000).
1.8.4.6 Miscellaneous drugs
Prophylaxis has also been explored with histamine, clonidine (a-2-adrenoreceptor 
agonist), the herbal treatment feverfew, magnesium and amantadine (for review see 
Siberstein et al., 2001). Although trials have been small and not statistically powered, 
some efficacy has been suggested with magnesium and feverfew. Interesting 
laboratory data has demonstrated a possible reduced brain tissue magnesium 
concentration during a migraine attack and a reduced magnesium content in 
erythrocytes, serum, CSF, and saliva both during an attack and interictally (Mauskop 
et al., 1998; Peikert et a l , 1996).
1.9 Genetics of Migraine
Within the general population, 12-16% of the population suffers recurrent attacks 
fulfilling IHS criteria to be classified as migraineurs (for review see Ferrari & Hann, 
2001). The question that genetic studies then need to address is the susceptibility of 
certain individuals to this trigger. The inheritance of migraine was reported as early as 
the seventeenth century (Willis, 1682) but despite intensive research over the last forty 
years, it still remains an area of controversy. The lack of clarity may be due to the
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methodological difficulties in examining large patient groups and in many inheritance 
studies, subjects are selected from clinical populations. Family histories are also taken 
from the subjects without relatives being interviewed on a first hand basis, which 
given the subjective nature of the disease is unlikely to provide the degree of accuracy 
required for validity. Further complicating factors in these investigations is the high 
prevalence of migraine, hence a positive family history cannot necessarily be assumed 
to indicate a genetic component.
Despite the issues above, several genetic epidemiological studies have shown an 
increased familial risk amongst first-degree relatives in the development of migraine 
without aura of 1.9 and those with migraine with aura of 3.8 when compared to the 
general population (Russell & Olesen, 1995). Of greater significance in the assessment 
of the contribution of genetic and environmental factors to migraine, is the use of twin 
studies. The basis of twin studies is the comparison of monozygotic (MZ) twins, who 
share all of their genes and dizygotic (DZ) twins, who like ordinary siblings share 50% 
of their genes by descent. In a recent study Ulrich & Gervil (1999), found a higher 
concordance rate for MZ rather than DZ twins in both migraine with aura and 
migraine without aura, however as the concordance rate was less than 100%, 
multifactoral inheritance (i.e. environmental and genetic factors) is likely to influence 
the development of the disease. Other studies have also shown that genetic 
heterogeneity (i.e. the development of the migraine phenotype resulting from different 
genotypes) is likely to be responsible for both migraine without aura and migraine 
with aura (Ulrich et al., 1997).
Due to the likely multifactoral nature of migraine without aura and migraine with aura,
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little progress has been made in the identification of candidate genes. However, 
significant advances have been made in the study of familial hemiplegic migraine 
(FHM), a rare autosomal dominant subtype of migraine with aura. Patients suffering 
with FHM, as well as having either typical migraine without aura or migraine with 
aura, experience attacks characterised by migrainous head pain, nausea, photophobia 
or phonophobia accompanied by hemiparesis and in some patients, progressive 
cerebellar ataxia has also been reported (Hann et al., 1997). In the early 1990's, genetic 
studies identified a linkage of FHM patients to chromosome 19pl3 markers, in over 50 
% of cases (OphofF et al., 1994). Further studies identified the FHM candidate region 
as a aiA subunit gene (CACNA1A) for the P/Q voltage gated calcium channel, 
specifically transcribed in the cerebellum, cerebral cortex, thalamus and hypothalamus 
(OphofF et al., 1996). The potential of a dysfunctional calcium channel in these areas 
is of particular relevance to migraine due to the involvement of these structures in 
controlling descending modulation of areas receiving trigeminal afferent signals. 
Central 5-HT release, which has been strongly implicated in migraine 
pathophysiology, is also controlled by these neuronal calcium channels and hence an 
inappropriate 5-HT level may be involved in the triggering of an attack (Codignola et 
al., 1993).
Despite the demonstration of mutations in chromosome 19 as part of the migraine 
spectrum, additional genes need to be investigated to fully explain the susceptibility of 
some individuals to migrainous symptoms. The last few years have seen an increasing 
interest in this area and several other possibilities have been investigated e.g. increased 
frequency of the dopamine D2 receptor allele (Peroutka et al., 1997), X-chromosome 
linked factors (Nyholt et al., 1998). There is also significant co-morbidity of migraine
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with diseases such as epilepsy, Raynaud’s phenomenon and several psychiatric 
disorders, which may provide future insights to genetic disposition factors. At present 
however, the identification of different mutations between families, on genes such as 
CACNA1A significantly hamper the development of transgenic animal models.
1.10 Summary & Aims
The literature reviewed in this chapter suggests that migraine is an extremely complex 
neurobiological disorder that can be influenced by many factors. Thus, the study of the 
disease is generally considered in different phases, as such this thesis has focused on 
investigation of the part of the migraine attack that results in the actual head pain and 
associated facial allodynia and hyperalgesia. While it is likely that central brain 
structures are crucially involved in this process, there is also considerable evidence to 
suggest that hyperexcitability of the trigeminovascular system is a consequence of 
migraineous pathology. This thesis has focused on possible mechanisms involved in 
the sensitisation of the Vc and sought to characterise whether the differential response 
to dural stimulation under sensitised and non-sensitised conditions is related to the 
clinical difference between migraineurs and non-migraineurs and details of each study 
are summarised in more details below.
1.10.1 Study 1 -GTN  
Glyceryl trinitrate (GTN) infusion in both migraine patients and healthy volunteers 
induces an immediate and often pulsatile headache in nearly all subjects, which in 
healthy volunteers typically subsides at the end of the infusion (Iversen et al., 1989). 
However, a sub-population of migraineurs reportedly develops a migraine headache
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that resembles their own spontaneous migraine headaches, approximately 4 to 5 hours 
after the start of the infusion (Christiansen et al., 1999). Hence, GTN may trigger a 
sequence of intracellular events that are responsible for the generation of some of the 
pathophysiological process that occur during spontaneous migraine attacks. The aim 
of this study was to investigate the effect of GTN on components of the 
trigeminovascular system using intravital microscopy, single unit electrophysiological 
recordings in the Vc and c-fos immunohistochemistry.
The underlying susceptibility migraineurs appear to have to GTN infusion compared 
to non-migraineurs has also been examined by looking at the effect of GTN following 
the induction of central sensitisation. While central sensitisation is generally accepted 
to play a role in the clinical features of migraine (Burstein et al, 2000), the origin of 
sensitisation is unknown with arguments for both a peripheral (Burstein et al., 2001) 
and central driven mechanism (Knight et al., 2002). However, both arguments agree 
that central sensitisation at the level of the Vc is a likely consequence, as such, in these 
studies, inflammatory mediators were injected into the face in areas innervated by the 
second division of the trigeminal nerve. As described earlier, these primary afferents 
synapse in the Vc and show considerable convergence with primary afferent fibres 
innervating dural blood vessels, hence it is likely that peripheral sensitisation of 
primary afferent V2 afferents will generate central sensitization in an area where 
afferents from the dura, synapse.
1.10,2 Study 2-Prostaglandins
PGs were implicated in the pathology of migraine as long ago as 1960's, when PGEi 
infusion in healthy volunteers was found to induce headache and facial flushing in two
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out of three subjects, with one subject, who had no history of migraine, complaining of 
visual symptoms preceding the headache (Bergstrom et al., 1965). This study was later 
expanded and PGEi infusion was reported to induce a pulsating headache in all eight 
subjects studied. In some subjects this was accompanied by migrainous features such 
as aura-like symptoms, temporary unilateral localisation of head pain, abdominal pain 
and nausea (Carlson et al., 1968).
In naturally occurring migraine attacks, PGs have also been identified in the saliva of 
patients (Vardi et al., 1983). Furthermore, a significant increase in the plasma 
concentration of PGE2 during the headache compared to the headache free period has 
been reported in sufferers of menstrual migraine (Nattero et al., 1989). Despite these 
findings, and the known effectiveness of NSAIDs, which have been reported to be 
almost as efficacious as sumatriptan in the treatment of acute migraine pain (Diener et 
al., 1999), it is only in the last few years that experimental exploration examining the 
involvement of PGs in generating head pain has been carried out. Hence, the aim of 
studies in this part of the thesis was to investigate whether PGs can sensitise primary 
afferent fibres innervating the MMA resulting in a facilitated response of Vc neurons, 
leading to the generation of central sensitisation, as assessed by in vivo 
electrophysiology.
1.10,3 Study 3-Wind-up
In this study, we have thus explored whether temporal summation or “wind-up” occurs 
in second-order Vc neurons following activation of dural afferent using an electrical 
stimulation protocol. Wind-up of cells receiving C-fibre input, but not A8-fibre input, 
from cutaneous areas is a well-known electrophysiological phenomenon and can
-83-
generate an experimental state of central sensitisation (Woolf, 1996). The dura mater 
is almost exclusively innervated by A5 and C-fibres (Andres et al, 1987) and while 
cutaneous A5- fibres do not show wind-up, whether visceral A5- fibres are capable of 
“winding-up” is not known. Hence, both the A8 and C-fibre component of the 
response were examined for wind-up and compared to the response of Vc neurons 
receiving cutaneous input form the face. Additionally, as previously discussed for 
study 1, central sensitisation has been reported to occur during migraine and generate 
the facial hypersensitivity reported by migraine patients during an attack (Burstein et 
al 2000). Hence, as part of this study, we have examined whether the experimental 
induction of central sensitisation alters the wind-up response, as previously reported to 
occur in the dorsal horn (Herrero et al, 1996; Stanfa et al., 1992).
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2 Methods
Methodological studies in this thesis largely used the technique of in vivo 
electrophysiology to investigate the activity of second order neurons within the Vc. 
However, the techniques of intravital microscopy and immunohistochemistry were 
also used to support electrophysiological data.
2.1 Electrophysiology and Intravital microscopy
2.L1 Preparatory surgery and anaesthesia
All studies were conducted under terminal anaesthesia in accordance with a project 
license issued by the Home Office of the United Kingdom under the Animals 
(Scientific Procedures) Act, 1986.
Male Sprague-Dawley rats (280-400g) were anaesthetised using isoflurane (3-5% in 
oxygen; Abbott Laboratories Ltd., Kent, UK.). Depth of anaesthesia was assessed by 
the absence of a flexor reflex to pinching of the hind-paw and comeal blink reflex. 
Rectal temperature was monitored and maintained at 37-38°C with a heated blanket 
and thermistor (Harvard apparatus Ltd). Two cannulae (2.5FG and 2FG; 3S 
healthcare, UK.) were placed in the internal jugular vein for constant anaesthetic 
infusion and test compound administration. The carotid artery was exposed and 
cannulated (3FG) with saline containing heparin (10 units ml"1) for blood pressure 
monitoring using a real time analysis programme (Spike 2.01, Cambridge Electronic
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Design, Cambridge, UK). The trachea was then cannulated (6FG; 3S healthcare), 
isoflurane anaesthesia discontinued and a bolus dose of sodium pentobarbitone 
(Saggatal, 20 mgkg'1) given. A constant infusion of sodium pentobarbitone (Saggatal, 
20 mgkg’1 hr'1) was then used to maintain anaesthesia. This anaesthetic regime had 
previously been found in the laboratory to produce a reliable, stable state of 
anaesthesia suitable for invasive surgery over periods of up to 10 hours. Animals were 
mechanically ventilated at a rate of between 85 and 90 cycles a minute (Harvard 
Apparatus Ltd. Edenbridge, Kent, UK). At the end of experiments, animals were 
euthanased by an intravenous injection of pentobarbital (Euthanal).
During optimisation of this method, blood gases measurements were taken at two 
hourly intervals over 8 hours in 10 rats and respiratory rate and tidal volume adjusted 
to optimise parameters using this anaesthetic protocol. It was found that ventilating 
with room air was sufficient to maintain blood gas reading in the range: pCC>2 35- 
45mmHg, pC>2 90+ mmHg, pH of 7.35-7.45 (this is within the physiological range for 
the anaesthetised rat). Due to problems with regular access to a blood gas analyser, in 
subsequent experiments, blood gas measurements were only taken at the end of an 
experiment.
For experiments in study 3 of this thesis, muscular paralysis was required to allow 
electrical stimulation of sensory nerve fibres in the face without generating muscular 
responses. For these experiments, the non-depolarising muscle relaxant, vecuronium 
bromide was administered as a constant infusion (O.lmgkg1 hr'1) during 
electrophysiological recording only. Depth of anaesthesia was assessed by the absence 
of fluctuations in blood pressure and heart rate (using a pulse oximeter; Nonin, UK) 
under veterinarian supervision.
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2.1.1.1 Exposure of the middle meningeal artery
The head of the rat was placed in a stereotaxic frame (Kopf Instruments, Tujunga, CA, 
USA) and a longitudinal incision made in the scalp. The parietal bone of the skull was 
exposed and gently thinned, using a saline-cooled drill (Foredom Electric co., Bethel, 
USA) to visualize a branch of the MMA. Care was taken to ensure that the bone 
membrane remained intact, creating a closed cranial window over the MMA. Bipolar 
stimulating electrodes (Clark Electromedical NEX-200) were then placed into contact 
with the skull over the area of the MMA to allow transcranial stimulation of the 
perivascular neurons innervating the MMA. The area was covered with warm mineral 
oil to prevent drying.
2.1.1.2 Exposure of the trigeminal nucleus caudalis
A skin incision was made from the back of the skull to the level of Ci, the overlying 
neck muscle was separated along the midline using blunt dissection, and held out of 
the way by the use of retractors. The alanto-occipital membrane and dura mater were 
incised to exposure the medulla and the pia mater was left intact. Due to the angle of 
the head, the area was continually bathed in cerebrospinal fluid hence it was not 
necessary to provide additional covering.
2.1.2 Intravital microscopy
The technique of intravital microscopy was developed by Shepheard et al. (1997) for 
the specific non-invasive measurement of the diameter of a particular dural vessel 
through a closed cranial window. Previously, laser Doppler flow measurements were 
used to assess meningeal blood flow as an indication of vascular changes occurring in
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animal migraine models (Kurosawa et al., 1995). However laser Doppler flow 
measurements are reliant on both blood cell velocity and concentration and hence a 
recorded increase in flux, cannot be assumed to be entirely contributable to 
vasodilatation alone. Intravital microscopy now provides a significant advance in the 
investigation of dural blood vessel diameter in studies of both vasodilatation and 
vasoconstriction and avoids many of the problems associated with an open cranial 
window such as brain swelling. The disadvantage of intravital microscopy is the 
necessity to drill the skull over the area of interest to visualise the blood vessel under 
study, which typically result in a constriction of the blood vessel. However, during 
optimisation of this technique, the MMA following visualisation was found to dilate 
maximally within 30 minutes after the cranial window had been formed, with no 
further dilatation observed during an observation period of two hours. Hence, in all 
experiments, the preparation was left for one hour after drilling before experimental 
protocols were initiated.
2.1.2.1 Data measurement
Following formation of a cranial window, the MMA was viewed under green filtered 
light using an intravital microscope (Moritex Europe Ltd.) attached to a computer 
equipped with a WinTV video capture card (Hauppage, U.K.). Dural blood vessel 
diameter was continuously measured using a video dimension analyser (Living 
Systems Instrumentation, USA) and MMA diameter, blood pressure and heart rate, 
were recorded using a Notocord Hem 3.3 Data Analysis system.
2.1.2.2 Analysis o f data
Data was measured in arbitrary units and responses were calculated as the mean
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percentage increase over resting diameter ± standard error of mean (SEM). For 
statistical analysis, data was analysed for significance of drug effects with a repeated 
measure analysis of variance (ANOVA) followed by Bonferroni’s post hoc test for 
multiple comparisons. A probability (P) value < 0.05 was considered significant.
2.1.3 Electrophysiology
In vivo electrophysiology was used for the examination of neuronal activity in the Vc 
resulting from manipulations of the appropriate receptive field. Current technology 
does not permit access directly to the peripherally located sensory receptors, hence 
only indirect interpretations of the events occurring at the sensory nerve ending itself 
could be carried out. The measurement of neuronal activity relies on an electrode that 
detects changes in the concentration of extracellular ions resulting from an alteration 
in membrane potential following the transmission of an action potential. Typically, 
action potentials involve a rapid alteration in membrane potential of around lOOmV 
following an influx of charged sodium and calcium ions into the cell and an efflux of 
potassium ions out of the cell. These conductance alterations result in rapid membrane 
potential alterations that can be measured during electrophysiological experiments.
Electrodes used in this study, were made of tungsten and coated with paraffin along 
the length except for the tip (World Precision Instruments,). The area of the exposed 
tip is directly related to the electrical resistance of the electrode, with small tip 
electrodes having a higher resistance than larger tip electrodes as they restrict the area 
from which potentials can be recorded. The electrodes used for studies in this thesis, 
were purchased with known resistances of 2 ± 0.1 Mil, which is considered to be a 
high resistance electrode and ideal for measurement of single neuronal activity.
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However, the disadvantage of high resistance electrodes is the difficulty in identifying 
cells as the electrode has to be in extremely close proximity to the cell before a signal 
can be detected.
When an electrode is advanced through the Vc, the types of neuronal activity 
encountered include:
a) an injury response; this occurs when the electrode damages cells and results 
in high frequency spikes for a few seconds before the recorded activity is 
“lost”, presumably as the cell dies.
b) spontaneously active cells; these are the most commonly observed cells and 
their activity can be as low as a few spikes per minute to tens of spikes per 
second. The majority of spontaneously active cells encountered during studies 
in this thesis, did not also respond to stimulation such as electrical stimulation 
of the MMA or mechanical stimulation of the FRF.
c) cells responding to stimulation, such as electrical stimulation of the MMA or 
mechanical stimulation of the FRF, which were the cell types used for this 
thesis.
To identify single units within the Vc, activated by either dural or facial stimulation, 
an electrode was lowered into the Vc by use of a micromanipulator (model FMC100, 
Newport Corporation, Irvine CA, USA). The electrode was then advanced through the 
tissue in steps of 15 pm (using the electrical micromanipulator drive), while a search 
stimuli was applied. In some cases this was an electrical stimulus (Harvard Apparatus 
Ltd.) delivered to the MMA at 1Hz, 3mA and 0.3ms and in other experiments, 
involved light stroking of the face using a cotton tip. Identification of a cell whose
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activity was linked to stimulation of the receptive field were assessed both manually 
using an oscilloscope and using an on-line analysis program, which is described more 
fully in appendix B.
The identified cell linked to stimulation was then characterised by latency of response 
(i.e. A-8 or C-fibre), WDR, NS or LT (see section 1.3.6.1), depth of recording and 
amplitude of response. The boundaries for A5 and C-fibre responses were based on the 
observations that following MMA stimulation, two distinct groups of responses were 
seen. The first group of responses appeared 7-25 ms after stimulation, attributed to A- 
5 fibre input, and the second group appeared 40-80 ms after stimulation, attributed to 
C-fibre input. With an estimated conduction distance of 25 mm, and assuming a time 
of 1 ms for synaptic transmission (Eccles, 1964), a range of conduction velocities of 
1.0-4.0 ms"1 for A-8 responses and 0.30-0.65 ms"1 for C-fibre responses was observed, 
in general agreement with standard definitions (Guyton and Hall, 1996).
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2.1.3.1 Data capture
The methodology for extracellular recording of action potentials has changed very 
little during the past 50 years, with the exception of the technology available for the 
processes of data capture. These have progressed from recording nerve activity on tape 
and Polaroid pictures of oscilloscope traces, to the introduction of data-acquisition 
software which not only allows the recording of large quantities of data but also allows 
sophisticated analysis of the raw data. The basic recording set up used in these studies 
is shown diagrammatically below.
Data
storage
Spike
processor
Amplifier 
& filter
i .
o s c i l l o s c o p e
Loud
speaker R e c o r d i n g  
e l e c t r o d e  
&  h e a d s t a g e
Vc
Figure 9 Electrophysiological recording system
Following the detection o f a voltage change in the Vc by a tungsten electrode, the 
signal is amplified and filtered, processed by a PC and observed an a oscilloscope. 
Data is also digitally stored for any off-line analysis.
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To allow experiments to be done without using a faraday cage, the system is grounded 
through the animal and the stereotaxic frame and differential recording allows 
subtraction of the signal from the animal from the neuronal signal. The signal is then 
amplified by the headstage (NL100AK, Neurolog, Digitimer, Herts, UK). The signal 
then passes to an AC-pre-amp module where the signal is split to (1.) an AC amplifier 
(NL104A) and (2.) a digital tape recorder for storage (Sony). If further data analysis is 
required at the end of an experiment, other than that obtained during on-line analysis 
the digital tape can be replayed and is essentially fed through the AC amplifier in the 
same way as the raw signal. From the AC amplifier the signal is filtered (NL125, 
bandwidth 500-5KHz, Neurolog.), to remove background noise and further split to the 
oscilloscope and to a CEDI401 plus (Cambridge Electronic Design) where it is passed 
through an analogue to digital converter before being relayed to a computer with Spike 
2 software (version 2.1).
The characteristics of the neuronal signal were assessed using both an oscilloscope and 
a window discriminator system in Spike 2 software. The width of the window 
discriminator is set at the start of recording to exclude background noise, i.e. such as 
from low level activity in the tissue or from electrical external source. Every neuronal 
spike whose height falls in the window discriminator then results in an electrical pulse, 
which is counted as a single event. The studies in this thesis were designed to follow 
the activity of a single cell. Therefore, the window was set "tightly" around the cell to 
exclude activity from other units in the vicinity of the electrode, such as from 
spontaneously active cells, or other cells that began to respond to stimulation, such as 
occurred during some sensitisation experiments. However, electrodes are susceptible 
to “drift” (i.e. small movement, estimated not to be any greater than 10pm), which
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results in a decrease in the amplitude of the detected signal, possibly as a result of the 
animals respiratory movements or expansion of tissue following small amounts of 
direct heat during microscope placement of the electrode. Hence, a compromise must 
be made when setting the window discriminator between allowing for drift and 
excluding “noise” and other cells.
Stimulus artefact
it*
Electrically evoked 
neuronal response
Upper discriminator 
level
Lower discriminator 
level
Figure 10 Window discriminator to isolate single units
The figure above shows a typical neuronal response recorded in the Vc following 
electrical stimulation o f the MMA. Dashed lines represent the window discriminators 
which could be manually set to optimise recording and exclude baseline variation.
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The output of the window discriminator can then be displayed in various formats in 
spike 2, such as post-stimulus histograms or raster plots (number of events on the Y 
axis and time on the x-axis). In the majority of experiments, analysis was conducted 
throughout the experiment using a script file created using Spike 2 software and a 
detailed account is given in appendix c. In brief, automated analysis was used to count 
the number of events occurring in a defined period after a stimulus, such that cells 
responding with both an A-5 and C-fibre component could be differentially analysed. 
Spontaneous activity could also be distinguished form evoked activity by comparing 
spontaneous activity occurring during periods of evoked activity with that in a time 
period preceding the stimulus. Spontaneous activity could also be assessed during the 
periods in-between electrical stimulation by counting the mean spikes per second. 
Where there was uncertainty that events picked up by the window discriminator were 
generated by the cell under study i.e. if a second cell started to fire or in the presence 
of external electrical noise, off-line analysis was conducted. In the first case the raw 
signal could be played back from the DAT tape and the window discriminator height 
re-set. However if the interference still fell within the discriminator band, the raw 
signal was re-analysed using a waveform discrimination programme in Spike 2. The 
basis of this programme was the separation of different spike shapes onto different 
templates, the DAT was then re-played and events could be differentially analysed 
depending on which template they fell into. If it was still not possible to separate the 
events generated from the cell under test from other events, the experiment was 
excluded. The exclusion of data due to being unable to discriminate single units was 
relatively rare and in the entire course of studies in this thesis, 16 experiments were 
discarded on this basis. However, re-analysis was more common, especially during
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PGE2 (study 2) and GTN (study 1) experiments and approximately 1/10 experiments 
was re-analysed by either resetting the height of the window discriminator or by 
waveform analysis.
2.L3.2 Experimental protocols
Electrical stimulation protocols were driven from a programme designed in Spike2 
software (a detailed explanation can be found in appendix B). Trains of electrical 
stimulation, typically 20 or 50 repetitions at 1Hz, 3 and 5 minutes apart respectively, 
were applied to either the dura mater or face. Baseline evoked neuronal responses 
were established over at least 3 trains of electrical stimulation where a variation in the 
evoked response of less than 10% was considered acceptable. Electrical stimulation 
strength was ideally set to elicit one neuronal response per stimulus (approx. 1.5 X 
threshold), however this was not always possible and in some cases a single stimuli 
resulted in 2-3 responses.
Mechanical stimulation of the FRF was also used in several experiments. 
Characterisation experiments of this methodology used an air jet blower, Von-Frey 
hairs and a cotton tip probe and serrated forceps. The disadvantage of the air jet 
blower in the first case was the inability to test both innocuous and noxious 
stimulation, furthermore, it was extremely difficult to set the pressure to a level where 
it only resulted in the activation of a single unit. Von-Frey hairs generally gave an 
inconsistent response, hence for all studies using mechanical stimulation, a cotton tip 
probe and serrated forceps were used to elicit responses to a light brush and pinch of 
the FRF. The area of the face that was most sensitive to afferent stimulation was
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marked on the face by marker pen (area typically 1 cm) and the response to a light, 
non-noxious 10-second brush and a noxious 5-second pinch stimulation of this area, 
assessed.
2,1,3,3 Analysis of data
Electrophysiological data following electrical stimulation protocols is represented, 
where appropriate, as mean ± standard error of the mean, frequency of response or the 
number of spikes per second. Responses to electrical stimulation of the MMA were 
normalised as the total response to the train of stimulation directly before treatment 
and expressed as a percentage of this response. Mechanically evoked FRF evoked 
responses were normalised with respect to control responses and expressed as a 
percentage of this response. Statistical analysis was carried out as appropriate for 
individual studies and is described more frilly in each section. In all cases, a 
probability (P) value < 0.05 was considered significant.
2 .2  I m m u n o h i s t o c h e m i s t r y
2,2,1 Animal preparation
It has previously been found in our laboratory that the level of c-fos expression in the 
spinal cord is increased if animals are “stressed” before the induction of general 
anaesthesia. Hence, to avoid any undue stress during the induction of anaesthesia, for 
at least a week before the start of an experiment, animals were regularly handled and 
habituated to the anaesthetic induction box. Furthermore, with the exception of one 
study, designed to replicate a previously published study, a period of two hours was
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left between the induction of general anaesthesia and the start of an experimental 
protocol.
The strain of rat (either Sprague-Dawley or Wistar) and the anaesthetic regime used 
for c-fos expression studies are discussed in more detail in the study 1 methods 
section. In all studies, after the induction of anaesthesia, core temperature was 
maintained between 36 and 38°C by means of a rectal probe connected to a 
homoeothermic heating blanket controller and depth of anaesthesia was monitored by 
the absence of withdrawal reflex. At the end of experiments, euthanasia was 
performed using an overdose of sodium pentobarbitone (lOOmg) and perfused 
transcardially with 200 ml of saline containing heparin (10 units ml"1) followed by 500 
ml of 4% paraformaldehyde in 0.1 M phosphate buffer (pH 7.3). The brains and upper 
cervical spinal cord were removed and post fixed in 4% paraformaldehyde for 24 
hours. Brains were then placed in a cyroprotectant (30% sucrose in phosphate buffered 
solution) at 4 °C for 48 hours and frozen at -70°C before sectioning.
2.2.2 Tissue processing
When removed from the freezer, brains were fast frozen onto cryostat mounts in 
isopentane for approximately 30 seconds and then left to equibrilate at cryostat 
temperature of -20°C. Serial 50pm coronal sections were cut from 0.1mm rostral to 
area postrema to the C2 level. Every fifth section was taken for immunoprocessing 
(typically 45-50 sections per experiment) ensuring a systematically random sampling 
of tissue. Sections were placed into a 24 well tissue culture plate containing phosphate
buffered saline (PBS) + sodium azide (0.01%). Remaining sections were stored at 4°C.
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Immunoprocessing was carried out on free floating sections with the avidin-biotin 
procedure using a commercially available kit. Sections were incubated in 10% normal 
goat serum (NGS) in phosphate buffered saline (PBS) and 0.2% triton for 1 hour. 
Primary fos antibody (Sigma Genosys) was reconstituted in distilled water and 
dilutions were made in rabbit polyclonial antisera, NGS and PBS containing 0.2% 
triton (1:20,000 dilution) and incubated with sections for 40 -  44 hrs at 4°C. Sections 
were then washed thoroughly in PBS for 10 minutes at room temperature and 
secondary biotinylated rabbit anti-sheep antibody (Vector Laboratories, UK), diluted 
in immunobuffer, PBS, and NGS (1:300 dilution) added to sections for 30 minutes. 
Following PBS wash, sections were placed in ABC-peroxidase complex (Vector 
laboratories) for 30 minutes and then in a 40% solution of DAB (3,3’- 
diaminobenzidine tetrahydrochloride, Sigma) and hydrogen peroxide for 1 minute. 
Following a PBS wash, sections were mounted onto gelatin-coated slides, air-dried 
overnight, dehydrated by immersion in increasing concentrations of ethanol -  50%, 
70%, 75%, 95%, and 100%- and cover slipped.
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The above figure shows the Immunohistochemical process for the labelling o f c-fos 
protein, a.) Following sectioning, tissue was placed in 24 well plates, b.) Fos primary 
antibody (extracted from the blood serum o f an animal, immunised against fos 
protein) is incubated with the tissue, c.) This primary antibody acts as an antigen for a 
secondary antibody, obtained from a separate species immunised with the IgG o f the 
primary species. The secondary antibody is biotinylated and coupled to an enzyme 
system, d.) avidin labelled with peroxidase is reacted with the biotin molecules. 
Application o f DAB to the tissue then yields a reaction with the peroxidase, which 
results in a dark brown precipitate which can be easily identified using a microscope.
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2.2.2.1 Cell counting 
c-fos immunoreactive nuclei were identified using a light microscope and cells 
considered to be “^ os-positive” if they showed black staining as a round structure as 
shown in the picture below. Various intensities of staining were observed and all 
distinguishable from background were included in the analysis.
Figure 12 c-fos im mu no reactivity in the Vc
c-fos immunoreactivity in the Vc, shown by black round staining. The intensity o f  
staining was variable and hence all that was distinguishable from background was 
counted as fos-positive staining,
Sections were orientated in the rostral-caudal plane by virtue of the distinct anatomy 
of the sections. Using area postrema as an anatomical reference point, the location of 
individual sections could be identified by reference to a stereotaxic atlas (Paxinos & 
Watson 1998) and back calculation using the thickness of sections and number of 
sections to area postrema. In this manner, the profile of c-fos immunostaining 
throughout the rostro-caudal extent o f the Vc + C1/C2 was established.
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3  S t u d y  1 -  M o d u l a t i o n  o f  t h e  t r i g e m i n o v a s c u l a r  s y s t e m  w i t h  g l y c e r y l  t r i n i t r a t e  
b e f o r e  a n d  a f t e r  t h e  i n d u c t i o n  o f  c e n t r a l  s e n s i t i s a t i o n
3 .1  I n t r o d u c t i o n
3.1.1 Biological effects o f GTN
The immediate biological effects of GTN are likely to be due to nitric oxide (NO) 
donation, which occurs by both an enzymatic process (glutathione-S-transferase and 
cytochrome P450) and a thiol reaction. NO is a free radical with a short half-life and in 
addition to vasodilator effects, it is released at synapses and has been implicated in the 
modulation of peripheral and central neurotransmission. Endogenously NO is 
synthesised by nitric oxide synthases, of which there are three isoforms. Endothelial 
(type III) and neuronal (type I) nitric oxide synthases are constitutively expressed and 
are involved in numerous physiological functions (Yun et al., 1996). The inducible 
(type II) form is up regulated in response to inflammatory stimuli and as such, has 
been suggested to be a possible mediator of the delayed migraine response following 
GTN infusion. Indeed, Reuter and colleagues have previously found that there is a 
significant increase in inducible NO synthase protein expression four hours after GTN 
administration in the rat meninges (Reuter et al, 2001). This time course corresponds 
well with the time course of clinical onset of the delayed headache in migraineurs 
following GTN infusion.
Due to the highly lipophilic nature of both GTN and NO, both are able to easily 
penetrate the blood brain barrier and generate widespread central nervous system 
effects. Of particular relevance to migraine pathophysiology, increased c-fos
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expression in the Vc has been demonstrated following a large systemic dose of GTN 
(Tassorelli & Joseph, 1995). Modulation of neuronal activity in the Vc following GTN 
administration, may result from several different actions. For example, GTN may 
directly modulate neuronal activity in the Vc, alternatively, GTN may generate 
inflammation in the dura mater with resultant alteration in primary afferent input into 
Vc. GTN administration has also been shown to modulate supraspinal sites that send 
descending projections to the Vc (Pardutz et al., 2002; Tassorelli et al., 1997).
GTN
|  X  I n d i r e c t
\  I  - t r a n s m i t t e r  r e l e a s e  
J  L  i n f l a m m a t o r y  m e d i a t o r s
Neuron
Figure 13 Possible sites of action of GTN
GTN is highly lipophilic and easily crosses the blood brain barrier. Following in vivo 
administration, tissue distribution has been found to be significantly higher than that 
in plasma, with the highest levels found in brain and heart tissue (Torfgard & Ahnler, 
1991). The main bioconversion product o f GTN is NO, which is able to act as a 
neuronal signal transmitter, resulting in both direct effects and indirect effects by 
causing the release o f other neurotransmitters. GTN is also able to cause direct and 
indirect effects on blood vessels by the direct release o f NO in the blood vessel wall 
and subsequent activation o f cGMP and cGMP-dependant kinase as well as 
modulation o f the contractile state o f the vessel by activating transmitters such as 
CGRP, (Diagram adaptedfrom Tassorelli et al., 1999).
I n d i r e c t -
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3.1.2 Central sensitisation and GTN
As discussed in the introduction, the susceptibility of migraineurs to agents such as 
GTN or red wine may be due to a “CNS hyperexcitability”, such as might occur with 
various ion channels pathophysiologies in brainstem structures such as the PAG or 
hypothalamus. Under these conditions, primary afferent activation following GTN 
administration may generate a greater than normal central activation. Hence, the effect 
of GTN infusion following the induction of central sensitisation with capsaicin, 
formalin, NGF and PGE2 was explored. To generate a more complete picture of the 
effect of these mediators on a larger population of Vc neurons than could be obtained 
with single-unit electrophysiological recording, c-fos expression in the Vc was also 
assessed.
Experimentally, capsaicin generates acute excitation and sensitisation of C-fibres, with 
subsequent primary hyperalgesia (Baumann et al., 1991; LaMotte et al., 1992) and 
secondary hyperalgesia (LaMotte et al., 1991; Torebjork et al., 1992). This correlates 
well with studies in human volunteers, who report an intense burning pain lasting for 
15-60 seconds with subsequent allodynia and hyperalgesia following capsaicin 
injection. Capsaicin exerts its effect through the vanilloid (VR-1) receptor, a ligand 
and heat gated ion channel present on small diameter sensory neurons (Caterina et al., 
1997). The presence of VR-1 has been demonstrated on the cell bodies of trigeminal 
afferents in the rat trigeminal ganglion (reported ranges vary from 14 to 26% of cell 
bodies; Ichikawa & Sugimoto, 2000 & 2001) and also in laminae I and II of the Vc.
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Peripheral formalin injection produces a long-lasting nociceptive response in animals 
and as such, formalin injection is widely used as a model of pain for the investigation 
of novel pain drugs. The formalin pain model has two distinct phases with an acute 
pain behavioural response seen 3-5 minutes after formalin injection, followed by a 
quiescent period of 10-15 minutes. The second pain behavioural response starts 15-20 
minutes after formalin injection and lasts for a further 20 to 40 minutes (Lebrun et al., 
2000). This biphasic nature can also be observed using electrophysiological recording 
following the injection of formalin into the receptive field (Puig & Sorkin, 1995). The 
initial phase is directly attributable to activation of sensory afferents while the second 
phase is the subject of debate. However, differential time-related roles of different 
transmitter systems in the induction and maintenance of formalin induced pain have 
been clearly shown (Chapman & Dickenson, 1995).
The high-affinity NGF receptor, trkA, is selectively expressed by nociceptive sensory 
neurons particularly those containing sensory neuropeptides such as substance P and 
CGRP (McMahon, 1996). Furthermore, recent studies have suggested that NGF is a 
peripherally produced mediator of some persistent pain states, notably those associated 
with inflammation and systematic or local application of exogenous NGF produces a 
rapid and prolonged behavioural hyperalgesia in both animals and humans (Mendell et 
al., 1999; Tal, 1999, Bennett, 2000). Additionally, some work carried out in our 
laboratory suggested that NGF has a sensitising effect of cultured trigeminal neurons 
(Jenkins et al., personal communication). The rationale for the use of PGE2 to induce 
sensitisation is discussed more fully in the introduction to study two, but was based on 
the known effectiveness of NSAIDs in the treatment of acute migraine pain indicating 
a prostaglandin-mediated sensitisation may be responsible for at least a component of
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the hypersensitivity seen during migraine (Diener et a l, 1999).
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3.2 Methods
3.2.1 Intra-arterial infusions and topical administration of GTN
Electrophysiological recordings and intravital microscopy were carried out as 
described in section 2.1. For experiments involving intra-arterial GTN infusions, a 
second cannula was placed rostrally in the same carotid artery cannulated for blood 
pressure monitoring, for GTN infusion to the cerebral circulation.
3.2.1.1 Intravital microscopy
Due to the technical difficulty of this intravital microscopy, the protocol was designed 
to minimise the number of experiments performed, hence GTN vehicle and different 
GTN doses were tested in a sequential manner in the same animal. Following 
establishment of a steady baseline diameter of the MMA (over at least fifteen minutes) 
an experimental protocol of GTN vehicle (glucose-saline) intra-arterial infusion 
followed by GTN intra-arterial infusions at 2, 5 and lOpgkg'W n'1 was started. 
Infusions were sequential and each dose of GTN and GTN vehicle were infused for 
twenty minutes with a five-minute gap left between doses or, where a response was 
seen, five minutes after return of MMA diameter to pre-treatment baseline values. 
After infusion of GTN (lOpgkg'Wn*1), a bolus intravenous dose of CGRP was 
administered (300ngkg_1) for comparison with data previously obtained in the 
laboratory (A. Honey, unpublished data). The sequential infusions were then repeated
i.e. GTN vehicle for twenty minutes followed by GTN infusion 2, 5 and lOpgkg^min’1 
for twenty minutes each.
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GTN vehicle infusion
GTN 1 Ojagkg-1 min-1
GTN vehicle infusion
GTN 5(igkg-lmin-l
CGRP 300ngkg
GTN 10ggkg-lmin-l
GTN 5pgkg-lmin-l
Figure 14 Intravital microscopy-experimental protocol
For experiments examining the effect o f  intra-arterial GTN infusion using intravital 
microscopy, sequential infusions (20 minutes each) were examined with a 5 minute 
gap left between infusions or where a response was seen, the time for vessel diameter 
to return to normal plus 5 minutes. Following infusion o f GTN vehicle, and GTN at 2, 
5 and lOpgkg-1, a bolus dose o f CGRP (SOOngkg1) was given intravenously and the 
GTN vehicle and GTN infusions were repeated.
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In separate experiments, following establishment of a steady baseline diameter of the 
MMA, GTN vehicle (200pl) was applied over the cranial window on a gauze swab for 
5 minutes. The gauze was removed, the skull rinsed with saline and re-covered with 
mineral oil and blood vessel diameter continuously monitored. After fifteen minutes, 
this procedure was repeated with GTN (200pl of200pmol solution).
SSS
Branch of MMA visible Gauze swab saturated with
through the thinned GTN or GTN vehicle for
Cranial window Topical administration
F i g u r e  1 5  T o p i c a l  a p p l i c a t i o n  o f  G T N  o v e r  t h e  c l o s e d  c r a n i a l  w i n d o w
For topical application o f GTN or GTN vehicle, a gauze swab was saturated with the 
appropriate solution and placed over a region o f the MMA that could be visualised 
under a microscope following thinning o f the skull to form a closed cranial window. 
(Diagram adaptedfrom Ellrich et al, 1999).
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3.2.1.2 Electrophysiology
Reproducible baseline responses to trains of electrical stimulation (50 stimulations, 
every 5 minutes at 1Hz) were established over at least fifteen minutes where less than 
10% variation was seen in the response to successive trains. Intra-arterial infusions of 
GTN (Spgkgmin1) or vehicle (glucose-saline) were then administered over twenty 
minutes. In separate experiments, topical administration of GTN vehicle and GTN was 
carried out as described for intravital microscopy. Electrophysiological data was 
analysed using a repeated measure ANOVA followed by Bonferroni’s post hoc test for 
multiple comparisons and P < 0.05 was considered significant.
3.2.2 Intravenous infusions of GTNfollowing induction of central 
sensitisation
3.2.2.1 Electrophysiology
Baseline electrophysiological recording of second order neurons in the Vc responding 
to electrical stimulation of the MMA with A6- latency were carried out as described 
above.
Formalin (0.3 or 0.5 or 1 or 2% in 50pl of saline) or capsaicin (3mM) or vehicle 
(formalin vehicle -saline; capsaicin vehicle-10% ethanol, 10% Tween 80 in saline) 
were administered adjacent to the FRF of the test Vc neuron. The effects of capsaicin 
application directly to the cranial window overlying the MMA were also tested. In 
these experiments, capsaicin (3mM) was applied over the cranial window on a gauze 
swab for a period of 2 minutes before the area was washed with saline and re-covered 
with mineral oil. In separate experiments, topical capsaicin application, the effects of
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intravenous GTN infusion (2 or 5ngkg‘1min'1 over 30 minutes) was assessed. In the 
experiments, GTN or GTN vehicle infusion was started 10 minutes after capsaicin 
administration and continued for 30 minutes.
As both formalin and capsaicin directly activate primary afferent neurons, in this study 
both mediators were administered adjacent to the receptive field to avoid directly 
altering the characteristics of the cell under study. Hence, any effect on neuronal 
activity could be assumed to result from central changes, most likely occurring 
through the process of “heterosynaptic facilitation” (Thompson et al., 1993).
3.2.3 Immunohistochemistry
For all studies in this section, immunoprocessing of tissue was carried out as described 
in section 2.2. Except were stated, male Sprague-Dawley rats (300-430g) were 
anaesthetised using 5% isoflurane in oxygen. An angiocath (interocath 22G) was 
inserted in a tail vein (patency was ensured with regular 0.1ml flushes of heparinised 
saline, 10 unit/ml). a-Chloralose (80 mg/kg i.v.) was administered as a slow bolus 
(over 2 minutes), isoflurane anaesthesia gradually reduced and animals allowed to 
respire spontaneously. Further doses of a-chloralose (20 mg/kg i.v. or 40mg/kg i.v. 
depending on the duration of the experiment) were given at approximately hourly 
intervals.
3.2.3.1 Experimental protocol using formalin as a mediator o f central
sensitisation
Following a two-hour stabilisation period (measured from the time of first
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administration of a-chloralose), formalin (0.5% or 5% in 50jxl) or vehicle (saline) was 
injected into the maxillary or infraorbital region of the face. Ten minutes later, GTN 
(Spgkg’W n '1) or vehicle (glucose saline) was infused into the tail vein for 30 minutes. 
Either two or four hours after GTN infusion, euthanasia was performed via a 
pentobarbital overdose.
3.2.3.2 Experimental protocol using capsaicin as a mediator o f central
sensitisation
In the first instance, animals were subjected to a two-hour stabilisation period 
following administration of a-chloralose, as described for formalin. GTN (2 pgkg'1 
min'1) or vehicle (glucose saline) was then infused into the tail vein for 30 minutes. 
Immediately following the infusion period, a 50pl bolus dose of capsaicin (0.02%) or 
vehicle (10% ethanol, 10% Tween 80 and saline) was injected intradermally into the 
infraorbital region of the face, using a Hamilton syringe. One-and-a-half hours after 
the end of the GTN infusion, euthanasia was performed via a pentobarbital overdose.
During the course of these studies, reports examining an almost identical protocol 
using a combination of capsaicin and GTN were published (Jones et al., 2001). The 
authors of this study reported that intradermal injection of capsaicin injection into the 
periorbital area increased c-fos expression in the Vc and furthermore, GTN infusion 
facilitated the expression compared to vehicle infusion. Hence, to allow a comparison 
between methodologies, the experimental conditions of this paper were replicated as 
part of this thesis. Briefly, male Wistar rats (200-250g) were anaesthetised with an 
intraperitoneal injection of urethane (1.5g/kg). The left femoral vein was cannulated
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and GTN (2-2.5 jigkg’1 min'1) or GTN vehicle was infused for 30min, without any 
stabilisation period, following surgery. Immediately following the infusion period, a 
50|il bolus dose of capsaicin (0.02%) or vehicle (10% ethanol, 10% Tween 80 and 
saline) was injected intradermally into the infraorbital region of the face. One-and-a- 
half hours after the end of infusion, euthanasia was performed via a pentobarbital 
overdose.
3,2.33 Experimental protocol using Prostaglandin E2 (PGE2) and Nerve 
Growth Factor (NGF) as a mediator of central sensitisation
As described for capsaicin and formalin above, following induction of anesthesia with 
a-chloralose, animals were given a two hour stabilization period. The following 
combination of drugs were then injected intradermally into the infraorbital region of 
the face as two separate injections immediately following each other.
i.) NGF (2.5pg in 50pl) and PGE2 (2pg in 50pl)
ii.) NGF vehicle (saline, 50jnl) and PGE2 (2pg in 50pl)
iii.) NGF (2.5pg in 50pl) and PGE2 vehicle (saline, 50pl)
Ten minutes after injection of the inflammatory mediator, GTN (5pgkg_1 min"1) or
GTN vehicle was infused through the tail vein for 30 minutes Two hours after GTN 
infusion, euthanasia was performed via a pentobarbital overdose.
3.2.3.4 Statistical analysis
Data from all immunohistochemistry experiments were considered in terms of both
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total c-fos expression in all sections processed and mean c-fos expression per section. 
Tissue from each complete study, usually consisting of the following 4 groups, was 
processed together, i.e. all reactants for a particular study were from the same batch, 
hence allowing an accurate comparison within a study group.
i.) inflammatory mediator vehicle & GTN vehicle
ii.) inflammatory mediator vehicle & GTN
iii.) inflammatory mediator & GTN vehicle
iv.) inflammatory mediator & GTN
A considerable variation in baseline c-fos expression was observed between study 
groups, even for identical treatments e.g. inflammatory mediator vehicle & GTN 
vehicle, which may in part be due to tissue processing rather than experimental 
variation. Hence, these studies were limited to comparisons of raw data within groups 
and the magnitude of any increased effect between study groups. Data was analysed 
using a repeated measures ANOVA followed by Bonferroni’s post hoc test for 
multiple comparisons and P < 0.05 was considered significant.
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3.3 Results
Data from electrophysiological and intravital experiments included in this study was 
from animals with acceptable respiratory and cardiovascular parameters for the 
anaesthetised rat and was in the range: pCC>2 35-45mmHg, pC>2 90+ mmHg and a pH 
of 7.35-7.45. However, respiratory and cardiovascular parameters were not assessed in 
animals used for the immunohistochemistry section due to the non-invasive nature of 
the experimental protocol.
Data from this study in considered in the following sub-groups;
Intravital Microscopy
Intra-arterial infusion 
Topical GTN administration 
Electrophysiology
Intra-arterial GTN infusions 
Topical GTN application over the MMA 
Intravenous GTN infusions-
Using Formalin to induce CS 
Using Capsaicin to induce CS 
Immunohistochemistry with intra-venous GTN infusion 
Using Formalin to induce CS 
Using Capsaicin to induce CS 
Using PGE2 and NGF to induce CS
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3.3.1 Intravital Microscopy
Mean arterial blood pressure (MABP) was not significantly affected by infusions of 
GTN up to doses of Spgkg'W n'1 however, infusion of lOpgkg'W n'1 resulted in a 
depression of MABP of 38 ± 6 mmHg (n = 3), evident 6 to 9 minutes after the start of 
the infusion. Topical administration of GTN also significantly depressed MABP by 27 
± 5 mmHg (n = 7) within 20 seconds of application. GTN vehicle had no significant 
effect on cardiovascular parameters in any experiments (P > 0.05).
3.3.1.1 Intra-arterial infusion
Sequential infusions of GTN vehicle, GTN (2, 5, or lOpgkg^min'1) were carried out 
for 20 minutes with 5 minutes between infusion where no effect on MMA diameter 
was seen or where an effect was seen, the time to return to baseline diameter plus 5 
minutes. No effect on MMA diameter was seen following infusions of GTN vehicle or 
GTN (2 or Spgkg'W n'1; n = 3). However following infusion of GTN (10pgkg‘1min‘1) 
an increase in MMA diameter of 58 ± 10% was seen (n = 3). Following return of 
MMA to baseline levels, CGRP (300ngkg_1) was then administered and resulted in a 
dilatation of the MMA of 152 ± 11% above resting diameter (n = 3). GTN vehicle and 
GTN (2, 5, or 10pgkg'1min'1) infusions were then repeated following vessel 
normalisation. Here, GTN vehicle and GTN infusion (2pg kg'1 min"1) again had no 
effect on blood vessel diameter (n = 3), however GTN (5pg kg'’min'1) resulted in a 
dilatation of the MMA of 33 ± 10% above baseline (n = 3). GTN (10pg kg'’min'1) 
again generated a dilatation of the MMA of 76 ± 18% (n = 3). The low numbers in this
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study do not permit statistical analysis and ideally another 2 to 3 animals would have 
been included in the group, however, due damage to the equipment, this was not 
possible during the time course of this thesis.
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T i m e S t a g e  o f  e x p e r i m e n t E f f e c t
0  m i n u t e s B a s e l i n e  d e t e r m i n a t i o n -
1 5  m i n u t e s G T N  v e h i c l e N o  e f f e c t  o n  M M A  d i a m e t e r  ( n  =  3 )
4 0  m i n u t e s G T N  - 2 p g k g ' l m i n * 1 N o  e f f e c t  o n  M M A  d i a m e t e r  ( n  =  3 )
6 5  m i n u t e s G T N  - 5 f i g k g ‘ l m i n ~ 1 N o  e f f e c t  o n  M M A  d i a m e t e r  ( n  =  3 )
9 0  m i n u t e s G T N  - 1 0 | i g k g ‘ l m i n * 1 t  o f  5 8  ±  1 0 %  a b o v e  r e s t i n g  d i a m e t e r  ( 6 4  ±  1 2  
s e c o n d s  a f t e r  t h e  s t a r t  o f  i n f u s i o n  ( n  =  3 ) .  M M A  
d i a m e t e r  r e t u r n e d  t o  b a s e l i n e  l e v e l s  1 1 8  ±  1 9  
s e c o n d s  a f t e r  t h e  e n d  o f  i n f u s i o n .
1 1 7  m i n u t e s C G R P t  o f  1 5 2  ±  1 1  %  a b o v e  r e s t i n g  d i a m e t e r  ( 1 6  ±  3  
s e c o n d s  a f t e r  t h e  s t a r t  o f  i n f u s i o n  ( n  =  3 ) .  M M A  
d i a m e t e r  r e t u r n e d  t o  b a s e l i n e  l e v e l s  2 8 8  ±  2 7  
s e c o n d s  a f t e r  a d m i n i s t r a t i o n .
1 2 7  m i n u t e s G T N  v e h i c l e N o  e f f e c t  o n  M M A  d i a m e t e r  ( n  =  3 )
1 5 2  m i n u t e s G T N  - 2 p g k g ' l m i n * 1 N o  e f f e c t  o n  M M A  d i a m e t e r  ( n  =  3 )
1 7 7  m i n u t e s G T N  - 5 | i g k g ' I m i n ' 1 |  o f  3 3  ±  1 0 %  a b o v e  r e s t i n g  d i a m e t e r  ( 7 6  ± 2 1  
s e c o n d s  a f t e r  t h e  s t a r t  o f  i n f u s i o n  ( n  =  3 ) .  M M A  
d i a m e t e r  s t a r t e d  t o  r e t u r n  t o  b a s e l i n e  l e v e l s  d u r i n g  
t h e  i n f u s i o n  a n d  i n  a l l  c a s e s  h a d  r e t u r n e d  t o  
b a s e l i n e  l e v e l s  b y  t h e  e n d  o f  i n f u s i o n
2 0 2  m i n u t e s G T N  - l O f i g k g  ' m i n * 1 t  o f  7 6  ±  1 8 %  a b o v e  r e s t i n g  d i a m e t e r  ( 3 2  ±  9  
s e c o n d s  a f t e r  t h e  s t a r t  o f  i n f u s i o n  ( n  =  3 ) .  M M A  
d i a m e t e r  r e t u r n e d  t o  b a s e l i n e  l e v e l s  2 0 6  ±  3 3  
s e c o n d s  a f t e r  a d m i n i s t r a t i o n .
Table 5 Summary o f the effects o f GTN infusion on MMA diameter
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3.3.1.2 Topical GTN administration
In these experiments, direct application of GTN (200pmol1) to the cranial window, as 
described in section 3.2.1.1. was examined. Topical application of GTN or GTN 
vehicle to the cranial window disrupted the initial signal following application, 
obscuring the first few seconds of the response; hence, the onset of action of GTN in 
resulting in dilatation of the MMA in these experiments cannot be accurately assessed. 
However, once the gauze containing GTN was in place, a maximum dilatation of the 
MMA of 142 ± 20% (n = 3) above baseline diameter (n = 3) could be observed. The 
dilatation persisted throughout GTN application (5 minutes) and MMA diameter 
returned to baseline level 256 ± 35 seconds after the gauze was removed. Application 
of GTN vehicle to the cranial window also resulted in an increase in MMA diameter 
over baseline of 28 ± 22% (n = 3). However, MMA diameter returned to baseline 
during application (95 ± 16 seconds after gauze application) suggesting that the small 
dilatation may be due to the process of mechanical stimulation when the gauze was put 
in place.
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Figure 16 Dilatation of the MMA following GTN
Data is represented as the mean maximum percentage increase over resting diameter, 
assessed by intravital microscopy following GTN intra-arterial infusion, CGRP 
administration and topical application o f GTN to the area overlying the MMA. 
Following GTN infusion (5 pgkg1 m in1), no effect was seen on MMA diameter (n = 3), 
however GTN infusion (lOpgkg1min1) resulted in a dilatation o f the MMA o f 58 ±  
10%; n =  3). In the same animals, a bolus dose o f CGRP (300ngkgI) resulted in a 
dilation o f MMA o f 152 ±11%  (n = 3) above resting diameter and GTN infusions 
were then repeated. Here, GTN infusion (5pgkg1 miri1 ) resulted in a dilatation o f the 
MMA o f 33 ±  10% above baseline (n =  3) and GTN (10pg kg'1 m in1) generated a 
dilatation o f the MMA o f 76 ±  18% (n = 3). In separate animals GTN application 
(200frnioV!) to the area overlying the MMA resulted in a dilatation o f the MMA o f 142 
±20% (n =  3).
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3.3.2 Electrophysiology
Electrophysiological recordings were made from seventeen cells in the Vc of 
seventeen rats. All cells responded to electrical stimulation of the dura mater (l-6mA, 
0.1-0.8ms, 1Hz) with a mean latency of 18 ± 4 ms, consistent with A5 fibre responses. 
All cells could also be activated by non-noxious stimulation of the face and hence 
were classified as WDR.
3.3.2.1 Intra-arterial GTN infusions
For cells tested with intra-arterial GTN vehicle infusion, electrical stimulation of the 
MMA during baseline measurements resulted in a mean number of responses to one 
stimulation train of 73 ± 9 (n = 5).Vehicle infusions did not significantly alter baseline 
recordings, at any time point during the experiment in any cell tested (P > 0.05). For 
cells tested with intra-arterial GTN infusion, electrical stimulation of the MMA during 
baseline measurements resulted in a mean number of responses to trains of fifty 
electrical stimulations of 66 ± 13 (n = 6). Following GTN infusion (Spgkg^min1), 3/6 
cells showed an increased firing rate above baseline and 3/6 cells showed an inhibition 
of MMA-evoked neuronal activity. When considered together, the mean response of 
all 6 cells showed a significant decrease in neuronal activity compared to both baseline 
measurements and GTN vehicle infusion (P < 0.05) and data is summarised in the 
table below.
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GTN vehicle GTN Spgkg'W n'1
Baseline Infusion Baseline Infusion
Mean ± SEM 1.0 ± 0.01 1.0 ±0.02 1.0 ± 1.0 0.9 ± 0.08
Range of 
normalised 
values
0.24 0.68 0.26 2.79
Table 6 Effects o f GTN on MMA-evoked, Vc responses
The above table gives the mean normalised recordings and the normalised data range, 
prior to GTN or GTN vehicle infusion and during the infusion.
Four of six cells tested with intra-arterial GTN infusion were spontaneously active 
with mean ongoing rates of activity of 0.5, 0.8, 0.9 and 1.6 spikes per second during 
the pre-treatment period. Following intra-arterial GTN infusion spontaneous activity 
was inhibited to a maximum of 58 ± 12% (n = 4) below pre-treatment values.
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Electrophysiological recordings were made as described in section 2.1-2.2. A. Data is 
represented as the mean normalised response to trains o f fifty electrical stimuli 
applied to the MMA, recorded every five minutes. Error bars for GTN infusions are 
shown in the “plus” direction, and for GTN vehicle, in the” minus” direction. GTN or 
vehicle were infused between 0 and 20 minutes. B. Box-whisker plots show the range 
o f the normalised responses recorded prior to GTN vehicle infusion (n =12 
measurements from 4 animals), during and after GTN vehicle infusion (n =92 
measurements from 4 animals), prior to GTN infusion (n =20 measurements from 6 
animals), during and after GTN vehicle infusion (n =174 measurements from 6 
animals). GTN resulted in a significant decrease in evoked neuronal activity compared 
to baseline and to GTN vehicle infusion (P < 0.05, ANOVA followed by Bonferroni’s 
post hoc test for multiple comparisons), whereas GTN vehicle had no significant effect 
on neuronal activity compared to baseline measurements (P > 0.05).
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33.2.2 Topical GTN application over the MMA
For cells tested with topical GTN application over the MMA, electrical stimulation of 
the MMA during baseline measurements resulted in a mean number of responses to 
trains of fifty electrical stimulations of 59 ± 9 (n = 4). The overall effect of topical 
GTN application (200pl of 200pmol solution) on MMA-evoked Vc firing was not 
significantly different to baseline measurements (P > 0.05). However, when the 
response of individual experiments were considered two out of four cells showed an 
increased response and two cells showed a decrease to MMA stimulation above 
baseline.
For cells tested with topical GTN vehicle administration, electrical stimulation of the 
MMA during baseline measurements resulted in a mean number of responses to trains 
of fifty electrical stimulations of 71 ± 6 (n = 3). Topical vehicle application resulted in 
a significant increase to MMA-evoked firing of 24 ± 2% (mean number of response to 
one stimulation train of 88 ± 3; n = 3; P  < 0.05) over pre-treatment evoked firing, five 
minutes after application that had returned to pre-treatment levels 10 minutes after 
application.
3.3.3 Intravenous GTN infusions
3.3.3.1 Formalin induced sensitisation
Mean arterial blood pressure (MABP) was not significantly affected by formalin 
injection up to 1%, however; injection of formalin, 2 and 5% resulted in an elevation 
of MABP of 15 ± 2mmHg and 22 ± 5mmHg, respectively. Electrophysiological
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recordings were made in 26 cells in 26 rats. All cells responded to dural stimulation in 
the range consistent with A-5 fibre mediated responses with a mean latency of 13 ± 
3ms (range; 9-2 lms). All cells also received a convergent input from the face 
following non-noxious stimulation and were hence, classified as WDR. In the first 
instance, a low dose of formalin (0.3%) was used to investigate formalin-induced 
sensitisation, as no sensitisation was seen at this dose, the concentration of formalin 
was increased incrementally to 0.5, 1 and 2%. Formalin or formalin vehicle followed 
by either GTN or GTN vehicle infusion did not produce any sensitisation of the 
evoked response to MMA stimulation at any dose tested. While the numbers in this 
study were low and we cannot rule out the possibility that with more experiments, a 
sensitising effect of formalin would be seen, the purpose of the experiment was to look 
at the effects of GTN following a robust sensitisation at the level of the Vc and not at 
the effect of formalin per se., hence no attempt was made to increase the numbers in 
this study and capsaicin was explored as an alternative inducer of central sensitization.
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R a t s M e a n  c e l l
d e p t h
( u m )
M a x  i n c r e a s e  
o v e r  b a s e l i n e  
r e s p o n s e s  ( % )
C o m m e n t
Formalin vehicle & 
GTN 2pgkg'1 min'1
3 1025 ±115 8 ± 5
Formalin vehicle & 
GTN Spgkg'1 min'1
2 968 18
Formalin 0.3% & 
GTN Sfxgkg'1 min'1
2 1011 5
Formalin 0.5% & 
GTN Spgkg'1 min'1
3 870 ±119 17 ± 6
Formalin 0.5% & 
GTN vehicle
3 804 ±108 14 ±3
Formalin 1% & 
GTN 5pgkg_1 min'1
3 862 ± 89 27 ±25 1 cell “lost” after 
15 minutes
Formalin 1% & 
GTN vehicle
3 671 ± 92 32 ±13
Formalin 2% & 
GTN 5figkg_1 min*1
2 982 Cells “lost” 5 
and 15 minutes 
after formalin
Formalin 2% & 
GTN vehicle
3 1029 ±238 17 ± 13
Table 7 Summary of the maximum responses seen following formalin & GTN
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Administration of 5% formalin around the FRF was also examined and while no 
sensitisation of cells responding to MMA stimulation could be observed, pressor 
effects on blood pressure, that were unrelated to depth of anaesthesia, can be seen in 
response to electrical stimulation of the MMA. While this could be a non-specific 
effect, it may indicate the development of generalised central hypersensitivity.
200 
150
B lo o d  
p r e s s u r e  
m m  H g
50 
0
~ ~ I - - - - - - - - - - - - 1 - - - - - - - - - - - - - - - 1 - - - - - - - - - - - 1 - - - - - - - - - - - - - - - - - 1 - - - - - - - - - - - - - - 1 - - - - - - - - - - - - - - 1 - - - - - - - - - - - - - - V- - - - - - - - - - - - 1 - - - - - - - - - - - - - - - - 1 - - - - - - - - - - - - - - 1 - - - - - - - - - - - - - - 1 - - - - - - - - - - - - - - 1 - - - - - - -
1000 2000 3000
S e c o n d s
F i g u r e  1 8  F o r m a l i n  ( 5 % )  i n t o  t h e  F R F  g e n e r a t e s  p r e s s o r  e f f e c t s  o n  b l o o d  
p r e s s u r e
Trace shows blood pressure recording during an electrophysiology experiment where 
5% formalin was administered into the FRF (marked by arrow). Black blocks at the 
top of the trace show where trains of electrical stimuli applied to the MMA. Fifteen 
minutes after formalin administration, pressor effects on blood pressure were evident 
possibly indicating the development of generalised central hypersensitivity.
5 %  f o r m a l i n
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3.3.3.2 Capsaicin induced sensitisation
Electrophysiological recordings were made from 20 cells in the Vc of 20 rats 
responding to electrical stimulation of the MMA with a mean latency of 15 ± 2ms 
(range; 8-25ms). Cells were located in the depth range 415-1550pm below the pial 
surface. Mean arterial blood pressure (MABP) was not significantly affected by 
capsaicin.
3.3.3.2.1 Topical capsaicin application over the MMA
For cells tested with topical application of capsaicin (3mM) over the MMA, electrical 
stimulation of the MMA during baseline measurements resulted in a mean number of 
responses to one electrical stimulation train of 59 ± 8 (n = 5). Following capsaicin 
application, an increase in the evoked response to MMA stimulation occurred which 
reached a maximum of 48 ± 15% (mean number of response to one stimulation train 
of 79 ± 9; n = 5; P < 0.05) over pre-treatment values, 35 minutes after application. 
Electrical stimulation of the MMA during baseline measurements for cells tested with 
capsaicin vehicle (10% ethanol, 10% Tween 80 in saline) resulted in a mean number 
of responses to one electrical stimulation train of 71 ± 14 (n = 4). This firing rate was 
not altered from pre-treatment levels at after capsaicin vehicle at any time point during 
the experiment (n = 3).
3.3.3.2.2 Topical capsaicin application over the MMA and GTN
In separate experiments, topical application of capsaicin (3mM) over the MMA was
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followed by infusion of either GTN vehicle or GTN infusion (Sugkg'Wn'1). Electrical 
stimulation of the MMA during baseline measurements in these studies resulted in a 
mean number of responses to one electrical stimulation train of 63 ± 11 (n = 6). 
However, the mean maximum increase over pre-treatment levels seen following 
capsaicin and GTN infusion (35 ± 9%; n = 3) was not greater than the maximum 
increase seen following capsaicin and GTN vehicle infusion (39 ± 15 %; n = 3).
3.3.3.2.3 Injection o f capsaicin in the FRF
Baseline responses to electrical stimulation of the MMA in experiments where 
capsaicin was injected into the area adjacent to the FRF resulted in a mean number of 
responses to one electrical stimulation train of 73 ± 10 (n = 3). Following sub­
cutaneous injection of capsaicin into a region just outside the FRF, an increase in the 
response to electrical stimulation of the MMA occurred 20 minutes after capsaicin 
administration compared to vehicle and pre-treatment values (n = 3).
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Capsaicin vehicle (n = 3) 
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Minutes
F i g u r e  1 9  M e a n  n o r m a l i s e d  e v o k e d  r e s p o n s e s  f o l l o w i n g  c a p s a i c i n
Electrophysiological recordings were made as described in section 2.1-2.2. Data is 
represented as the mean normalised response to trains of fifty electrical stimuli 
applied to the MMA, recorded every five minutes. Capsaicin was given at time 0, over 
the MMA (A) and into the FRF (B). Application of capsaicin over the MMA resulted in 
a sensitisation of 48 ±  15% (n = 5) that remained for the duration of the experiment 
whereas capsaicin administration around the FRF resulted in a lesser sensitisation 
that occurred 20 minutes after administration and returned to pre-treatment levels by 
the next stimulation train.
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3.33.2.4 The effect of capsaicin on FRF stimulation
All cells tested with capsaicin or capsaicin vehicle had a FRF that typically extended 
over an area of the face innervated by the first or second division of the trigeminal 
nerve. The mean number of spikes resulting from brush and pinch stimulation of the 
FRF was variable between cells with a range for pre-treatment brush stimulation of 
29-114 spikes per 10 second stimulus and a range for pre-treatment pinch stimulation 
of 37-180 spikes per 5 second stimulus, hence, data is expressed as the normalised 
increase over pre-treatment responses. Application of capsaicin vehicle to the MMA 
resulted in an increased response to brush and pinch stimulation of 40 ± 12% and 23 ± 
10% respectively (n = 4; P < 0.05) over pre-treatment values. However capsaicin 
(3mM) application over the MMA produced a much larger increase to brush and pinch 
stimulation than that of vehicle of 300 ±81%  and 310 ± 35% (n = 4; P < 0.05) 
respectively. The maximum responses seen for both capsaicin and vehicle occurred 30 
minutes after application.
The response to brush and pinch stimulation of the FRF following capsaicin 
administration into the area surrounding the FRF was also significantly increased, 30 
minutes after capsaicin application. The mean maximum response to brush and pinch 
was 101 ±21% and 30 ± 13% respectively (n = 3; P < 0.05) which was significantly 
greater than the increase seen following application of capsaicin vehicle, where the 
mean maximum response to brush and pinch was 10 ± 9% and 6 ± 4% respectively (n 
= 3; /5> 0.05).
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( a )  C a p s a i c i n  a p p l i c a t i o n  o v e r  t h e  M M A
] Capsaicin vehicle (n = 3)
Capsaicin 3mM (n = 4)
B r u s h  P i n c h
( b )  C a p s a i c i n  a d m i n i s t r a t i o n  i n t o  t h e  F R F
4-i
2  2-
H Capsaicin vehicle (n = 3) 
I  Capsaicin 3mM(n = 3)
B r u s h  P i n c h
Figure 20 Response to facial receptive field stimulation following capsaicin
Electrophysiological responses to a 10-second brush and 5-second pinch were 
assessed 3 times before capsaicin administration, 30, 45 and 60 minutes after 
capsaicin. Data represents mean maximum normalised increased responses compared 
to control readings when capsaicin was applied over the MMA (a) and into the FRF 
(b). Capsaicin administration in both sites resulted in a significant increase in brush 
and pinch stimulation compared to capsaicin vehicle, which was maximal thirty 
minutes after capsaicin application (P < 0.05; repeated measures ANOVA).
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3.3.4 Immunohistochemistry
Following immunohistochemical processing of all tissue in these studies, c-fos 
expression was observed almost exclusively in lamina I / II, ipsilaterally to the 
stimulus.
contralateral ipsilateral
Figure 21 c-fos immunohistochemistry observ ed in the Vc
Picture shows c-fos expression in the superficial ipsilateral Vc, following application 
o f capsaicin into the face, c-fos expression could not be observed in the contralateral 
Vc. Scale bar, 200pm
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3.3.4.1 Formalin
Administration of formalin vehicle and GTN vehicle or formalin vehicle and GTN 
both generated an increase in mean total c-fos expression, however, this was not 
significantly different between the two treatment groups in tissue taken from animals 
euthanased, two or four hours after the end of the stabilisation period (P > 0.05, 
ANOVA, repeated measures followed by Bonferroni’s post hoc test for multiple 
comparisons). Administration of formalin and GTN vehicle or formalin and GTN both 
resulted in a significantly greater mean total c-fos expression than combinations using 
formalin vehicle (P < 0.05). However, GTN did not significantly increase total c-fos 
immunoreactivity above that seen in formalin and GTN vehicle treated animals in any 
of the groups studied (P > 0.05).
The table 8 shows the total mean fos counts in this study. While there is some 
redundancy in the counts, i.e. formalin vehicle and GTN vehicle were looked at twice 
at the 2 hour end-point, this is the result of processing from each study being 
completed together. For example, in the first instance, Formalin (0.5%) / formalin 
vehicle and GTN / GTN vehicle infusion were examined and the tissue processed 
together. When no sensitising effect of GTN was seen, Formalin was then examined at 
5%, however, because of variation in tissue processing, it was not considered 
acceptable to use data for formalin vehicle and GTN vehicle from the earlier study 
with formalin, 0.5%.
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2  h o u r  t i m e  p o i n t  
0.5% 5%
4  h o u r  t i m e  p o i n t  
0.5% 5%
F o r m a l i n  
v e h i c l e  &  
G T N  v e h i c l e
1 8 8 1 5 4  
(n  = 5 )
1 3 9  ± 3 6  
(n  =  5 )
7 8 1 1 1  
(n  =  5 )
1 1 0  ± 4 8  
(n  =  5 )
F o r m a l i n  
v e h i c l e  & 
G T N
2 1 2 1 7 6  
( n =  5 )
1 8 7  ± 6 4  
( n =  5 )
1 2 9  ± 4 0  
(  n  = 5 )
1 3 7  ± 5 3  
( n = 6)
F o r m a l i n  &  
G T N  v e h i c l e
1 0 1 1  1 9 4
(n  = 5 )
1 3 7 6 ± 1 5 1  
( n  =  5 )
7 4 6  ± 1 1 0  
( n = 5)
8 7 8  ± 1 4 2
(n  = 5)
F o r m a l i n  &  
G T N
1 0 7 9 1 2 0 2  
(n = 5)
1 4 0 2  ±  2 3 5  
(n  = 6)
5 8 7  ± 4 3  
(n = 5 )
7 6 7  ±  9 4  
( n = 5)
Table 8 Total mean fos counts following treatment with formalin and GTN
Table shows total mean c-fos expression following treatment with combination of 
formalin (0.5% and 5%), formalin vehicle, GTN (5figkg1min1) and GTN vehicle a t 
both the two and four hour end point.
When data was considered as mean c-fos expression per section, formalin, 0.5% 
followed by GTN infusion (Spgkg'W n'1) resulted in a significant increase in c-fos 
positive nuclei in sections taken from two areas (0.97 and 0.85mm caudal to area 
postrema) compared to formalin, 0.5% and GTN vehicle infusion (P < 0.05, repeated 
measures ANOVA followed by Bonferroni’s post hoc test for multiple comparisons). 
This effect occurred in tissue taken from animals where euthanasia was carried out 4 
hours after the stabilisation period and was not evident in the 2 hour study, or where 
formalin was used at a higher concentration of 5%.
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F i g u r e  5  F a c i l i t a t i o n  b y  G T N  o f  c-fos e x p r e s s i o n  i n d u c e d  b y  f o r m a l i n
c-fos expression was assessed as described in section 2.3. Data represents mean c-fos 
expression per section from animals treated with either formalin and GTN vehicle 
infusion or formalin and GTN infusion and perfused 4 hours after GTN infusion. The 
mean c-fos expression induced by formalin, was significantly facilitated by GTN 
infusion compared to vehicle infusion in two sections (P < 0.05 =*, repeated measures 
ANOVA).
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3.3.4.2 Capsaicin
Mean total c-fos expression from all sections in each animal were compared in the 
different drug combination groups and between the different anaesthetic protocols (a- 
chloralose versus urethane). Mean total c-fos expression was not significantly different 
for tissue taken from treatment groups receiving capsaicin vehicle and GTN vehicle or 
capsaicin vehicle and GTN (P > 0.05). Treatment with capsaicin and GTN vehicle or 
capsaicin and GTN both resulted in a significantly increase in the mean total c-fos 
expression over either of the treatment groups with capsaicin vehicle (P < 0.05). 
However, GTN did not significantly increase total c-fos immunoreactivity above that 
seen in capsaicin and GTN vehicle treated animals (P > 0.05). There was also no 
effect of the different anaesthesia protocols on c-fos expression in any of the treatment 
groups {P > 0.05). Additionally, the absence of a stabilisation period after surgery did 
not appear to effect total c-fos expression.
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c-fos expression was assessed as described in section 2.3. Data represents total c-fos 
expression assessed at the 90-minute end point, following capsaicin vehicle and GTN 
vehicle infusion, capsaicin vehicle and GTN infusion, capsaicin and GTN vehicle 
infusion and capsaicin and GTN infusion. Statistical significance was assessed using a 
repeated measures ANOVA. There was no statistical significant difference in total c- 
fos expression seen in any treatment group in animals treated under either anaesthetic 
regime (P > 0.05). In both groups, capsaicin resulted in a significant increase in c-fos 
expression compared to animals receiving capsaicin vehicle (P <0.05), however GTN 
failed to significantly increase total c-fos expression induced by capsaicin in any 
treatment group (P > 0.05).
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While the total c-fos expression showed that GTN did not significantly increase c-fos 
immunoreactivity induced by capsaicin, there was some evidence for a facilitation by 
GTN when mean c-fos expression per tissue section were examined. This facilitation 
occurred in animals anaesthetised with isoflurane and a-chloralose. The facilitation 
was restricted to sections from two locations around area postrema where mean c-fos 
expression per tissue section following both GTN infusion and capsaicin injection 
were 93 ± 17 (n = 5) and 84 ± 16 (n = 5) compared to 56 ± 9 (n = 5) and 50 ± 14 (n = 
5) following GTN vehicle infusion and capsaicin injection (P < 0.05).
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—□ — Capsaicin vehicle & GTN (n = 6) 
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c-fos expression was assessed as described in section 2.3. Data represents mean c-fos 
expression per section from animals anaesthetised with isoflurane and a-chloralose 
and treated with either i.) Capsaicin vehicle and GTN vehicle infusion, ii.) Capsaicin 
vehicle and GTN infusion, iii.) Capsaicin and GTN vehicle infusion and iv.) capsaicin 
and GTN infusion. The mean c-fos expression induced by capsaicin, was significantly 
facilitated by GTN infusion compared to vehicle infusion in sections taken from two 
areas (P < 0.05 =*, repeated measures ANOVA).
-140-
3.3.43 PGE2 and NGF
The mean total c-fos expression following administration of NGF with PGE2 and NGF 
with PGE2 vehicle was not altered by either GTN infusion (5pgkg'1min'1) or GTN 
vehicle infusion (each treatment group, n = 3). However, following administration of 
PGE2 and NGF vehicle, GTN infusion result in a increase in mean total c-fos 
expression compared to c-fos expression following administration of PGE2 and NGF 
and GTN vehicle (33 ± 7 and 16 ± 3, respectively).
40-co
a.30-
-  20 -ct -*-» o *—»
cat
i> 10-
0-1
I GTN vehicle infusion 
I GTN infusion S^xgkg'min
■ II
NGF & NGF & NGF vehicle &
PGF_2 vehicle PGE2 PGE2
F i g u r e  2 4  c-fos e x p r e s s i o n  f o l l o w i n g  a d m i n i s t r a t i o n  o f  P G E 2, G T N  a n d  N G F
c-fos expression was assessed as described in section 23. Data represents total c-fos 
expression assessed at the 2-hour end point following application of either NGF and 
PGE2 vehicle or NGF and PGE2 or NGF vehicle and PGE2 into the face.
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3.4 Discussion
3.4.1 Intra-arterial GTN infusions
These result in section 3.3.2.1.demonstrate that GTN infusion is able to alter the 
activity of second order neurons receiving input from the ophthalmic division of the 
trigeminal nerve, both during and following the infusion. The observation of both 
inhibitory and excitatory effects on neuronal activity is consistent with previous 
studies that have described a similar effect following intravenous infusions of GTN; an 
increase in neuronal activity in 4/5 cells tested and an inhibition of neuronal response 
in 1/5 cells (Jones et al., 2001). This variability may be the result of recording from 
functionally distinct second order cells within the Vc and indeed evidence exists for a 
differential action of nitric oxide on the firing of neurons elsewhere in the spinal cord 
(Pehl & Schmid, 1997). Although the recording position of each neuron was not 
examined immunohistochemically, the depth of recording from the pial surface gives 
an indication of the lamina position, with the highest concentration of lamina I and II 
neurons found between 0 and 250pm and lamina V-VI neurons between 500 and 
1000pm below the pial surface (Urch & Dickenson, 2003). Indeed, cells in this study 
appeared to fall into superficially located cells (65 to 295pm) and deeper located cells 
(780 to 1025pm). However, there was no correlation between cells recorded in 
superficial and deep layers with the response to GTN. The variability in the response 
to GTN may also be related to the differential modulation of Vc neurons by 
descending pathways and studies using GTN infusion in decerebrate animals, where 
the influence of higher order structures is removed, would likely provide an insight
- 142-
into this.
Topical GTN administration into the peripheral receptive field around the MMA 
(section 3.3.2.2) was almost identical to the effect of intra-arterial infusions; hence, a 
peripheral effect may be responsible for the observed effects on neuronal activity, 
although, given the highly lipophilic nature of GTN, a central effect cannot be ruled 
out. GTN infusion at a rate of Spgkg’W n"1 did not increase MMA diameter as 
assessed by intravital microscopy (section 3.3.1), but nonetheless altered MMA- 
evoked firing in Vc neurons (section 3.3.2.1), hence, increased Vc neuronal activity is 
not caused simply by dilatation of the MMA with an associated increase in primary 
afferent neurone firing. This is in agreement with recent clinical findings showing that 
GTN does not alter middle cerebral artery diameter but robustly generates migraine in 
2 / 3 of migraineurs studied (Goadsby et al, 2004). Therefore, it seems likely that in 
the time period examined, GTN is exerting a direct effect on primary afferent neurons.
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Stimulating
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Intra-arterial GTN infusion
Figure 25 Site of action of GTN
The above schematic shows the recording set up for electrophysiological studies 
described. Both Topical and intra-arterial infusion o f GTN resulted in a significant 
alteration o f MMA-evoked Vc firing, however, intra-arterial infusion o f GTN (5pgkg 
lm in1) did not result in dilatation o f the MMA, indicating that GTN acts directly on 
the peripheral terminal o f the primary afferent neuron, although due o the lipophilicty 
o f GTN, tissue diffusion and a central action cannot be ruled out.
Administration of CGRP in these studies resulted in vasodilatation of the MMA in 
agreement with previous studies (section 3.3.1.1; Cumberbatch et al., 1999). 
Interestingly, following this dilatation, a second GTN infusion resulted in 
vasodilatation of the MMA during infusion at 5pg kg' 1 min*1, which in the first infusion 
had no effect on MMA diameter. Hence, it is likely that either the first series of GTN 
infusions or CGRP generated a higher sensitivity to the effects of GTN. This increased 
sensitivity may underlie the delayed headache seen clinically following GTN infusion
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in migraineurs, for example, GTN facilitated release of CGRP or other inflammatory 
mediators may ultimately lead to an alteration in gene expression and up-regulation of 
pronociceptive receptors or mediators.
Release of inflammatory mediators in the dura mater following both topical and 
systemic GTN infusions have been previously examined (Reuter et al., 2001). The 
cytokine, interleukin 1P was found to be induced, with peak levels observed one and 
six hours after GTN infusion, interleukin 6 was also increased in dural macrophages 
and cerebrospinal fluid six hours after GTN infusion. Both interleukin ip  and 
interleukin 6 are known to be involved in the development of oedema and A5 
sensitisation (Macmicking et al., 1997). Dose dependant increases in Type II nitric 
oxide synthase (or inducible nitric oxide synthase) mRNA was also detected in the 
dura mater at two hours with corresponding increases in the protein at four, six and ten 
hours after GTN infusion. However, whether interleukin or nitric oxidase synthase up- 
regulation occurs differentially in migraine sufferers and healthy volunteers remains to 
be explored.
3,4.2 The effect o f GTN in combination with inflammatory mediators
The application of capsaicin to the dural receptive field resulted in a significant 
facilitation of evoked Vc responses (section 3.3.3.2.1). Significant enhancement of 
FRF responses was also seen, indicating the development of central sensitisation 
(section 3.3.3.2.4.). However, when capsaicin was administered into an area outside 
the FRF facilitation of electrically evoked MMA-responses was much less pronounced 
(section 3.3.3.2.3.) although significant c-fos expression could be observed following
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the same capsaicin stimulus (section 3.3.4.2.). This suggests that while capsaicin 
administration into the facial skin can generate a robust central neuronal activation, the 
pool of neurons activated may not coincide with those activated following MMA 
stimulation. Alternatively, the differential response following dural and facial 
capsaicin application may represent different sensitivities of the primary afferent 
neurons to capsaicin stimulation.
R e c o r d i n g
e l e c t r o d e
B i p o l a r
S t i m u l a t i n g
e l e c t r o d e s
Capsaicin
application
Vc
+++
N o n - n o x i o u s  s t i m u l a t i o n
Figure 26 Topical capsaicin application results in central sensitisation
Capsaicin application over the MMA resulted in a significantly facilitated response 
both to MMA-evoked firing and the response to facial stimulation indicating the 
development o f central sensitisation.
Within the rat, trigeminal system formalin has been examined as a sensitizer of 
cutaneous afferents (Clavelou et al., 1989) and of deeper tissue afferents in the 
temporomandibular joint (Roveroni et al., 2001) with enhanced nociceptive behaviour
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observed in both models. Furthermore, following sub-cutaneous facial formalin 
injection, considerable c-fos expression can be observed in laminae I, II and V of the 
VBNC as well as in the adjacent ventrolateral reticular formation (Wang et al., 1994). 
Interestingly, cells exhibiting c-fos expression following facial injection of formalin, 
were co-localised with the glutamate NMDA receptor (94% of cells showing c-fos 
immunoreactivity) and with NO synthase (14% of cells showing c-fos 
immunoreactivity) (Leong et al., 2000). The electrophysiological response of Vc 
neurones to electrical stimulation of the facial receptive field has also been examined 
following facial formalin injection. Here, a small number of the tested neurons were 
not affected by formalin whereas most either an early and short-lasting increase in the 
response or two phases of facilitation separated by a short period of quiescence 
(Raboisson et al., 1995). Thus, the failure of facial formalin injection to facilitate 
responses of Vc neurons to electrical stimulation of the MMA in this thesis (section 
3.3.3.1), despite a robust induction of c-fos expression (section 3.3.4.1), further 
demonstrates that significant differences exist in the response of Vc neurons when 
activated by cutaneous and dural inputs.
In the study designed to replicate the facilitation by GTN of c-fos expression induced 
by capsaicin, described by Jones et al. (2001), the authors were contacted to ensure 
identical conditions (i.e. rat strain and supplier, anaesthetic doses). However, GTN 
infusion failed to increase total c-fos expression induced by capsaicin in any 
experiments of this thesis (section 3.3.4.2.), moreover GTN had no effect on capsaicin 
induced sensitisation of Vc electrophysiological response (section 3.3.3.2.2). This lack 
of facilitation of total c-fos expression by GTN was also evident in studies using 
formalin to stimulate c-fos expression (section 3.3.4.1.). However, facilitation by GTN
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of c-fos expression induced by capsaicin and formalin was observed in sections from 
two areas, which corresponded to the Vc. The facilitation was more evident in the 
experiments using formalin rather than capsaicin as a mediator of sensitisation. 
However, this may be related to the end-points of the experiment, as tissue was taken 
from animals four hours after GTN infusion in the formalin study but in order to allow 
comparison of data in the capsaicin study with a previously published study (Jones et 
al, 2001), the end-point was ninety minutes.
The facilitation of c-fos expression following GTN infusion, that is highly specific to 
the Vc and maximal four hours after GTN infusion, supports the hypothesis that in 
migraine subjects, GTN is specifically able to act on a subset of neurons that are more 
sensitised than in controls to generate a delayed headache. The origin of the central 
sensitisation is still a subject of speculation; however, following completion of this 
thesis, an up-regulation of the 5-HT2A receptor in migraineurs has been proposed to 
underlie the delayed headache response to GTN (Srikiatkhachom et al., 2002). 
Although this hypothesis is still speculative, the efficacy if 5-HT2 antagonists in 
migraine prophylaxis (see section 1.8.4.3.) make this an attractive prospect.
Sensitisation elicited by PGE2 application into the division of V2 was also facilitated 
following GTN infusion. However, the numbers in this study were small and further 
experimental data is needed to support these results. As such, study 2 in this thesis has 
focused on sensitisation generated by prostanoids in the trigeminal system. Evidence 
for a role of prostaglandins in mediating the biological effect of GTN were implicated 
in a recent study (Tassorelli et a l , 1997). Here, indomethacin, which inhibits the 
cyclo-oxygenase (COX) enzyme, responsible for the production of prostaglandins,
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resulted in a significant reduction in c-fos expression in the Vsp and several 
supraspinal nuclei compared to when GTN was administered alone. Other evidence 
has also emerged in the last few years that further implicate prostaglandins in the 
pathology of migraine and this is discussed in section 4.1.
In summary, the differential response following GTN infusion in healthy volunteers 
and migraineurs can not yet be adequately explained by available animal models. It is 
possible that migraineurs have a greater susceptibility to cytokines and other 
inflammatory mediators released in the dura mater following GTN infusion. However, 
it is also possible that peripheral activation occurs in a similar manner in both healthy 
volunteers and migraineurs and the difference lies in the response of either second or 
third order neurons, which may be modulated by receptor expression such as the 5- 
HT2A receptor. It is also possible that the effects of GTN infusion trigger a migrainous 
cascade within the central nervous system completely unrelated to any putative 
inflammatory mechanism.
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T r e a t m e n t _______________________________
Intra-arterial / topical GTN infusion - 
Intravital microscopy
S u m m a r y _______________________________
Vasodilatation maximally following 
CGRP and topical GTN application. 
Possibly greater vasodilatation after 
sensitization
Intra-arterial GTN infusion -Vc 
electrophysiology
Capsaicin over the MMA and intravenous 
GTN infusion - Vc electrophysiology
Capsaicin into the FRF and intravenous 
GTN infusion - Vc electrophysiology
Formalin into the FRF and intravenous 
GTN infusion - Vc electrophysiology
Formalin into the FRF and intravenous 
GTN infusion - c-fos 
immunohistochemistry
Capsaicin into the FRF and intravenous 
GTN infusion - c-fos 
immunohistochemistry
PGE2 and NGF into the FRF and 
intravenous GTN infusion - c-fos 
immunohistochemistry_______________
Inhibitor and excitatory response seen
Sensitization of both electrical evoked 
and mechanically evoked response. Not 
facilitated by GTN
Sensitization mechanically evoked and 
electrically evoked response
No sensitization seen
Robust c-fos expression following 
formalin. Some evidence for facilitation 
by GTN in specific discrete area of the 
Vc
Robust c-fos expression following 
capsaicin. Some evidence for 
facilitation by GTN in specific discrete 
area of the Vc
Numbers small but c-fos expression 
induced by PGE2 may be facilitated by 
GTN
Table 9 Results summary of study 1
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4  S t u d y  2  T h e  R o l e  o f  P r o s t a n o i d s  i n  s e n s i t i s a t i o n  o f  t h e  t r i g e m i n o v a s c u l a r  
s y s t e m
4 .1  I n t r o d u c t i o n
The role of prostaglandins (PGs) in causing pain has been the subject of much research 
since the proposal in the early 1970's that aspirin-like drugs exert their effects by 
interfering with their production (Vane, 1971; Ferreira, 1972). PGs were first 
discovered in the 1930's by a group of medical students, who identified them as an 
active substance present in semen that was able to cause contraction of uterine smooth 
muscle. During the 1960's, the crystalline form of PGE2 and PGF2Q were identified 
(Bergstorm & Sjovall, 1960), and some years later it was discovered that PGs were 
part of a large class of compounds, now known as eicosanoids. The eicosanoids, as 
well as PGs, encompass other classes of compounds such as thromboxanes, 
leukotrienes and lipoxins, all of which are derived from the unsaturated fatty acid, 
arachidonic acid (AA). AA itself is liberated from cell membranes by the action of 
various phospholipases, following cellular activation by various physiological and 
pathophysiological factors such as inflammation, hormonal influences and increased 
intracellular calcium.
Following the liberation of AA from the cell membrane, intermediate products PGG2 
and PGH2 are produced by the action of an enzyme, variously known as prostaglandin 
H synthase or prostaglandin endoperoxidase synthase or more commonly as cyclo- 
oxygenase (COX). Further enzymatic conversion by various prostaglandin synthases, 
isomerase and thrombaxane synthases, gives rise to the functionally active 
eicosanoids, which are released from the cell following synthesis.
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P h o s p h o l i p i d s
(cell membrane)
Phospholipase C
Diacylglycerol
Phospholipase D
Phosphatidic acid
DAG kinase
DAG lipasePhospholipase A-
Glycerol
Arachidonate
Figure 27 Liberation of AA from cell membranes by the action of phospholipases
The initial and rate limiting step in eicosanoid synthesis is the release o f AA from cell 
membranes. Arachidonic acid (or arachidonate) is liberated from cell membranes in 
either a one-step process, involving phospholipase A2 or a two step process involving 
either phospholipase C and then DAG lipase or phospholipase D and then 
phospholipase A 2.
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At least two types of the COX enzyme are known to exist (COX-1 and COX-2), with a 
third isoform recently proposed (Willoughby et al., 2000). Both COX-1 and COX-2 
are membrane-associated enzymes that are inhibited by the action of non-steroidal 
anti-inflammatory drugs (NSAIDs). The COX-1 isoform is constitutively expressed in 
many tissues and responsible for the beneficial effects of PGs. In the periphery, the 
COX-2 isoform appears to be induced following a range of pathophysiological stimuli 
and as such, many selective COX-2 selective inhibitors have now been designed to 
treat a wide range of conditions from cancer pain to chronic inflammation. However, 
in the spinal cord, both COX-1 and COX-2 appear to be constitutively expressed, 
although a significant increase in COX-2 but not COX-1 expression over basal levels 
has been reported under experimental conditions of peripheral inflammation (Hay & 
de Bellroche, 1997, 1998; Beiche et al., 1998). A similar pattern of COX expression is 
found in neurons, but not glial cells of the brain, with both isoforms present under 
basal conditions and an up-regulation of COX-2 in response to stress (Yamagata et al., 
1993).
The functional metabolic PG products of arachidonic acid have been classified as 
types D, E, F and I and once released into the intracellular space, by an as yet, 
undefined mechanism, exert their effects by acting on specific receptors in the plasma 
membrane. The receptors for these functional PGs are designated by a "P" and 
preceded by their main agonist type of PG, i.e. PGD2, PGE2, PGF2 and PGI2 act on 
DP, EP, FP and IP receptors respectively. All of these receptors are G-protein coupled 
receptors and exert their effects by activating intracellular signalling cascades 
depending on their G-protein coupling. Studies in this thesis have focused on PGE2 
only, hence, the following review will concentrate on the EP receptors, although it
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should be remembered that there is considerable evidence to suggest cross-reactivity 
of PGE2 with other PG receptors.
There are four main sub-types of the EP receptor, namely EPj, EP2 EP3 and EP4 
(Kennedy et al., 1982), each having distinct signal transduction pathways. These 
signal transduction pathways have been investigated following agonist induced 
changes in the levels of second messengers (for review see Narumiya et al., 2001).
^  1
EPi activation appears to result in an increase in Ca mobilisation with subsequent 
PKC activation, EP2 and EP4 are coupled through Gs to increase cAMP and EP3 has 
several splice variants as a result of post-translational modification that can either
^  I
increase intracellular Ca , or inhibit or stimulate cAMP.
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Phospholipases
Arachidonic acid
Intermediates
PGL PGD, PGF2„ TxA
EP1 EP2 EP3 ■ EP4
Gs Gi.Gs, Gq Gsunknown GsG-protein unknown multipleGq?
CAMP
PLC
FP TPDP
Cox2Cox1
PGE
Figure 28 Prostaglandin synthesis
Following release o f AA into the cytosol, cyclo-oxygenase enzymes act in a two step 
process to produce PGG2 which is further converted to PGH2. The fate o f these 
intermediate products then varies between cell types, with various prostaglandin 
synthases producing the various functional products.
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Of the EP receptors, EP3 and EP4 receptors are widely distributed in most tissues 
throughout the body, whereas EPi distribution is restricted to the stomach, kidneys and 
lungs and EP2 appearing to be largely induced via inflammatory stimuli. Within the 
nervous system, EP3 is widely distributed in the brain and there is significant EP4 
expression in the hypothalamus and lower brain stem. With the use of PCR and 
immunohistochemical techniques, mRNA for all four EP receptors has recently been 
detected in the spinal cord (Kawamura et al., 1997; Beiche et al., 1998), dorsal root 
ganglion and trigeminal ganglion cells (Jenkins et al., 2000; Negishi et al., 1995), with 
EP3 expressed in 50% of all DRG's, with a pre-dominance in small sized cells.
Given this distribution of EP receptors in the nervous system, a role in pain signal 
transmission seems likely, although exploration has been hampered by the lack of 
selective agonists and antagonists currently available. However, a limited number of 
compounds with some selectivity at the different EP sub-types have recently been 
made accessible and are summarised in the table below.
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EPi EP2 EP3
A g o n i s t s -17-phenyl-
trinor-PGE2
-iloprost
-sulprostone
-Butaprost 
-AH13205 
-Misoprostol
-Sulprostone -NONE 
-SC-46275 
-ONO-NT-012 
-SC 46275
A n t a g o n i s t s -ZM325802 -AH6809 -NONE -GW627368
-SC51322 -AH22921
-SC19220 -AH23848
-ZD6416
-AH6809
-ONO-NT-
012
Table 10 Ligand availability for the EP receptors
Summary o f available ligands acting on EP receptors; Iloprost is a partial agonist at 
EP 1 receptors but also a potent full agonist at IP receptors; Misoprostol also has an 
effect at EP3 receptors; AH-22921 and AH-23848 are also antagonists at TP 
receptors.
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Prostanoids contribute to the development of pain by acting both peripherally and 
centrally. Peripherally, they play a major role in generating peripheral sensitization by 
increasing the sensitivity of the peripheral terminals of high-threshold pain fibres. 
Centrally administered PGs produce marked alterations in pain behaviour, including 
exaggerated responses to noxious stimuli as well as pain responses to normally 
innocuous stimuli.
PGs, mainly PGE2 and PGI2, are rapidly produced following tissue injury or 
inflammation at the site of injury in response to noxious mechanical, thermal, and 
chemical stimuli. Bradykinin is one of the most potent algogans and is considered to 
mediate hyperalgesia during inflammatory processes and partly depend on a 
sensitization action of PGE2. PGs can be also released within the spinal cord by 
noxious, but not innocuous, stimuli applied to peripheral tissues. Enhanced spinal 
release of PGE2 and induction of COX-2 in the spinal cord are major consequences of 
peripheral inflammation, and these two events may be linked when inflammation is 
prolonged, (for review see Ito et al., 2001). The action of PGs in generating peripheral 
inflammation, oedema and localized swelling following tissue injury is well known, 
however, the source and mechanism of action of PGs in the inflammation process is 
not yet well characterized. A recent study showed that both macrophages and mast 
cells are likely to be a source, although other sites of production such as sensory 
neurons and vascular endothelium are also likely to be involved in their release (Ma & 
Eisenach, 2002).
The mechanism by which PGs generate peripheral sensitisation was initially thought 
to result from induction of a heightened responsiveness of sensory neurons to the
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effects of other mediators, although data now indicate that PGE2 is able to cause a 
direct activation of sensory neurons (Baba et al., 2001). The cellular mechanism by 
which PGs exert their effects on peripheral neurons is thought to involve activation of 
several different ion channels with resultant activation of the cAMP second messenger 
system and neuropeptide release, which has been confirmed in in vitro experiments by 
the use of PKA inhibitors (Aley & Levine, 1999). PGE2 has also been shown to alter 
the activation potential of tetrodotoxin-resistant sodium currents (TTX-R /n3) to more 
negative potentials (England et al., 1996), facilitate the capsaicin-induced current 
(Lopshire & Nicol, 1998), increase the activation of the hyperpolarization-activated 
cation current (4; Ingram & Williams, 1996) and attenuate calcium-activated 
potassium currents (Gold et al., 1996). The ability of PGE2 to modulate the activity of 
the TTX-R /n3 through a PKA-related mechanism has been further explored by studies 
using knockout mice deficient in the SNS channel (sensory neuron-specific 
tetrodotoxin (TTX)-resistant voltage-gated sodium channel), responsible for the TTX- 
R /n3 and in mice deficient for RI, a regulatory subunit of the PKA enzyme. In these 
mutant mice, a defective nociceptive response following intraplantar PGE2 was seen, 
compared to wild type mice, indicating PKA phosphorylation of sensory neurone 
membrane channels is likely to be involved in the sensitising effects of PGE2 
(Malmberg et al., 1997). Further determination of the role of PGs in peripheral 
sensitisation, may be aided by the use of specific knockout mice deficient in the EPj, 
EP2 (Kennedy et ah, 1999), EP3 (Ushikubi et al., 1998) and EP4 (Sakuma et al., 1994) 
receptors, however at present, the peripheral site of PG action in generating pain 
remains largely undiscovered.
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Figure 29 Peripheral sensitisation following PG release
The mechanism o f prostaglandins induced sensitisation o f peripheral neurons is not 
fully understood. However preliminary investigation has shown that following cellular 
insult, prostaglandins are released into the extracellular space and act on cell surface 
receptors to cause a variety o f intracellular effects in surrounding sensory neurons 
such as activation o f protein kinases and subsequent modulation o f ion channels.
The involvement of PGE2 in dural sensitisation has been demonstrated in the in vitro 
model of neurogenic inflammation described in Chapter 1. Following electrical 
trigeminal ganglion stimulation and exposure of the dura mater to inflammatory 
mediators, PGE2, and CGRP release were significantly elevated over basal levels 
(Ebersberger et al., 1999). This was further examined in the same model using ATP 
and low pH solutions to stimulate the dura mater (Zimmermann et al., 2002). These 
authors hypothesised that the enhanced PGE2 release seen following exposure to ATP, 
resulted from activation of the Gq/11 protein coupled to P2Y receptors leading to 
activation of IP3 mediated intracellular calcium increase. Interestingly, CGRP release 
was not detected after exposure of the dura mater to ATP but was seen after exposure 
to low pH. Hence, it is possible that during a migraine attack, an initial PGE2 release 
may generate dural inflammation and a subsequent decrease in pH, triggering CGRP 
release. Indeed, PGE2-induced CGRP release in the peripheral trigeminal system has 
been shown in cultured adult rat trigeminal ganglion neurons (Jenkins et al., 2001). 
Furthermore, CGRP release is also increased following stimulation with PGD2, PGI2 
and the EP2 agonist, butaprost.
As previously discussed, PGE2 also forms part of the "soup" of inflammatory 
mediators, that when applied to an open cranial window generates an increase in the 
response of second order neurons within the Vc (Burstein et al., 1998). Given the 
evidence now available from in vitro studies to support a role of PGE2 in initiating 
dural inflammation, this study has focused on the specific ability of PGE2 to sensitise 
the trigeminal system, evidenced by an increased activity of second-order neurons in 
the Vc.
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Additionally the effect of, the efficacious migraine treatment, naratriptan (see section 
I.8.3.2.) has been examined. Naratriptan (N-methyl-3-(l-methyl-4-piperidinyl)-lH- 
indole-5-ethane-sulphonamide), a 5HT1B/1D receptor agonist has no effect in a 
variety of antinociceptive tests but selectively inhibits neurogenic plasma protein 
extravasation in the dura in anaesthetized rats (ID50 = 4.1 micrograms kg-1) (Connor 
et al., 1997). Additionally, naratriptan has previously been shown to inhibit Vc 
response to dural stimulation in the rat and cat (Cumberbatch et al, 1998; Goadsby & 
Knight, 1997), moreover this effect appears specific for the Vc as dorsal horn 
responses to noxious stimulation of the hindpaw were unaffected by naratriptan 
(Cumberbatch et al, 1998). The purpose of using naratriptan following the induction 
of sensitisation with PGE2 in this study was to look for any differential effect 
compared to the efficacy of naratriptan in the un-sensitised state, thereby examining 
the possibility that the induction of sensitisation in migraineurs may be responsible for 
the proportion of migraineurs that are unresponsive to triptan therapy.
EPi and EP4 antagonists were also examined in this model of PGE2 sensitisation to 
determine whether PGE2 was acting through either of these receptors. Due to the lack 
of selective EP2 antagonists, the selective EP2 agonist, butaprost was also examined 
for it’s ability to generate sensitisation in a similar manner to PGE2. The possibility 
that PGE2 was acting through the EP3 receptor was not examined due to the lack of 
availability of selective compounds.
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4.2 Methods
Electrophysiological recording of second order neurons in the Vc responding to 
electrical stimulation of the MMA with A5-fibre latency were carried out as described 
in section 2 .1.
4.2,1 Receptive field characterisation
Following identification of a Vc neuron that responded to electrical stimulation of the 
MMA, mechanical stimulation of the face was used to test for a convergent cutaneous 
input and only cells activated both by dural and facial stimulation were studied. The 
area of the face that was most sensitive to afferent stimulation was then marked on the 
face by marker pen (area typically 1 cm) and the response to a light, non-noxious 10- 
second brush and a noxious 5-second pinch stimulation of this area, assessed three 
times. The preparation was left for 10 minutes to minimize sensitisation from FRF 
stimulation, before trains of electrical stimulation (50 repetitions at 1Hz, 5 minutes 
apart) were applied to the dura mater overlying the MMA. No attempt was made to 
follow changes in FRF size during the course of an experiment, as in characterisation 
studies of Vc electrophysiology, considerable variation was found in FRF size after 
noxious stimulation such as pinch responses, which is in agreement with findings 
made by Dubuisson et al., (1979). FRF’s responses to brush and pinch stimuli were re­
tested 30 minutes after PGE2 stimulation and then at 15-minute intervals for the 
remainder of the experiment.
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4.2.2 Evaluation of the sensitising effects o f PGE2
PGE2 or PGE2 vehicle was applied either topically over the MMA or subcutaneously 
injected into the FRF or given as an intra-arterial infusion following establishment of 
baseline recording to trains of electrical stimulation where a variation of less than 10% 
was seen). For topical application, a gauze swab (approx. 5mm x 5mm), containing 
100(0.1 of PGE2, ImM, or PGE2 vehicle (1% ethanol, 99% saline) was applied on the 
thinned cranial window below the bipolar electrodes for 5 minutes. A higher 
concentration of PGE2 was used for topical application experiments compared to 
subcutaneous injection into the FRF or for the intra-arterial infusions due to the 
unreliability of compound penetration through the cranial window. During PGE2 
application, electrical stimulation was turned off to avoid problems with spread of the 
electrical stimulus to adjacent muscles. The gauze was then removed, the skull rinsed 
with saline, dried and re-covered with mineral oil. A caveat of this study was the use 
of ethanol as part of the PGE2 vehicle, as alcohol is known to be a trigger for migraine 
(Martelletti et al., 1991). However, the concentration of ethanol used was low and in 
control experiments, vehicle had no significant effect on Vc firing, although the 
possibility that a facilitation of the PGE2 effect was related to the ethanol vehicle 
cannot be excluded.
For FRF application, PGE2 (O.lmM in 50 pi) or PGE2 vehicle (1% ethanol, 99%, 
saline in 50 pi) was administered subcutaneously into the area of the FRF that was 
most sensitive to afferent stimulation. For intra-arterial infusions of PGE2, a second 
cannula was placed in the same carotid artery, cannulated for blood pressure 
monitoring, towards the cranial circulation. A constant pressure was applied by a slow
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saline infusion (0.4ml/hr) to prevent back-flow from the circulation. PGE2 (O.lmM) or 
PGE2 vehicle was then administered over 5 minutes in 0.1ml. Following PGE2 or 
PGE2 vehicle administration, electrical stimulation trains were continued for the 
remainder of the experiment.
4.2.3 Naratriptan inhibition of PGE2 sensitised responses
In separate experiments, the inhibitory effect of Naratriptan (3mgkg_1 in 0.2ml or 
Naratriptan vehicle in 0.2ml, administrated as a bolus intravenous dose), was also 
tested. Experiments were carried out as described for topical application of PGE2 and 
naratriptan administered immediately after application of PGE2 or PGE2 vehicle.
4.2.4 Prostanoid receptor subtypes involved in PGE2- sensitisation
4.2.4.1 EP2  agonist
Due to lack of selective EP2 antagonists available, the EP2 agonist, butaprost was 
assessed for its ability to generate sensitisation in comparison to PGE2. Both topical 
administration (lOOpl of 5nM solution) and intra-arterial infusion (0.1 ml of 5nM 
solution over 5 minutes) were tested using the protocol described for PGE2 above. The 
vehicle used to dissolve butaprost was the same as for PGE2 (1% ethanol and 99% 
saline for final dilutions).
4.2.4.2 EPj antagonist
ZM325802 (EPi antagonist) or vehicle (1% dimethyl sulfoxide (DMSO), 66% PEG200 
and 33% distilled water) was applied topically (5mM solution in a
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volume of 50pl) on a gauze swab over the MMA for 5 minutes, the skull was then 
washed and dried and topical PGE2 administered, as above. The effects of the 
antagonist were also tested following intravenous administration (3mgkg_1 in 0.2ml). 
Here topical application of PGE2 was carried out as described above with the 
antagonist given immediately after application of the gauze swab to the closed cranial 
window.
4.2.4.3 EP4 antagonist
GW627368 (EP4 antagonist) or vehicle (1% dimethyl sulfoxide (DMSO), 66% PEG200 
and 33% distilled water) was also tested topically and intravenously as described 
above for ZM325802 at a concentration of 2mM and a dose of 0.2mgkg_1 respectively.
4.2.5 Statistical analysis
Data is represented, where appropriate, as mean ± standard error of the mean, 
frequency of response or the number of spikes per second. Responses to electrical 
stimulation of the MMA were normalised as the total response to the train of 
stimulation directly before treatment and expressed as a percentage of this response. 
Statistical analysis was carried out using repeated measures ANOVA followed by 
Bonferroni’s post hoc test for multiple comparisons (Origin 7 package, Originlab 
Corporation, USA). P < 0.05 was considered significant. Mechanically evoked FRF 
responses were normalised with respect to control responses and expressed as a 
percentage of this response. Statistical analysis was carried out using Student’s /-test 
(Origin 7 package; P < 0.05 was considered significant).
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4.3 Results
Data from 92 animals have been included in the analysis. All had acceptable 
respiratory parameters for the anaesthetised rat and were in the range: pCC>2, 35- 
45mmHg; pC>2, 90+ mmHg and pH, 7.35-7.45. Data from two animals were not 
included as O2 concentration fell below this range. Mean arterial blood pressure 
(MABP) and heart rate during baseline recordings from all studies was 112 ± 
17mmHg and 376 ± 23 beats per minute respectively. Naratriptan caused a small 
temporary reduction of MABP and heart rate of 11 ± 8mmHg and 15 ± 6, respectively, 
however this typically lasted no longer than 20 seconds. Intra-arterial infusion of 
PGE2, butaprost and vehicle all caused a small increase in MABP and heart rate of 9 ± 
4mmHg and 12 ± 5, respectively, which occurred 30 seconds to 2 minutes after the 
start of infusion and remained elevated for the remainder of the experiment. No 
significant effect on MABP or HR was seen in other experiments.
All cells responded to electrical stimulation of the MMA with A5-fibre latency and a 
mean response latency of 15 ± 3ms (range: 8.5 to 26.1ms) and a mean amplitude of 
response of 0.42 ± 0.1 OmV (range: 0.12 to 0.60mV). The mean threshold of electrical 
stimulus strength (current amplitude and pulse duration) to elicit neuronal responses of 
second order neurons in the Vc was 2.9 ± 0.6mA and 0.3 ± 0.06ms respectively, 
however stimulation at threshold resulted in only one neuronal response in some cells 
where as other cells showed two or three responses.
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4.3.1 Topical PGE2 application to MMA
For cells tested with PGE2, electrical stimulation of the MMA during baseline 
measurements resulted in a mean number of responses to trains of fifty electrical 
stimulation of 86 ± 14 (n = 8). Following application of ImM PGE2 to the area over 
the MMA, 7/8 cells showed an increased firing rate above baseline. The mean 
maximum response occurred to the first stimulation train after PGE2 application where 
the mean number of spikes was 162 ± 30 (n = 8). However, the onset of the maximum 
response was variable between cells with 3/8 cells responding with a maximum 
increase in firing in the first stimulation train after PGE2 application, 2/8 cells in the 
second stimulation train and 1/8 cells in the third and fourth train. One of eight cells 
was unaffected by PGE2.
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Before PGE2 application After PGE2 application
C e l l  1
C e l l  2
f*MjWkAIWh/1Wk*
F i g u r e  3 0  N e u r o n a l  r e s p o n s e s  t o  e l e c t r i c a l  s t i m u l a t i o n  o f  t h e  M M A ,  b e f o r e  a n d  
a f t e r  P G E 2 a p p l i c a t i o n
Figures show the response of two-second order neurons in the Vc to electrical 
stimulation of the MMA before and after PGE2 application. Cell 1 responded to MMA 
stimulation with latency of 15.5ms and amplitude of 0.38mV; 10 minutes after 
application of PGE2, the same cell showed an increased response to an identical 
stimulus. Cell 2 exhibited three responses to electrical stimulation of the MMA at 
threshold stimulation levels, the latency of response was in a range of 10.4 to 13.8ms 
and amplitude of response was 0.2lmV; following PGE2 treatment the same cell 
typically gave an increased number of responses to the same stimulus.
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The application of PGE2 vehicle to the MMA caused a small increase in the firing rate 
of Vc neurons in the first stimulation train after application, from pre-treatment values 
of 79 ± 8 (n = 4; mean number of response to one stimulation train) to 93 ± 4 (n = 4; 
mean number of response to one stimulation train). However, the mean increase in 
evoked neuronal activity after PGE2 treatment (88 ± 15% over pre-treatment levels; n 
= 8) was significantly greater than that seen following treatment with PGE2 vehicle 
(17 ± 2 % over pre-treatment levels; n = 4; P < 0.05). In 6 cells the increased firing 
rate that occurred following PGE2 application returned to baseline levels 30 minutes 
after PGE2. However, 1 cell showed an increased firing rate for the remainder of the 
experiment and 1 cell showed a second phase of increased firing. This “second wave” 
of increased responses occurred 35 minutes after PGE2 application and lasted for a 
further 20 minutes before returning to baseline levels.
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Figure 31 Post-stimulus histograms of electrically evoked responses
Post-stimulus histograms showing examples o f single cells responding to electrical 
stimulation o f the MMA before treatment (ai, bi), during treatment with either PGE2, 
(ImM; aii) or vehicle, (1% ethanol, 99% saline, bii) and 45-60 minutes after treatment 
(recovery; aiii, biii). Each histogram represents the frequency o f responses occurring 
at a given latency following electrical stimulus application, taken from 3 stimulation 
trains (50 stimuli in a single train at 1 Hz) over a 15 minute time period during the 
indicated treatment phase.
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Figure 32 Effect of PGE2 applied to the MMA on neuronal activity
(a.) Trace example o f a recording o f MMA-evoked activity from a single Vc neuron. 
Blocks at the bottom o f the trace represent the occurrence o f electrical stimulation 
trains (50 stimuli at 1 Hz) and individual lines represent the number o f spikes 
recorded at a given time point. Electrical stimulation was turned off during PGE2 
application (marked by arrow), (b) The mean response o f all 8 cells tested with PGE2 
application (marked by arrow) are shown. Data is normalised with respect to the total 
response to the electrical stimulation train given immediately before PGE2 application 
and indicates mean ±  SEM. A significant increase in MMA evoked neuronal activity 
which reached a maximum o f 88 ±  15% (n =  8)  over the maximum increase evoked by 
PGE2 vehicle was seen, 5 minutes after PGE2 application (*P < 0.05; repeated 
measures ANOVA). (c.) Five o f seven cells that showed an increased firing rate 
following PGE2 application returned to pre-treatment firing levels 30 minutes after 
PGE2. However, 1/7 showed an increased firing rate throughout the experiment and 
1/7 cells showed two phases o f increased firing which are shown graphically as the 
mean number o f spikes to trains o f 50 stimuli.
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Three of eight cells tested with PGE2 were spontaneously active with mean ongoing 
rates of activity of 0.4, 1.1 and 2.3 spikes per second during the pre-treatment period. 
This was significantly facilitated 10 minutes after PGE2 application with a mean 
maximum increase in firing o f ll6 ± 3 1 %  over pre-treatment values (n = 3; P < 0.05). 
In all three spontaneously active cells, the increased firing rate remained elevated for 
20 minutes after PGE2 application before returning to pre-treatment levels for the 
remainder of the experiment.
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Figure 33 Effect of PGE2 applied to the MMA on spontaneous neuronal activity
Spontaneous activity o f a single Vc neuron. The above figure shows the number o f  
spikes per second, assessed in the 250 seconds between periods o f  electrical 
stimulation and displayed as the cumulative total response to three such periods in the 
15 minutes preceding PGE2 application (a) and the 15 minutes immediately after 
PGE2 application (b).
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4.3.2 Effect o f Topical PGE2  on responses evoked by stimulation of the FRF
All cells included in PGE2-sensitisation experiments were classified as wide-dynamic 
range neurons based on their response to mechanical stimulation of the FRF. In most 
experiments the FRF, extended over both the first and second division of the 
trigeminal nerve. However, in some experiments the FRF included the area innervated 
by the third division of the trigeminal nerve. The mean number of spikes resulting 
from brush and pinch stimulation of the FRF was variable between cells with a range 
for pre-treatment brush stimulation of 15-53 spikes per 10 second stimulus (n = 24 
samples in 8 cells) and a range for pre-treatment pinch stimulation of 19-67 spikes per 
5 second stimulus (n = 24 samples in 8 cells). However, all cells showed a significant 
facilitation to brush and pinch stimulation after PGE2 application, although this did not 
reach significant levels until 30 minutes after PGE2 application. The mean maximum 
facilitation occurred at a median time point of 60 minutes after PGE2 application in a 
range of 30-75 minutes and was 332 ± 103% (n = 24 samples in 8 cells) and 402 ± 
102% (n = 24 samples in 8 cells) over pre-treatment levels for brush and pinch 
stimulation, respectively (P < 0.05). PGE2 vehicle application also resulted in a 
significant increase in brush and pinch responses over baseline responses of 110 ± 
57% (12 samples in 4 cells) and 103 ± 42% (12 samples in 4 cells), respectively (P < 
0.05). However, the maximum response to PGE2 vehicle was significantly less than 
the facilitation seen following PGE2 application and occurred at a median time point 
of 30 minutes after application (P < 0.05; n = 4).
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Figure 34 Response to FRF stimulation after PGE2 application
Neuronal responses o f a single Vc neuron activated both by electrical stimulation o f 
the MMA and mechanical stimulation o f the FRF. The shaded area o f the schematic 
shows the extent o f the FRF and the line indicates the area used to study the response 
elicited by stimulating the FRF. Traces show the number o f spikes elicited following a 
10 second brush and 5 second pinch o f the FRF before, 30 and 60 minutes after PGE2 
administration to the thinned cranial window over the MMA.
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4.3.3 Naratriptan experiments
Naratriptan co-administered with PGE2 evoked a significant decrease in electrically 
evoked neuronal activity from pre-treatment values of 78 ± 6 spikes per stimulation 
train to 37 ± 9 spikes per stimulation train in the first stimulation train after 
administration (n = 4). Naratriptan co-administered with PGE2 vehicle (n = 4) evoked 
a similar decrease from 74 ± 11 to 36 ± 6 spikes per stimulation train (n = 4). The 
mean maximum inhibition of neuronal responses (85 ± 6 % for naratriptan and PGE2, n 
= 4, and 79 ± 10% for naratriptan and PGE2 vehicle) occurred in the fourth stimulation 
train, 20 minutes after naratriptan administration and responses did not increase again 
during the remainder of the experiment (90 minutes). Two of four cells tested with 
naratriptan and PGE2 vehicle exhibited a low level of ongoing activity during baseline 
recordings (0.6 and 0.9 spikes per second), which in both cases was completely 
abolished immediately after naratriptan administration and did not return during the 
remainder of the experiment. There was no significant difference in the inhibitory 
effect of naratriptan in animals receiving either PGE2 or PGE2 vehicle at any time 
point (P > 0.05). Brush and Pinch responses to stimulation of the FRF were not 
significantly altered from baseline measurements at any time point in either animals 
treated with naratriptan and PGE2 or naratriptan and PGE2 vehicle. Naratriptan vehicle 
had no effect on either electrically evoked firing or mechanical stimulation of the FRF 
compared to pre-treatment responses (n = 3).
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Figure 35 Effect of naratriptan of MMA-evoked responses in the presence of 
PGE2
Data represent the total response to the train o f electrical stimulation where maximum 
response was seen normalised to the total response to the electrical stimulation train 
before drug treatment. Naratriptan co-administered with PGE2 (n = 4) and 
Naratriptan co-administered with PGE2 vehicle (n = 4) evoked a significant decrease 
in electrically evoked neuronal activity that occurred immediately after administration 
(P < 0.05, repeated measures ANOVA). The maximum inhibition of neuronal 
responses occurred in the fourth stimulation train, 20 minutes after naratriptan 
administration and responses did not increase again during the remainder o f the 
experiment (90 minutes). There was no significant difference in the inhibitory effect of  
naratriptan in animals receiving either PGE2 or PGE2 vehicle (P > 0.05). Naratriptan 
vehicle had no significant effect on evokedfiring compared to pre-treatment responses 
(n = 3; P > 0.05).
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4.3.4 Administration of PGE2  into the FRF
Mean pre-treatment responses to trains of fifty electrical stimulation applied to the 
MMA were 89 ± 17 (n = 4). Administration of PGE2 in the FRF did not significantly 
alter MMA-evoked neuronal firing (maximum change from pre-treatment levels was - 
16 ± 3%; 75 ± 3 spikes per stimulation train; n = 4; P < 0.05). There was also no 
significant effect of PGE2 vehicle on MMA-evoked neuronal firing (maximum 
change from pre-treatment levels was -10 ± 4%; 83 ± 8 to 75 ± 3 spikes per 
stimulation train; n = 4; P > 0.05). The response to brush and pinch stimulation 
following PGE2 or PGE2 vehicle administration into the FRF was not significantly 
altered at any time point studied (P > 0.05).
4.3.5 Intra-arterial administration of butaprost and PGE2
Mean pre-treatment responses to trains of fifty electrical stimulation applied to the 
MMA for cells tested with butaprost, PGE2 and vehicle were 81 ± 9 (n = 3), 75 ± 10 (n 
= 3) and 71 ± 4 (n = 3) respectively. In the second stimulation train following intra- 
arterial infusion (10 minutes after the start of the infusion), the mean normalised 
response of cells treated with butaprost (14 ± 4% below pre-treatment levels; 70 ± 3; n 
= 3) and PGE2 (19 ± 3% below pre-treatment levels; 61 ± 11; n = 3) was significantly 
lower than cells treated with vehicle (14 ± 4% above pre-treatment levels; 81 ± 5; n = 
3; P < 0.05). However, there was no significant difference in mean normalised 
responses between butaprost and vehicle for any other stimulation train in the 
experiment (70 minutes), although there was a slight increasing trend for responses in 
cells treated with PGE2, 35 minutes after the infusion but this did not reach significant
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levels (P > 0.05). The response to brush and pinch stimulation was no significantly 
altered following infusion of butaprost, PGE2 or vehicle at any time point studied.
4.3. 6  Topical application of butaprost
Topical application of butaprost over the MMA had no significant effect on neuronal 
firing and the mean responses to trains of fifty electrical stimulation applied to the 
MMA during pre-treatment recordings and after application of butaprost was 64 ± 14 
and 58 ± 6 (n = 5) respectively {P > 0.05). The response to brush and pinch of the FRF 
following topical butaprost application was significantly elevated over pre-treatment 
responses (72 ± 37% and 49 ± 22% for brush and pinch stimulation respectively) 30 
minutes after butaprost. However, this increase was not significantly different to the 
effect of vehicle and was significantly less than the facilitation induced following 
PGE2 application over the MMA (P < 0.05).
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Figure 36 Comparison of the effect of butaprost and PGE2 following intra- 
arterial infusion and topical application over the MMA
Electrophysiological recordings were made as described in section 2.1-2.2. Data is 
represented as the mean normalised response to trains o f fifty electrical stimuli 
applied to the MMA, recorded every five minutes, (a.) Butaprost, PGE2 or vehicle 
infusion was started at time 0 for 5 minutes. A significant decrease in neuronal firing 
was seen, 10 minutes after the start o f intra-arterial infusions o f butaprost and PGE2 
(P < 0.05, repeated measures ANOVA). After this time point, there was no significant 
difference in the mean normalised response between PGE2, butaprost or vehicle, (b) 
Butaprost or vehicle application was made at time 0 for 5 minutes. Butaprost or 
vehicle had no significant effect on evoked firing compared to pre-treatment levels (P 
>0.05).
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4.3.7 GW627368 and ZM325802
The investigation of the effects of the EPi and EP4 antagonist were severely hampered 
by the effect of the vehicle required to dissolve the compounds. Both compounds were 
experimental compounds produced by GlaxoSmithkline and had previously been 
tested in behavioural pain models where no effect of the vehicle used (1% DMSO, 
66% PEG200 and 33% distilled water) was seen on baseline measurements 
(unpublished data, pain group, Neurology CEDD, GlaxoSmithkline). Due to the effect 
of vehicle on PGE2 sensitisation in these experiments, a variety of different vehicles 
were tested, however, only vehicle containing 1% DMSO, 66% PEG200 and 33% 
distilled water was sufficient to allow the compound to dissolve while still leaving a 
component of the PGE2 sensitisation seen in earlier experiments.
Intravenous or topically administration of the antagonist vehicle with PGE2, resulted 
in a mean maximum facilitation of Vc responses above pre-treatment levels of 36 ± 
4% (n = 5) and 37 ± 3% (n = 5) respectively. This was significantly less than the 
facilitation of 88 ± 15% (n = 8) over pre-treatment levels seen in earlier experiments 
when PGE2 was applied over the MMA without co-administration of the antagonist 
vehicle. However as no facilitation occurred following intravenous or topical 
administration of the antagonist vehicle with PGE2 vehicle (mean maximum change of 
Vc responses relative to pre-treatment levels of -4 ± 5% (n = 5) and 2 ± 6% (n = 5) 
respectively) a window of PGE2 sensitisation remained despite the “knock-down” 
effect of the antagonist vehicle.
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Responses to stimulation in the FRF were also decreased following administration of 
the antagonist vehicle and PGE2, compared to PGE2 alone, with a mean maximum 
response to brush and pinch of 118 ± 16% and 131 ± 12% respectively (n = 5) after 
intravenous administration and 154 ± 20% and 133 ± 21% respectively (n = 5) after 
topical administration. The facilitation of the FRF responses following antagonist 
vehicle and PGE2 was not significantly different from the maximum responses 
observed following administration of PGE2 vehicle and antagonist vehicle, hence only 
responses to electrical stimulation of the MMA have been included here.
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R o u t e  o f  a n t a g o n i s t  a d m i n i s t r a t i o n
T R E A T M E N T T o p i c a l I n t r a v e n o u s
A n t a g o n i s t  v e h i c l e  & 37 ± 3% (n = 5) 36 ± 4% (n = 5)
p g e 2
A n t a g o n i s t  v e h i c l e  & 2 ± 6% (n = 5) -4 ± 5% (n = 5)
P G E 2 v e h i c l e
G W 6 2 7 3 6 8  &  P G E 2 11 ± 6% (n = 5) -6 ± 11% (n =  5)
v e h i c l e
G W 6 2 7 3 6 8  &  P G E 2 43 ± 8% (n =  4) 34 ±  11% (n =  5)
Z M 3 2 5 8 0 2  &  P G E 2 -11 +7% (n =  4) -16±3% (n = 4)
v e h i c l e
Z M 3 2 5 8 0 2  &  P G E 2 43 ±  3% (n =  5) 34 ±  6% (n = 4)
Table 11 Effects of EPi and EP4 antagonists on PGE2 sensitisation ofVc responses
The above table shows the mean maximum response over pre-treatment Vc firing for 
the different combinations of PGE2, PGE2  vehicle, an EP] receptor antagonist 
(ZM325802), an EP4 antagonist (GW627368) and the antagonist vehicle. Both 
intravenous administration and topical application over the MMA of the antagonist 
was tested. PGE2 or PGE2 vehicle was applied topically over the MMA. Application 
of the antagonist vehicle significantly inhibited the PGE2 sensitisation of Vc responses 
compared to the effects of PGE2 only (see section 4.3.1). The reduced sensitisation 
seen after PGE2 and antagonist vehicle was not significantly further reduced by either 
antagonist following either intravenous or topical application (P > 0.05).
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Figure 37 Effect of the EP! and EP4 antagonist on PGE2 sensitisation
Data represents the maximum normalised effect o f PGE2 relative to pre-treatment 
responses, applied either alone or preceded by topical application (a) or intravenous 
administration (b) o f antagonist vehicle (1% dimethyl sulfoxide (DMSO), 6 6 % PEG200 
and 33% distilled water) or the EP] or EP4 antagonist. In all experiments PGE2 
caused it's maximum effect 5-10 minutes after application. Antagonist vehicle 
significantly reduced PGE2 sensitisation (P < 0.05, repeated measures ANOVA) 
however, neither antagonist further reduced PGE2 sensitisation (P > 0.05).
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Administration of either the EPi or EP4 antagonist by both the topical and intravenous 
routes had no significant effect on pre-treatment MMA-evoked Vc responses (P > 
0.05).
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Figure 38 EPi and EP4 antagonists do not effect un-sensitised MMA evoked firing
Electrophysiological recordings were made as described in section 2.1-2.2. Data 
represents the mean normalised response to trains o f fifty electrical stimuli applied to 
the MMA every five minutes. Antagonists were applied at time 0, as described in 
section 4.2.4. Neither antagonist, applied topically over the MMA or given as an 
intravenous dose, had any significant effect on evoked firing compared to vehicle (P 
>0.05, repeated measures ANOVA).
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4.4 Discussion
These results demonstrate that PGE2 is able to generate sensitisation of dural primary 
afferent fibres innervating the MMA. Furthermore, the increase in afferent input 
following PGE2 application is sufficient to alter the behaviour of second order neurons 
within the Vc over a period that outlasts the peripheral stimulation, evidenced by the 
increased responses to stimulation in the FRF.
PGE2 caused an increase in the response to trains of electrical stimuli applied to the 
dura. However, the magnitude, duration and onset of this response were variable. This 
variability may be due to the penetration of PGE2 through the closed cranial window, 
as although the area of the window overlying the branch of the MMA could be 
reproduced accurately, the thickness of the window could not be measured under these 
experimental settings. Alternatively, the variability may have been a result of the 
differing thresholds of peripheral neurons; some of which may have been unavoidably 
sensitised by the mechanical disruption of drilling a cranial window. To control for 
this, further experiments where an open cranial window is used and PGE2 is applied 
directly to the dura mater could be carried out. However the advantage of the 
increased reliability in the response may be outweighed by the disadvantages of a 
craniotomy e.g. release of inflammatory mediators following removal of the dura 
mater that is strongly adhered to bone.
The increase in spontaneous activity in this study is also interesting as it is suggestive 
of a possible direct activation of neurons by PGE2. Despite previous reports of direct
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effects on membrane potential, spontaneous activity, calcium currents and 
neuropeptide release in sensory neurons (Evans et al., 2000; Nicol et al., 1992; White 
et al., 1996), PGs have long carried a dogma of being sensitising agents only, with no 
ability to activate neurons directly. A recent study (Smith et al., 2000) confirms the 
ability of PGE2 (1-10juM) to directly activate DRG neurons in culture, as well as 
facilitating the effects of bradykinin. The authors suggest a direct sensitising effect of 
prostaglandins is often not seen in other in vitro experiments due to a low efficacy at 
room temperature. While it is also possible that in these studies, the increase in 
spontaneous activity is the result of a sensitising action of PGE2 to an endogenous 
dural substance, present under resting conditions at an insufficient concentration to 
cause activation of primary afferents alone, a direct activating effect of PGE2 should 
not be ruled out.
Off-line analysis of spontaneously active cells in this study was conducted to find any 
correlation between pulsatile blood flow and peaks in neuronal firing after 
sensitisation with PGE2. Mean heart rate was unaltered by PGE2 application (396 ± 9 
beats/ minute (n=8), typically 1 beat every 0.15 seconds), hence if a correlation was 
occurring, a peak in neuronal firing should be evident approximately every 0.15 
seconds. However, no correlation was evident in any of the spontaneously active 
neurons in this study at any time point after PGE2 application. Therefore, it is unlikely 
that PGE2 sensitises peripheral terminals innervating the MMA to a degree where 
normal blood flow is sufficient to cause activation of sensory neurons, a theory that 
has been suggested to explain the throbbing nature of the migraine pain and the 
efficacy of vasoconstrictors in migraine (Yamamura et al., 1999).
The sensitisation to light brush and noxious pinch of the FRF occurred maximally 60
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minutes after the PGE2 stimulation, which corresponds well to clinical data showing 
allodynia on the ipsilateral side of the face occurs approximately lhour after the start 
of a migraine (Burstein et al, 2000). This increased response to facial stimulation is 
likely to be a reflection of lowered thresholds in second order neurons that receive 
convergent inputs from facial tissues and the dura. It is of interest to note that the 
facial hypersensitivity in this study was not seen until 30 minutes after PGE2 
application when the increased response to MMA stimulation had ended. This implies 
that while a peripheral input is necessary to initiate central changes, the maintenance is 
independent of an ongoing peripheral input. This is in good agreement with other 
studies where a brief input from primary afferents have been shown to alter dorsal 
horn neuronal activity over a significant period of time by shifting the membrane 
potential towards a more depolarised state (Woolf 1983). However, given that the 
response to noxious pinch of the FRF as well as the response to light brush of the FRF 
was still elevated after 1 hour, it is surprising that the response to noxious, peripheral 
MMA stimulation was not also still elevated at this time point. The difference in the 
sensitisation response from the two areas, may therefore represent a difference in 
central modulation of cutaneous and visceral inputs at the level of the Vc, a concept 
which has been further explored in study 3.
While the effects of PGE2 in this study are promising in the development of a model of 
in vivo dural sensitisation, in order to investigate the effects of PGE2 in a physiological 
system, further model development is required. One such development could involve 
the chronic implantation of a cannula over the dura around the MMA, which would 
allow the effects of PGs to be tested when any sensitisation caused by the surgery had 
subsided. Previous animal studies have shown that dural-evoked Vc responses can be
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inhibited following stimulation of the PAG (Knight & Goadsby, 2001) or enhanced 
following blockade of P/Q-type calcium channels in the PAG (Knight et al., 2002). 
Hence, it would be interesting to look at PGE2-induced sensitisation in animals where 
disruption of descending pathways from supraspinal structures such as the PAG had 
occurred, in order to assess whether sensitisation is greater following descending 
pathway disruption. This type of study may provide insight into the possibility that 
migraineurs have a genetic susceptibility to the effects of agents acting peripherally 
due to inefficiency of descending inhibitory controls from regions such as the PAG.
It is unlikely that application of PGE2 other than directly to the sites of interest will 
result in a measurable sensitisation, evidenced by the lack of effect of PGE2 in 
generating sensitisation following intra-arterial infusion. However, given the effects 
seen following PGEi infusion into migraineurs, a generalised increase in circulating 
PG level cannot be ruled out, and may be related to dose and duration of infusion. It is 
also true to say, that an increase in Vc activity cannot, with current methods, be 
directly correlated with headache scores in humans. Therefore, the effects of PGs 
should also be assessed in other in vivo animal models of migraine, e.g. the vasodilator 
effects of prostaglandins are well known, although there have been no studies that 
have looked at the direct vasodilator effect on the MMA. This could possibly be 
determined in the intravital model allowing the time course of any dilatation to be 
correlated with effects on neuronal activity and hopefully highlight any possible 
relationship of abnormal dilatation and enhanced neuronal activity.
The inhibitory effects of naratriptan that were similar in both the presence and absence 
of PGE2 is in keeping with a recent study which found that in a rat model, triptans
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prevented the induction of sensitization in central trigeminovascular neurons (recorded 
in the Vc), but not in peripheral trigeminovascular neurons (recorded in the trigeminal 
ganglion) (Levy et al, 2004). After sensitization was established in both types of 
neuron, triptan administration effectively normalized intracranial mechanical 
sensitivity of central neurons, but failed to reverse such hypersensitivity in peripheral 
neurons. In agreement with the rationale for the use of triptans in this study, the 
authors (Levy et al, 2004) proposed;
“In the early stages of migraine, central trigeminovascular neurons become 
activated in response to incoming impulses from meningeal nociceptors . At 
this stage, presynaptic inhibition by triptans should be sufficient to render the 
central neurons quiescent, resulting in a pain-free state. In migraine attacks 
associated with cutaneous allodynia, the central neurons eventually become 
sensitized and develop their own autonomous activity. At this stage, the same 
presynaptic inhibition by triptans becomes progressively inadequate to render 
central trigeminovascular neurons quiescent, resulting in only partial pain 
relief. In migraine attacks that remain allodynia-free, the central 
trigeminovascular neurons do not reach a state of sensitization and continue to 
be driven by incoming impulses from meningeal nociceptors. Therefore, the 
central presynaptic inhibition exerted by triptans should be sufficient to render 
the patient pain-free at any time during the attack”.
Responses to facial stimulation following naratriptan administration in this study 
remained unaffected throughout the experiment, lending weight to the theory that an 
increased peripheral stimulation is required to alter the activity of central neurons.
The investigation of the EP receptor responsible for PGE2 sensitisation in this model,
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in the first instance, showed that an action through the EPi, EP2 or EP4 receptor is 
unlikely to solely mediate the effect. However, the study was unable to rule at the 
possibility that PGE2 acts through more than one EP receptor to exert its effect. 
Furthermore, the study also showed that the EPi or EP4 receptor are unlikely to 
contribute to the evoked firing elicited by MMA stimulation in the un-sensitised state.
The modulation by EP receptors of un-sensitised MMA evoked responses is of interest 
in respect to results reported by Ellrich and colleagues (Ellrich et al. 1999). In that 
study, the non-steroidal anti-inflammatory drug, acetylsalicylic acid (ASA), given as a 
intravenous dose or applied topically to the dura mater and caused a significant 
reduction of second-order neuron activity recorded in the Vc, responding to 
mechanical stimulation of the dura mater, in the area of the MMA. While these results 
indicate an involvement of PGs in evoked trigeminal firing, it is not necessarily due to 
the effects of PGE2 and may well be an effect of other functional PGs, such as PGI2 or 
PGD2. A further caveat in comparing the results of this study, with the experiments 
described in this thesis, is the variation in methodology. In the model used by Ellrich 
and colleagues, a full craniotomy was performed, which may have resulted in the 
production of an inflammatory response per se. In addition, while they used electrical 
stimulation of the MMA to identify dural responsive cells within the Vc, the 
experimental protocol used mechanical stimulation of the dura mater, which may well 
activate a different subset of dural afferents compared to electrical stimulation.
As ASA is extremely effective in the treatment of migraine clinically, especially when 
given intravenously, understanding its mechanism of action within the trigeminal 
system is likely to provide a vital insight into the pathological processes occurring
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during migraine. However, this may be related to a central effect and as such it is 
interesting to note that when given intravenously, but not topically in the above animal 
model, a significant reduction of spontaneous Vc activity was seen (Ellrich et al., 
1999). It should also be remembered, that while the inhibitory effects of ASA on PG 
production are well known, it is also possible that ASA may have an effect on other 
signalling cascades.
The investigation of the role of EPi and EP4 receptors in dural PGE2 sensitisation in 
this study was hampered by vehicle effects, with a significant reduction of the PGE2 
sensitisation seen when vehicle was co-administered. This is likely to be the result of 
an effect of either PEG200 or DMSO as there are several sensitisation studies using 
compounds administered in water, with no vehicle effects. As vehicle had no effect on 
MMA-evoked firing in the control situation, it is likely that PGE2 results in activation 
of an intracellular cascade that is selectively inhibited by vehicle. While this 
modulation by vehicle could equally be due to the effects of PEG200 or DMSO, there 
are no reported effects of this type of effect for PEG200, however several others have 
reported similar decreased sensitisations by DMSO (van’t Erve et al., 1998).
While the reduction of sensitisation by vehicle in this model was considerable, a 
significant window of sensitisation of up to 40% over pre-treatment levels remained. 
Hence, it is worth considering that investigation of the effects DMSO may provide 
insight into a common final non-specific mechanism of neuronal sensitisation 
following initiation of sensitisation by different receptor pathways. However as 
DMSO is highly lipophilic and rapidly absorbed through skin, it is likely to have 
widespread effects throughout the body and this is supported by the similar effects on
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PGE2 sensitisation seen following both intravenous and topical vehicle administration.
Due to the vehicle effects, the results of these studies are not conclusive and an effect 
of the EPi and EP4 antagonists may have been "hidden". Although as either antagonist 
failed to reduce the remaining sensitisation, it is unlikely that an action through either 
of these receptors is entirely responsible for the sensitisation and to rule out an effect 
at severed receptors, a combination of antagonists needs to be assessed.
The lack of effect of the EP2 agonist, butaprost, in this model is slightly surprising as 
in an in vitro preparation of trigeminal ganglion neurons, butaprost was almost as 
effective as PGE2 in causing CGRP release (Jenkins et al., 2001). However, while the 
presence of EP2 mRNA in trigeminal ganglion cells has been confirmed, EP2 receptor 
expression has not been examined. Within the systems that have been studied, EP2 is 
largely thought to be induced following inflammatory stimulation, hence the process 
of neuronal culturing, where cells are subjected to considerable mechanical disruption, 
may be the factor responsible for inducing EP2 receptor expression. Accordingly, the 
role of the EP2 receptor in trigeminal signalling with relevance to migraine is not 
easily assessed at present as it is not currently known to what extent a dural 
neurogenic inflammation is part of the pathological events occurring during migraine. 
If a dural inflammation where to occur, it is possible that the antagonists at the EP2 
receptor may provide an attractive target for acute treatment.
It is also possible that PGE2 may also be acting through IP or DP receptors as a degree 
of cross talk between the receptors has previously been suggested (Kiriyama et al,
1997). If this were the case it may also be interesting to look at PGI2 or PGD2 induced
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sensitisation, or the effects of an IP or DP antagonist against PGE2 sensitisation.
In summary, the results in this study support the hypothesis that peripheral dural 
sensitisation generates an altered central neuronal activity that may underlie some of 
the clinical features of migraine such as head pain and facial skin hypersensitivity. 
While this study does not provide evidence for an endogenous source of 
prostaglandins in the development of dural sensitisation, the time course of 
sensitisation following application of PGE2, which is in agreement with that reported 
to occur following the onset of a migraine attack merits consideration of 
prostaglandins as an endogenous mediator of migraine. Hence, further investigation 
into the mechanism of action of prostaglandins in migraine, may not only lead to the 
development of a successful pre-clinical migraine model but may also generate new 
treatment strategies against migraine pain.
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5  S t u d y  3 - E x p l o r a t i o n  o f  t h e  c h a r a c t e r i s t i c s  o f  V c  n e u r o n s  w i t h  r e l e v a n c e  t o  
p r i m a r y  a f f e r e n t  i n p u t
5 .1  I n t r o d u c t i o n
Due to the anatomical similarities between the spinal dorsal horn and Vc, comparisons 
are often made regarding the mechanisms of responses to nociceptive stimulation in 
both systems. However, previous studies have shown fundamental differences in the 
responses of Vc neurons compared to those reported in the dorsal horn (Bereiter et al, 
2000; Cumberbatch et al., 1998). For example, the threshold of activation for C-fibre 
evoked responses has been reported to be significantly higher for VBNC neurons 
(between 6-8mA and up to 2ms,) compared to lumbar neurons (3-4mA; Bouhassira et 
al., 1987). Furthermore, diffuse noxious inhibitory controls have also been found to be 
more pronounced for trigeminal neurons than lumbar neurons and the mean discharge 
of trigeminal neurons has also been suggested to be less than those recorded at the 
lumbar region in similar experimental conditions (Villanueva et al., 1985, Dickenson 
etal ,  1980).
Due to the trigeminal system’s dual representation, it has also been shown that 
peripheral stimulation of the cornea results in activation of neurons in the VBNC in 
two distinct areas, namely the Vi /Vc border and the Vc / Ci border, which respond 
differently to the same stimulation (Meng et al., 1997). Moreover, as discussed in the 
previous chapter, the anti-migraine triptan drugs appear to specifically inhibit Vc 
responses and not dorsal horn response to noxious stimulation (Cumberbatch et al,
1998). Hence, while the trigeminal system is capable of generating responses that are 
comparable to those of the dorsal horn, the highly convergent nature of inputs to the
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Vc and the modulation they receive are poorly understood, especially in relation to the 
pathology of primary headache syndromes.
A further complication of the interpreting the response of Vc neurons to dural 
stimulation, is that this type of stimulation may be considered as a visceral input. Until 
the last decade or so, it was thought that data regarding nociceptive processing from 
cutaneous regions could be extrapolated to include the viscera. However, there are 
fundamental differences between pain arising from cutaneous and visceral areas, for 
example, mechanical trauma is an ineffective stimulus for visceral pain but highly 
effective for cutaneous areas. Visceral pain is also poorly localised, with secondary 
hyperalgesia evident at sites remote from the source compared to cutaneous pain, 
which is normally highly localised with considerable secondary hyperalgesia at the 
site of damage Additionally, visceral pain is associated with autonomic disturbances, 
which is a prominent feature of many migraine attacks, (for review see McMahon et 
al, 1995).
A further fundamental difference between sensory and visceral neurons is their ability 
to exhibit the electrophysiological phenomenon of “wind-up”. As described in section 
1.7.1., in somatic sensory neurons, the number of neuronal responses to a fixed 
stimulation increases throughout a stimulation train applied to a peripheral nerve. 
However, while visceral neurons do exhibit increased excitability following repetitive 
stimulation (Laird et al., 1995) they appear unable to "wind-up”. Furthermore, the 
relay of information to the central nervous system also varies between the somatic and 
visceral systems. Until recently, it was assumed that all nociceptive signals, visceral 
and somatic, ascended to the brain via the spinothalamic tract. However, the discovery
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of the dorsal column pathway, the spino (trigemino)-parabrachio-amygdaloid pathway 
and the spinohypothalamic pathway all of which carry visceral nociceptive 
information have added a new level of complexity to the dissection of higher order 
integration (Al-Chaer et al., 1988; Jasmin et al., 1997; Katter et al., 1996). The 
physiological basis for the differences between cutaneous and visceral pain is not 
clear, although there is some evidence that primary afferents innervating visceral 
structures form a discrete class of sensory receptors that fundamental differ in their 
activation properties from cutaneous receptors (Cervero & Laird, 1999; Gebhart, 
1995). A nociceptive specific type, an intensity coding type with a low threshold to 
natural stimuli and a group of "silent receptors" that only respond to stimuli in the 
presence of inflammation have all been proposed. As such, the investigation of the 
properties of dural afferents and the central neurons they synapse with is a crucial step 
in the investigation of migraine pathology.
During migraine, a considerable degree of central sensitisation may be present in the 
Vc, with many resultant neuroplastic changes in the "wiring" of neurons. This may 
result from dural inflammation (Moskowitz, 1992), or altered descending pain 
modulation (Goadsby et al., 1991), or both, and significantly affect the behaviour of 
Vc neurons. Certainly, under conditions of peripheral inflammation, wind-up of dorsal 
horn is enhanced, not only in the inflamed area but also when the stimulation is 
applied to adjacent areas (Herrero et al., 1996; Stanfa et al., 1992), with saturation of 
the wind-up response occurring significantly later than in control animals, indicating 
an increased maximum firing rate of neurons. Hence, in this study, mustard oil (MO), 
a well known C-fibre activator (Woolf & Wall, 1986; Reeh et a/., 1986) has been 
applied to the face to induce central sensitisation within the Vc, and the wind-up
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response further examined.
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5.2 Methods
Electrophysiological recording of second order neurons in the Vc responding to 
electrical stimulation of primary afferents innervating the MMA and face, with both 
A5- and C-fibre latency were carried out as described in section 2.1.
5,2.1 Wind-up o f Vc cells using dural stimulation
Neuronal identification was carried out with a search stimulus of 0.8ms, 6mA at 1Hz. 
Higher stimulus parameters were used than in the study 1 or 2 to elicit C-fibre 
responses as well as A-5 responses. Once a neuron in the Vc responding to dural 
stimulation had been identified, cells were characterized, by latency of response (i.e. 
A-5 or C-fibre input) and type (nociceptive specific, wide-dynamic range or low 
threshold). Where a FRF could be found, single unit recordings were made in response 
to light brush of the FRF by monitoring the response to a 10 second brush of the area 
and repeated three times to ensure reproducibility and to permit statistical analysis 
between individual cells. The preparation was then left for 10 minutes to minimise 
sensitisation from FRF stimulation before the electrical stimulation protocol was 
started.
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Figure 39 Brush responses of the FRF
Typical neuronal control response recorded in the Vc following brush stimulation o f 
the FRF. Each stimulation was for a ten second period and repeated three times to 
ensure reproducibility.
Two electrical stimulation protocols were tested as follows:
1)1 Hz, (1.5 X threshold X 20), repeated every 3 minutes for 30 minutes
2) 2 Hz, (1.5 X threshold X 20), repeated every 3 minutes for 30 minutes
Although other studies have typically used electrical stimulation parameters of 2ms 
pulses at 3 times C-fibre threshold at between 0.66 Hz and 1 Hz (Dallel et a l , 1999) to 
generate wind-up, in our experimental set-up, we have found that electrical stimulation 
pulses over 1 ms, recruit additional neuronal responses. Furthermore, we have also 
found that electrical stimulation at frequencies lower then 1Hz fail to produce reliable 
responses to electrical stimulation. This may be as a result of stimulating through a 
closed cranial window, such that there is dissipation of the current which would hence 
reduce the intensity of stimulation of primary afferent fibres. At the end of each
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stimulation protocol, FRF characterisation was repeated as described above. In some 
animals a further two or three cells were examined with a rest period of at least 30 
minutes between the end of one protocol and start of the next.
5,2, 1,1 Characterisation of AS and C-fibre responses
The classification of responses into A8 and C-fibre latencies were based on 
observations that following MMA stimulation, two distinct groups of responses were 
seen. The first group of responses appeared 7-25 ms after stimulation, attributed to A- 
5 fibre input, and the second group appeared 40-80 ms after stimulation, attributed to 
C-fibre input. With an estimated conduction distance of 25 mm, and assuming a time 
of 1 ms for synaptic transmission, a range of conduction velocities of 1.0-4.0 ms'1 for 
A-8 responses and 0.30-0.65 ms’1 for C-fibre responses was observed, in general 
agreement with standard definitions (Guyton & Hall, 1996).
5,2,2 Wind-up o f Vc cells using facial stimulation
Due to the problem of muscle contraction seen following electrical stimulation of the 
face, the neuromuscular blocking agent, vecuronium bromide, was administered in 
these experiments as described in section 2.1. Neuronal identification was carried out 
as the electrode was advanced through the Vc by lightly stroking the face and 
vibrissae, until a response was seen. The cell was then examined for response to 
noxious stimulation by application of pinch and pressure, and only those cells 
fulfilling the criteria of a wide-dynamic range (WDR) cell were examined (Hu et al., 
1981). For electrical stimulation, bipolar needle electrodes were inserted into the facial 
skin and secured with tape. A 1 Hz electrical stimulation protocol, as described for
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wind-up with dural stimulation was used for all cells in this study.
5.2.5 The effect o f MK-801, an NMDA antagonist, on MMA-evoked Vc 
responses
Following identification of a Vc neuron linked to MMA stimulation, an electrical 
simulation protocol (1Hz, 1.5 threshold X 50, repeated every 5 minutes) was started 
and following establishment of a steady baseline (< 10% variation), over at least three 
stimulation trains. The NMDA receptor antagonist, MK-801 (lm gkg1) or vehicle 
(saline) was then given intravenously in 0.2ml and electrophysiological recordings to 
MMA stimulation continued as above.
5.2,4 Wind-up o f Vc cells following the induction o f central sensitisation
Following identification of a Vc neuron linked to MMA stimulation, the size of the 
FRF was estimated using brush stimulation and the response to a 10 second brush 
stimulation was the carried out as described for the wind-up protocols above. Noxious 
pinch stimulation was not assessed in these experiments, as previous observations had 
shown that while the magnitude of the response to noxious stimulation remains 
constant for several hours, considerable variation in the size of the FRF occurs 
following noxious stimulation, which is in agreement with data form Dubisson et al, 
(1979). As MO was applied outside the FRF in these experiments, it was hence of 
interest to follow the size of the FRF.
Following FRF characterisation, an area of the face was then shaved (approx. 1cm2) 
adjacent to the FRF to facilitate topical MO application. An electrical simulation 
protocol (1Hz, 1.5 threshold X 50, repeated every 5 minutes) was then started and
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following establishment of a steady baseline (< 10% variation), over at least three 
stimulation trains, MO (10% in mineral oil) or vehicle (mineral oil) was applied to the 
shaved skin. The response to FRF stimulation was then re-examined 30 and 45 
minutes after MO application.
5.2.4.1 Data analysis
Data is presented as mean ± standard error of the mean. Wind-up for A5 and C-fibre 
responses were assessed separately. The neuronal response to individual stimulation 
trains were examined using logistic regression analysis (Origin 7 software package) to 
determine any increase in response from the first to the last stimulation in the train, 
where a significant regression {P < 0.05) was regarded as an indication of wind-up. A 
between train effect was then compared using a repeated measure analysis of variance 
(ANOVA followed by Bonferroni’s post hoc test for multiple comparisons, Origin 7 
software package) where P < 0.05 was regarded as significant. The effect of FRF 
before and after wind-up protocols was also compared using a repeated measure 
ANOVA followed by Bonferroni’s post hoc test for multiple comparisons where P < 
0.05 was regarded as significant. For MO experiments, responses to electrical 
stimulation of the MMA were normalised as the total response to the train of 
stimulation directly before treatment and expressed as a percentage of this response. 
Statistical analysis was carried out using repeated measure ANOVA followed by 
Bonferroni’s post hoc test for multiple comparisons (Origin 7 package, Originlab 
corporation, USA). P < 0.05 was considered significant.
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5.3 Results
Single unit recordings were made from 46 Vc neurons in 27 animals. Data from 2 
animals treated with MO, were not included in the quantitative analysis as cells were 
lost directly after MO application.
5.3.1 Wind-up of cells receiving a dural input
Electrophysiological recordings were made from 17 cells in the Vc responding to 
electrical stimulation of the MMA in eight rats. All had acceptable respiratory 
parameters for the anaesthetised rat: pC02, 35-45 mmHg; p02, 90+ mmHg and pH, 
7.35-7.45. Mean arterial blood pressure (MABP) and heart rate were 105 ± 7 mmHg 
and 382 ± 6 beats/minute, respectively. Cells were located in the depth range 350- 
1200 pm below the pial surface. Five of seventeen cells exhibited an A5- response 
only, 4/17 a C-fibre response only, and 8/17 both an A5 and C-fibre component. 
Average response latencies and dural stimulus threshold (current and pulse duration) 
were 14 ± 2 ms, 2 ± 0.6 mA and 0.3 ± 0.04 ms for A5, and 45 ± 7 ms, 6 ± 1.5 mA and 
0.8 ±0.1 ms for C-fibres. In one cell in this dural stimulation group, C-fibre input 
only, a FRF could not be found, whereas all other cells studied showed a convergent 
input from the face, assessed by non-noxious stimulation.
5.3.1.1 AS response
Of the 13 cells responding to MMA stimulation with A-5 fibre input latency, 6 were 
tested with the 1 Hz protocol (2 A5 only and 4 A5 + C-fibre) and 7 were tested with 
the 2 Hz protocol (3 A5 only and 4 A5 + C-fibre). For the 1Hz protocol, the mean
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number of spikes to the first and last stimulus in the first stimulation train were not 
significantly different (1.5 ± 0.3 and 1.7 ± 0.4 respectively; n = 6; P > 0.05). This lack 
of wind-up was observed in all stimulation trains in the experiment and the mean 
number of spikes to the first and last stimulus in the train in the last stimulation train 
of the protocol were not significantly different to those in the first stimulation train 
(1.4 ± 0.5 and 1.6 ± 0.3 respectively; n = 6 ; P >  0.05).
The number of spikes per stimulus was significantly greater during the 2Hz protocol 
than the 1 Hz protocol, however there was no significant wind-up effect observed in 
any cell. In the first stimulation train of the protocol, the mean number of spikes to the 
first and last stimulus in the train was 2.8 ± 0.8 (n = 7) and 3.1 ± 0.7 (n = 7) 
respectively. As for the 1Hz protocol, this was not significantly different for any 
stimulation trains in the experiment and the mean number of spikes to the first 
stimulation and last stimulus in the last stimulation train was 2.7 ± 0.5 (n = 7) and 2.9 
± 0.6 (n = 7) respectively (P > 0.05). In either the 1 Hz or 2 Hz protocol there was no 
significant difference between the number of spikes per stimulus for cells that showed 
an A5-fibre component only compared to cells that showed both an A8 and C-fibre 
component.
5.3.1.2 C-fibre response
Of the 12 cells responding to MMA stimulation with C-fibre input latency, 6 were 
tested with both the 1 Hz and 2 Hz protocol (2 cells with C-fibre only response and 4 
cells responding with both A-5 and C-fibre latency in each group). As for A5-fibre 
mediated responses, C-fibre responses showed no significant wind-up when tested
-207-
with either the 1 or 2 Hz protocol. For the 1Hz protocol, the mean number of spikes to 
the first and last stimulus in the first stimulation train was 0.9 ± 0.2 and 1.1 ± 0.3 
respectively (n = 6), which was not significantly different for any stimulation train in 
the experiment {P > 0.05). For the 2Hz protocol, the mean number of spikes to the first 
and last stimulus in the first stimulation train was 1.4 ± 0.5 and 1.7 ± 0.6 respectively 
(n = 6) which again was not significantly different for any stimulation train in the 
experiment (P > 0.05).
5.5.1.3 Brush-pinch responses
In most experiments the FRF, extended over both the first and second division of the 
trigeminal nerve, however, in two experiments, the FRF included the area innervated 
by the third division of the trigeminal nerve and in one experiment, no FRF could be 
found. Responses to brush of the FRF varied considerably between cells with a range 
of 17 to 312 spikes per 10 second brush stimulation (range observed from 96 brush 
stimulations in 16 experiments). However, there was no significant difference between 
the response to FRF stimulation before the start of the electrical stimulation protocol 
and that at the end of the electrical stimulation protocol for individual cells (P > 0.05).
5.5.2 Wind-up of cells following electrical stimulation of the FRF
Electrophysiological recordings were made from 18 cells in the Vc responding to 
electrical stimulation of the face and non-noxious stimulation of the face in eight rats. 
Eight cells showed responses consistent with the latency of A-5 fibre input only, five 
cells responded in the C-fibre range and five cells showed both an early and late 
response attributed to A-5 and C-fibre mediated inputs, respectively. In all
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experiments, infusion of neuromuscular block had a gradual depressant effect on 
MABP and HR. The mean MABP and HR at the start of neuromuscular block infusion 
was 112 ± 11 mmHg and 390 ±18 beats per minute, respectively, compared to two 
hours after the start of infusion, where mean MABP and HR were 89 ± 8 mmHg and 
327 ± 23 beats per minute, respectively.
5.3.2.1 A S  responses
Of the eight cells responding to electrical stimulation of the face with A-5 latency 
only, four cells tested were recorded in the superficial layers and four in the deeper 
layers of Vc, with a mean recording depths of 236 ± 43 pm and 704 ± 48 pm 
respectively below the pial surface. The five cells tested that demonstrated both A-8 
and C-fiber components were all located in deeper layers of the Vc, with a mean 
recording depth of 925 ± 57 pm. No significant difference in the stimulation 
parameters required to elicit responses were seen between cells recorded in superficial 
(7.1 ± 1.1 mA, 0.8 ±0.1 ms) and deep layers (6.9 ±1.3 mA, 0.9 ± 0.2 ms). In cells that 
exhibited both an A-5 and C-fiber component, stimulation parameters required to elicit 
the A-5 component of the response was not significantly greater than to elicit 
responses in cells responding with A-8 latency only (7.9 ±1.5 mA, 1.0 ± 0.3 ms), 
however, stimulation parameters generally had to be increased to see reproducible C- 
fiber responses (P < 0.05). All cells responding with A-5 fiber latency, showed no 
significant wind-up in any stimulation train and the mean number of spikes to the first 
and last stimulus in the first stimulation train was 1.9 ± 0.6 and 2.2 ± 0.5 (n = 12) 
respectively (n = 12) which was not significantly different in any stimulation train in 
the experiment (P > 0.05). However, one cell did show a small increase in response
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with successive stimulations in the last three stimulation trains only, however the 
increase did not reach significant levels (P = 0.074).
5 .3 .2 . 2  C-fibre responses
All cells responding to electrical stimulation of the FRF with C-fibre latency were 
recorded from the deeper layers of Vc with a mean recording depth of 1026 ± 83 pm 
below the pial surface. Stimulation parameters required to elicit C-fibers were of 
greater duration than those required to elicit A-5 responses with mean parameters of
9.2 ±1.8 mA and 1.7 ± 0.4 ms (n = 10). Six of ten C-fibers showed a significant wind­
up response to electrical stimulation of the face (P < 0.05) while the remaining four 
cells showed no significant wind-up (P < 0.05). Of the cells showing a wind-up 
response, the mean number of spikes to the first and last stimuli in the first stimulation 
train of the protocol was 1.8 ± 0.4 and 6.3 ± 0.3 respectively (n = 6; P < 0.05).
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Figure 40 C-flbre response following stimulation of the face
Graph shows all cells responding with C-fibre latency following electrical stimulation 
o f the face. Each data point represents the mean response to successive stimulations in 
a train o f 20 stimuli, recorded over 10 trains. Cells 1-6 represent those cells that 
showed a significant increase in response or “wind-up ” throughout the train (P < 
0.05; n =  6). Cells 7-10 represent cells showing no significant increase in response 
throughout each stimulation train (P > 0.05; n = 4).
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Interestingly, in the cells showing wind-up, the wind-up response in the last 
stimulation train in each experiment was significantly greater than in the first 
stimulation train of each experiment with a mean number of spikes to the first and last 
stimuli in the last stimulation train of the protocol of 2.2 ± 0.4 and 9.0 ± 0.7 
respectively (n = 6; P < 0.05). Additionally, the onset of the increased response was 
also faster, with the plateau of the response occurring by the 5th or 6th stimulation in 
the last train compared to the 8th or 9th stimulation in the first train. The increased 
“wind-up” seen throughout the course of an experiment appeared to be a gradual effect 
as the mean response to each train was not significantly greater than the train that 
preceded it {P > 0.05; n = 6; Figure 39a). However the mean increase in wind-up over 
the first train became significant by the 6th stimulation train or 18 minutes after the 
start of the wind-up protocol (P < 0.05; n = 6).
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Figure 41 Wind-up increases during the experiment
Graphs show the mean response o f cells showing wind-up following electrical 
stimulation o f the face, (a) The mean wind-up response to each stimulation train 
gradually increases throughout the course o f an experiment and by the 6th stimulation 
train wind-up is significantly greater than in the first stimulation train (P <0.05; n =  
6). (b) Mean wind-up in the ten stimulation train is significantly greater than in the 
first stimulation train (P <0.05; n = 6).
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5.3.2.3 Brush-pinch responses
The FRF of cells tested with electrical stimulation of the face extended over the first 
and second division of the trigeminal nerve in 13/18 cells, over the first division only 
in 2 cells, and in 3 cells included all three divisions of the trigeminal nerve. Responses 
to brush of the FRF varied considerably between cells with a range of 21 to 233 spikes 
per 10 second brush stimulation (range observed from 108 brush stimulations in 18 
experiments). However, there was no significant difference between the response to 
FRF stimulation before the start of the electrical stimulation protocol and that at the 
end of the electrical stimulation protocol for individual cells, even in cells where wind­
up of electrical stimulation was observed {P > 0.05).
5.3.3 MK-801
Electrophysiological recordings were made from 8 cells in the Vc responding to 
electrical stimulation of the MMA with C-fibre latency in eight rats. Mean arterial 
blood pressure (MABP) and heart rate were 102 ± 9 mmHg and 387 ± 6 beats/minute, 
respectively. The mean number of responses to trains of fifty electrical stimulation 
applied to the MMA during baseline measurements was 72 ± 5 (n = 8). Administration 
of MK-801 resulted in significant inhibition of the evoked response that was apparent 
in the first stimulation train after administration of 94 ± 6 % below pre-treatment levels 
(n = 4; P < 0.05). Responses remained inhibited for the remainder of the experiment 
(45 minutes). MK-801 vehicle had no significant effect of MMA-evoked Vc responses 
at any stage during the experiment (n = 4; P > 0.05).
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Figure 42 Effect of MK-801 on MMA-evoked Vc responses
Electrophysiological recordings were made as described in section 2.1-2.2. Data 
represents the mean normalised response of Vc neurons to trains of 50 electrical 
stimulations applied to the MMA. MK-801 (administered at time 0) resulted in 
significant inhibition of the evoked response that was apparent in the first stimulation 
train after administration of 94 ±  6 % below pre-treatment levels (n = 4; P < 0.05). 
MK-801 vehicle (saline) had no significant effect o f MMA-evoked Vc firing.
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5.3.4 Mustard Oil (MO) stimulation
Electrophysiological recordings were made from 11 cells in the Vc responding to 
electrical stimulation of the MMA with A5-fibre latency in 11 rats. All had acceptable 
respiratory parameters for the anaesthetised rat: pCC>2, 35-45 mmHg; pC>2, 90+ mmHg 
and pH, 7.35-7.45. Mean arterial blood pressure (MABP) and heart rate were 115 ± 13 
mmHg and 374 ± 10 beats per minute, respectively. Cells were located in the depth 
range 353-1296 pm below the pial surface. Average response latencies and dural 
stimulus threshold (current and pulse duration) were 13 ± 4 ms, 3 ± 0.5 mA and 0.3 ± 
0.08 ms
In two experiments, MO application to the face, resulted in the loss of neuronal 
activity, hence, only data from six cells treated with MO have been included in the 
analysis. The mean number of responses to trains of fifty electrical stimulation applied 
to the MMA during baseline measurements of cells treated with MO was 69 ± 7 (n = 
6). Following application of 10% MO to an area adjacent to the FRF, all 6 cells 
showed an increased firing rate above baseline. The mean maximum response 
occurred in the second stimulation train, 6 minutes after MO application where the 
mean number of responses to trains of fifty electrical stimulation was 103 + 18 (49 ± 
18% above pre-treatment firing, n = 6; P < 0.05). MO vehicle had no significant effect 
on response to electrical stimulation of the MMA and mean number of responses to 
trains of fifty electrical stimulation during baseline measurements and 10 minutes after 
MO vehicle application were 73 + 4 and 76 + 9 respectively (n = 3; P > 0.05).
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Figure 43 Effect of topical MO application on MMA-evoked Vc responses
Electrophysiological recordings were made as described in section 2.1-2.2. Data 
represents the mean normalised response of Vc neurons to trains of 50 electrical 
stimulations applied to the MMA. MO application (marked by the arrow) resulted in a 
significant facilitation of evoked response (P < 0.05, repeated measure ANOVA) 
compared to vehicle. ( 1  cell was “lost” 6  minutes after application).
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The duration of the significantly increased response following MO treatment was 
variable between cells in a range of six to sixty minutes. Within this range, there was a 
trend for the cells showing the largest increase in firing to have the most prolonged 
effect as shown in the table below.
M a x i m u m  i n c r e a s e  
o v e r  b a s e l i n e  ( % )
D u r a t i o n  
o f  e f f e c t  /  m i n u t e s
1 1 0 6 0
7 9 1 8
6 6 1 8
2 3 13
4 8 6
3 3 6
Table 12 Duration of MO effect
The above table shows the maximum percentage increase over baseline recordings to 
trains of 50 electrical stimulations applied to the MMA following the application of 
MO to an area adjacent to the FRF and the time for which firing was significantly 
elevated over baseline levels for all 6  cells tested with MO.
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Despite the presence of neuronal sensitisation, no cell tested with MO showed wind­
up in any stimulation train throughout the experiment. The mean number of spikes to 
the first and last stimulus in the stimulation train before MO was 1.4 ± 0.4 and 1.4 ± 
0.5 respectively and the mean number of spikes to the first and last stimulus in the 
second stimulation train after MO application was 2.0 ± 0.6 and 2.1 ± 0.5 respectively
(n = 6).
All cells included in this study were classified as wide-dynamic range neurons based 
on their response to mechanical stimulation of the FRF. Two cells showed a FRF that 
was restricted to the first division of the trigeminal nerve, three cells showed a FRF 
that extended over both the first and second division of the trigeminal nerve and in one 
cell the FRF extended over the second and third division of the trigeminal nerve. An 
increase in the estimated size of the FRF determined by mapping with brush stimuli 
was observed in 4/6 cells exposed to MO at the end of the experiment compared to 
initial examination. No increase in the size of the FRF was observed in any of the cells 
tested with vehicle.
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Pictures represent the size of the FRF of Vc neurons, responding to brush stimulation, 
before MO application and at the end o f the experiment.
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MO also caused a significant increase in the response to light brush of the FRF 
compared to pre-treatment responses and vehicle treated animals. Due to the large 
variation in raw data between cells, pre-treatment responses were normalised to a 
value of one and recordings taken thirty and forty-five minutes after either MO or MO 
vehicle application are given as a normalised value in comparison to this. Control data 
represents nine observations at each time point from three experiments and MO data 
represents eighteen observations at each time point from six experiments. Thirty 
minutes after MO application, FRF responses were significantly elevated over those 
from animals treated with MO vehicle with a mean normalised response of 2.64 ± 0.21 
(range; 1.7 - 4.8) and 1.27 ± 0.06 (range; 0.8 - 1.8) respectively in comparison to pre­
treatment responses (P < 0.05). At the 45 minute time point, responses following MO 
were still significantly elevated over those from animals treated with MO vehicle, with 
a mean normalised response of 3.63 ± 0.38 (range; 1.6 - 6.7) and 1.36 ± 0.08 (range; 
0.7 - 1.9) respectively in comparison to pre-treatment responses (P < 0.05).
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Graph shows responses to a 10 second brush, 30 and 45 minutes after MO and vehicle 
application compared to pre-treatment responses, which have been normalised to a 
value of 1. Control data represents 9 observations at each time point from 3 
experiments and Mustard oil data represents 18 observations at each time point from 
6 experiments. Mean normalised response, thirty minutes after MO and MO vehicle 
application was 2.64 ± 0.21 (range; 1.7 - 4.8) and 1.27 ± 0.06 (range; 0.8 - 1.8) 
respectively in comparison to pre-treatment responses (P < 0.05). At the 45 minute 
time point, responses following MO were still significantly elevated over those from 
animals treated with MO vehicle, with a mean normalised response of 3.63 ± 0.38 
(range; 1.6 - 6.7) and 1.36 ±0.08 (range; 0.7 -1.9) respectively in comparison to pre­
treatment responses (P < 0.05).
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5.4 Discussion
These experiments demonstrate that dural stimulation does not produce wind-up of 
second order Vc neurons. However, since this study demonstrates wind-up of neurons 
with facial stimulation, the methods employed are sensitive enough to detect the 
phenomenon. Moreover, this study also demonstrates that the process of wind-up 
following activation of C-fibres during electrical stimulation of the face, leads to a 
persistent increased neuronal hyperexcitability evidenced by the increase in wind-up 
throughout the course of an experiment. As wind-up of C-fibre responses can be 
demonstrated in the Vc following FRF stimulation and have previously been shown 
following tooth pulp stimulation (Hamba et al., 1992), the lack of wind-up in Vc 
neurons to dural stimulation is not a general characteristic of the trigeminal system. 
Rather, it is likely that the differential response following stimulation of dural and 
facial afferents relates to a difference in the processing of visceral and cutaneous 
inputs. This difference may be attributed to different classes of sensory receptors and 
pre-synaptic mechanisms, distinct populations of second order neurons with diverse 
post-synaptic mechanisms or central inhibitory mechanisms.
A major limitation of this study is the absence of recording from a convergent neuron 
responding to electrical stimulation of both the face and dura mater, which would 
allow categorical determination of whether the Vc neuronal population exhibiting 
wind-up in response to facial stimulation is the same population that do not wind-up 
following dural stimulation. However, the neuronal population responding to dural 
stimulation examined in this study also exhibited a mechanical FRF. As mechanical 
stimulation of the face was used to identify neurons for the electrical facial stimulation
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protocol and it was very rare it find a cell responding to mechanical stimulation but 
not electrical facial stimulation, it is likely that the population of Vc neurons extends 
over the same pool. However, an alternating electrical stimulation protocol between 
dural and facial afferents that activated a convergent Vc neuron would lend weight to 
the suggestion that the neuronal population is the same. Additionally, it would be of 
interest to observe whether there was sensitisation of the dural response following a 
wind-up response after facial stimulation.
Wind-up or temporal summation of afferent input is a central not peripheral 
phenomenon. In this study, the majority of neurons receiving a C-fibres input were 
found in the deeper layers of Vc. However, direct connections between nociceptive 
neurons and C-fibres are rarely found here, with the majority of C-fibres terminating 
in the superficial layers (Ambalvanar and Morris, 1992; Brown, 1981; Hunt et al., 
1987) and reaching the deeper layers via intemeurones located in the substantia 
gelatinosa. Hence, amplification of C-fibre input may occur either in the superficial or 
deeper layers and as such the difference between the response to dural and facial 
stimulation may result from differential intemeuron connections.
WDR neurons in the trigeminal nucleus oralis (Vo) have been found to resemble those 
in lamina V of the spinal dorsal horn in their response mechanical, thermal, chemical 
and electrical cutaneous stimuli as well as to non-noxious stimuli (Raboisson et al., 
1995). Activation of C-fibers in the Vo evoked by high intensity stimulation of their 
receptive field have also been shown to exhibit windup during low frequency 
(0.66 Hz) suprathreshold electrical stimulation with a dependence on NMDA receptors 
(Mendell, 1966; Wagman & Price, 1969; Urban & Randic, 1984; Woolf et al., 1988;
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Yoshimura & Jessell, 1989; Thompson et al., 1994; Woda et al., 2004). Features 
common to the Vo and lamina V of the spinal dorsal horn is that cutaneous C-fibers 
terminate in the superficial laminae of the dorsal horn only and do not contact directly 
WDR neurons located either in lamina V of the dorsal horn or in Vo (Light & Perl, 
1979a; Light & Perl, 1979b; Ralston, III & Ralston, 1982; Sugiura et al., 1986; 
Ambalavanar & Morris, 1992). Opioid receptors (Atweh & Kuhar, 1977; Arvidsson 
et al., 1995; Ding et al., 1996) as well as substance P (Sugimoto et al., 1997) are not 
seen in significant amount within these regions. Additionally, morphine has no direct 
effect upon lamina V Vo or dorsal horn WDR neuron activity but can inhibit their 
response to noxious stimuli when injected in the corresponding superficial laminae of 
the dorsal horn (Duggan et al., 1977; Fleetwood-Walker et al., 1988; Dallel et al., 
1998).
This evidence has led to the speculation that intemeurons that transmit the nociceptive 
input from the superficial laminae provide the glutamatergic input to deep dorsal horn 
and Vo WDR nociceptive neurons and windup depends upon NMD A receptor 
activation at the end of the pathway which allows WDR neuron activation by C-fibers 
(Woda et al., 2004). This would be in keeping with results presented in this thesis, 
where a dependence on NMDA receptors of MMA-evoked responses is demonstrated 
by the inhibition of responses following administration of an NMDA antagonist. As no 
wind-up is observed in the Vc following MMA stimulation it would suggest a 
modulation of afferent input before activation of the NMDA receptor.
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Studies examining wind-up in the Vc are sparse but there are reports of wind-up 
following tooth-pulp stimulation (Hamba et al., 1992) and of the FRF (Luccarini et al., 
2001). Interestingly, NMDA intrathecally applied at the level of the medulla was 
found to induce differential effects, either excitatory or inhibitory, on convergent 
(wide dynamic range) neurons of the Vc according to their location in the superficial 
or deeper laminae, with an increase in the evoked activity of superficial neurons and 
decrease in the activity of deeper neurons (Luccarini et al, 2001). This is in contrast to 
the spinal cord where NMDA has generally been reported to have an excitatory effect 
on the nociceptive activity of convergent neurons (Chapman et al., 1994; Sher et al., 
1994; Zhang, 1996,1998), although there is some evidence that an inhibition may also 
be the final result of NMDA receptor activation (Dickenson & Sullivan, 1990; 
Svendsen et al., 1999).
The authors of this study proposed that the inhibitory effect of NMDA on the activity 
of deep neurons is not likely explained by a direct action of the agonist at the level of 
the neurons since the micro-iontophoretic application of NMDA on deep neurons 
always induces excitatory responses (Zhang, 1996). It is possible that the NMDA- 
sensitive superficial neurons act as inhibitory intemeurons on deeper nociceptive 
neurons. Other differences also exist between convergent neurons in the superficial 
and deep laminae of Vc and deep convergent neurons typically exhibited consistent 
wind-up contrary to the mild wind-up of more superficial neurons (Dickenson & 
Sullivan, 1990). As Vc convergent neurons in the superficial laminae of the Vc are 
known to be contacted by enkephalinergic, noradrenergic and serotoninergic inhibitory 
pathways originating from supraspinal centers (Sessle, 2000). It is possible that
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facilitated superficial neurons were part of a local inhibitory circuit, which when 
activated trigger descending influences from a supraspinal loop resulting in neuronal 
inhibition in the deep laminae.
Also of interest in the study examining wind-up following electrical stimulation of the 
face is the time taken to reach the maximum level of wind-up or “plateau phase”, 
which in our study, decreased throughout the course of an experiment. This plateau 
phase can also be observed in dorsal horn neurons and both a supraspinal mediated 
inhibition (Gozariu et al., 1997) and a post-tetanic depression of neuronal firing 
(Woolf, 1983) have been proposed to counteract the increase in response that occurs 
throughout the electrical stimulation train. Interestingly, C-fibre evoked potentials 
recorded in the superficial dorsal horn are reported to continue showing a wind-up 
response through trains of up to 100 stimuli (Schouenborg, 1984). Given the apparent 
difference in modulation between wind-up of dorsal horn neurons and C-fibre evoked 
potential, we cannot rule out the possibility that neurons activated by visceral inputs at 
intensities sufficient to generate wind-up, activate powerful inhibitory pathways 
preventing the manifestation of wind-up. The triggering of inhibitory modulation by 
noxious stimulation is a well established process (Bouhassira et al., 1995; Fields & 
Basbaum 1993), which is demonstrated by loss of the plateau phase normally seen 
during wind-up of dorsal horn neurons following spinalisation (Gozariu et al., 1997). 
Activation of descending inhibitory systems, triggered by spatial summation of 
nociceptive inputs has been shown to be highly dependent on the integrity of areas 
situated in the most caudal part of the medulla in a negative feedback loop that is 
independent of the more rostral brainstem structures (Gall et al., 1998). It is possible 
that activation of dural afferents in a temporal manner may cause activation of a
-227-
similar inhibitory system. The involvement of brainstem structures such as the PAG, 
LC or hypothalamus in modulating wind-up of Vc neurons following tooth pulp 
stimulation has previously been demonstrated by a partial blockade of the response 
after conditioning stimuli applied to the arcuate nucleus of the hypothalamus (Hamba 
et al., 1992). However, their role in modulating the response to stimulation of the dural 
receptive field remains to be investigated but the importance of understanding where 
the deviation in visceral and cutaneous pathways occurs warrants further investigation 
of these inhibitory mechanisms.
This study also demonstrates that the process of wind-up following activation of C- 
fibres during electrical stimulation of the face, leads to increased neuronal 
hyperexcitability evidenced by the increase in wind-up throughout the course of an 
experiment. It is however, interesting that at the end of the electrical stimulation 
protocols, in cells showing wind-up, no enhancement of the response to mechanical 
stimulation of the FRF was seen. This observation is in keeping with current thinking 
that wind-up is able to generate some of the characteristics of central sensitisation but 
is not sufficient to model all of the central changes that might occur following 
peripheral injury (Herrero et al., 2000).
The experimental stimulation of dural afferents, as with many visceral structures, also 
adds a degree of complexity to the interpretation of the data, as surgery is normally 
required for access, hence, tissue sensitisation is likely. Regarding the study of dural 
and cerebral blood vessels and their central terminals, both closed cranial windows, 
where the skull is thinned and open cranial windows, where the bone is removed over 
the area of interest, have been previously used in experimental animal models
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(Cumberbatch et al, 1998, 1999; Burstein et al, 1998; Strassman et al, 1996). In 
preparations where an open cranial window has been used, the reported stimulus 
intensities required to activate both A5 and C-fibres are in the range; 0.8ms, 0.5-4mA 
and 1Hz (Burstein et al, 1998). However, in our preparation with a closed cranial 
window, these parameters would typically only elicit an A5-fibre mediated response, 
with C-fibre activation typically requiring at least double that current amplitude and 
pulse width. This difference in stimulation parameters between the studies may be due 
to dissipation of the stimulus with a closed cranial window but may also indicate a 
greater presence of peripheral sensitisation following a craniotomy. Nevertheless, in 
either preparation, some degree of sensitisation is likely, consequently, we are only 
able to speculate whether dural afferents are normally “silent” and become responsive 
during times of inflammation or whether they fall into a class of nociceptive-specific 
sensory receptors.
The character of Vc neurons following the induction of central sensitisation with MO 
was also explored here. In agreement with data from other studies, MO resulted in a 
sensitisation of evoked Vc neuronal responses (Bartsch & Goadsby, 2002; Hu et al., 
1992). Sensitisation typically lasted between 6 and 18 minutes, however in one cell, 
which also showed the largest response, sensitisation remained for the duration of the 
experiment (60 minutes). Interestingly this cell was found in the superficial layers of 
Vc, where as all other recordings were from the deeper layers of Vc. As MO was 
applied outside the FRF in these experiments, the observed facilitation of both noxious 
electrically and innocuous mechanically evoked responses are likely to be the result of 
central changes reflective of the process of heterosynaptic facilitation, which is further 
supported by the observed expansion of the FRF. Interestingly as with PGE2, the
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sensitisation of mechanical responses following MO application outlasted the 
sensitisation of electrically evoked responses, further emphasising that while a 
peripheral input is necessary to initiate central changes, the maintenance is 
independent of an ongoing peripheral input.
In summary, the manifestation of neuronal wind-up is likely to be a function of 
activation of differing neuronal pathways dependant on primary afferent input. As 
such, some forms of pain serve to cause reflex withdrawal from the nociceptive stimuli 
with ongoing pain and inflammation ensuring the affected area is rested to allow 
recovery from injury, such as may be the case with nociceptive inputs from skin, 
mucosa and teeth. However, migraine head pain seems unlikely to fulfil this type of 
protective role and is more akin to deep visceral pain. Indeed, theories of migraine are 
in good agreement with the pain having a visceral origin, indeed a recognised stimulus 
of visceral pain is ischaemia and it is postulated that pain may originate from the 
accumulation of inflammatory mediators in the ischaemic tissue (Malliani, 1986; Ness 
& Gebhart, 1990). A reduced blood flow in dural and cerebral afferents have long 
been suggested to occur during migraine attacks (Blau, 1978; Caekebeke et al., 1992; 
Diener & Limmroth, 1993; Shevel & Spierings, 2004) and the resultant build up of 
inflammatory mediators may underlie the activation of dural afferents. Indeed, the 
introduction of inflammatory mediators into to the dural receptive field is associated 
with an enhanced response in the Vc to both mechanical and electrical stimulation of 
the dura (Burstein et al, 1998). This study has demonstrated that wind-up of dural 
afferent input is not likely to contribute to central sensitisation in conditions of dural 
activation. Given the extensive data that has been generated on pain pathways 
originating from cutaneous sources in recent years and the relative lack of
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understanding of visceral pain pathways, understanding why wind-up does not occur 
following stimulation of dural afferents compared to facial stimulation may further the 
understanding of how central sensitisation is induced in conditions such as migraine.
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6 General Discussion
The results in this thesis support the hypothesis that a sensitisation of VBNC neurons 
generates an altered neuronal activity that may underlie some of the clinical features of 
migraine such as head pain and facial skin hypersensitivity. Furthermore, these studies 
also demonstrate that this central sensitisation can occur following introduction of 
inflammatory mediators into the peripheral dural receptive field. Hence, a crucial 
question that needs to be addressed is the physiological relevance to understanding 
migraine of the studies described.
W h a t  i s  t h e  p h y s i o l o g i c a l  r e l e v a n c e  o f  t h e s e  m o d e l s  t o  m i g r a i n e ?
One of the first issues that needs to be addressed regarding the studies described here 
is the validity of the models used. The main method used in these studies was in vivo 
electrophysiology. The advantage of this technique is that is allows the study of a 
single cell within the CNS in a physiological setting where the cell is under the 
influence of both supraspinal and local modulatory circuits. However there are also 
distinct disadvantages of this type of in vivo study, such as the effects of anaesthesia, 
as well as various unknown factors, for example the physiological relevance of 
electrical stimulation of the MMA. As discussed earlier electrical stimulation of the 
dura mater is almost certainly nociceptive in character. This is supported by many 
factors, such as the lack of innervation of the dura mater by A-p fibres, the elicitation 
of A-5 and C-fibre response following electrical stimulation. Additionally NMDA 
antagonists potently inhibit MMA evoked Vc activity (see section 5.3.3.) suggesting 
the involvement of the NMDA receptor in Vc evoked firing which is widely accepted
-232-
only to be involved in nociceptive signalling. Hence, how is the modulation of an 
already nociceptive signal by inflammatory mediators related to nociceptive 
processing in migraine headache?
Under physiological conditions, it is likely that the primary afferents innervating the 
dura mater are largely silent. During the pathophysiological processing occurring in 
migraine however a variety of factors could result in the systemic activation of the 
primary afferent fibres. In the first case, abnormal distension of intracranial vessels 
may result in mechanical activation, secondly, dural inflammation may result in the 
release of mediators directly capable of chemical stimulation, and either of these two 
processes may then stimulate the other to occur in a positive feedback cycle. Other 
possible mechanisms of trigeminal activation include activation by the efferent 
terminals of the autonomic nervous system or antidromic activation from the 
ophthalmic division of the trigeminal nerve. While it is not known if any or all of these 
factors actually occur to manifest as the throbbing head pain experienced during 
migraine, electrical stimulation of the MMA, which directly activates the nerve, is 
likely to be representative of the effects of all of the above situations. Hence, until 
more is known about the processes leading to dural activation, there is a good rationale 
for using MMA stimulation in preliminary models of migraine pain.
However there are several caveats of MMA stimulation, the most obvious being the 
visualisation of the vessel by thinning the overlying skull. The mechanical disruption 
occurring to the underlying tissue during drilling is undoubtedly going to generate 
some inflammation even in the hands of the most experienced surgeon. This is 
supported by the intravital microscopy studies, where once visualised through a
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microscope, the MMA was amplified onto a large TV screen and during the 15-20 
minutes after drilling, a significant vessel contraction could be observed. For this 
reason, experimental protocols were never started until at least 60 minutes after the 
completion of drilling. The other issue with electrical stimulation of the MMA for 
model purposes is the trains of stimuli used. The main stimulation parameters in these 
studies involved either trains of 20 stimuli applied every 3 or 50 stimuli applied every 
5 minutes. While this pattern of activation is unlikely to occur physiologically it 
obviously necessary to have defined periods of data collection that are statistically 
meaningful, allowing both comparison of mean response between stimulation trains 
and within stimulation trains. Furthermore, during the characterisation of this model, 
neuronal responses were found to be reproducible for 3 to 4 hours in response to either 
stimulation protocol. Even after this time point, the loss of reproducibility was largely 
due to drift of the electrode, such that neuronal responses fell below the discriminator 
window, rather than an alteration in the number of responses seen to each stimulation 
train. Hence, it is unlikely that electrical stimulation of the dura mater fundamentally 
altered neuronal characteristics of the cell under study; as such, the use of MMA 
stimulation is a good measure of trigeminal nociceptive signalling albeit in an un- 
physiological pattern of activation.
The use of c-fos expression following peripheral activation of A-5 and C-fibres also 
has limitations. Within the VBNC, the full range of receptors able to generate the 
induction of c-fos is not yet known, however several receptor agonist / antagonists can 
attenuate c-fos expression (e.g. NK-1 antagonist, 5-HTiB/id agonists, GABAa 
agonists) but not all of these compounds have anti-migraine like activity (for review 
see Mitsikostas & del Rio, 2001). In addition, c-fos expression represents slow nuclear
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changes, with mRNA alterations thought to be maximal approximately 2 hours after 
the stimulus and alterations in protein expression approximately 4 hours after the 
stimulus, hence it is unlikely to be involved in acute responses to peripheral 
nociceptive signals. The study of VBNC c-fos expression is a useful measure of the 
location of activated cells following trigeminal nociceptive firing but caution should 
be used in interrupting these data. It is possible to speculate that the induction and 
degree of c-fos induced may be an indicator of plastic changes occurring in the VBNC 
over prolonged periods of time. For example, the downstream processing of c-fos 
activation may modulate potential slow transcriptional changes responsible for 
receptor up-regulation, however, these possibilities currently remain unexplored.
A further question regarding the physiological relevance of these data concerns the 
species and strain used. While rats are frequently used to model many diseases 
because of their similar anatomy to the human, their relative ease of breeding, their 
tolerance to long periods of anaesthesia and the wealth of literature available about 
experimental procedures on them, there are also many complicating factors. With 
particular relevance to migraine, the 5-HT receptor pharmacology appears to be 
considerably different from the human and for this reason; much of the experimental 
work supporting development of the triptans was carried out on guinea pig tissue. 
However, in our laboratory, considerable problems were found in anaesthetising 
guinea pigs, hence for studies such as in vivo electrophysiology, which can involve 
periods of anaesthesia from 3 to 10 hours, rats are a reasonable species choice.
Despite awareness and the caution used in interpreting data from different species, 
there is less conclusive data concerning strain differences within species. The majority
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of studies in this thesis and all in vivo electrophysiology experiments used Sprague 
Dawley rats (supplied by Charles River). However a comparison of the effects of a full 
adenosine Ai agonist and partial Ai agonist has also been carried out in the same in 
vivo electrophysiology preparation using both Sprague-Dawley rats and Wistar rats, 
supplied by Bantin and Kingman laboratories (Bolton et al. unpublished data). In these 
studies, the full agonist significantly inhibited MMA evoked neuronal activity in both 
strains of rat, however the partial agonist inhibited MMA evoked neuronal activity in 
the Wistar rats only, with no effect on the evoked activity in Sprague dawley rats. 
While the mechanism of this different effect is only the subject of speculation and 
could either be specifically related to the involvement of the adenosine Ai receptor in 
trigeminal firing or a non specific pharmacokinetic effect, it does highlight 
considerable strain differences exist.
Strain differences have also been described by others for example, Benoliel and 
colleagues showed that following chronic constriction of the infraorbital trigeminal 
nerve, Lewis rats developed considerable hyperalgesia following a secondary insult 
that did not occur in Sprague Dawley rats (Benoliel et al, 2002),. However, following 
nerve ligation in the lumbar region, Sprague Dawley rats and Lewis rats showed very 
similar pain and hyperalgesia responses (Yoon et al., 1999). While current available 
data does not allow generalisation about which particular strain of rat is most suitable 
for a particular model, it does suggest that future work should give the issue more 
consideration before embarking on development of a particular model.
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D o  t h e s e  s t u d i e s  p r o v i d e  e v i d e n c e  f o r  a  p e r i p h e r a l  " g e n e r a t o r "  o f  m i g r a i n e ?
The issue of a peripheral versus a central "migraine generator" is the oldest and still 
the most controversial source of debate among migraine researchers. Many believe 
that certain migraine "triggers" are sufficient to initiate peripheral inflammatory 
processes in susceptible individuals. The consequence of peripheral activation then 
resulting in a sequential time order dependent generation of sensitisation in second and 
third order neurons in the VBNC and brainstem respectively. If this is the case, then 
other questions need to be addressed such as the presence of features that are likely to 
have a central origin, for example, premonitory symptoms, the episodic nature of the 
disease, nausea and sensitivity to light and sound.
It is possible that the symptoms of migraine that are of central origin are reactive 
responses to sequential sensitisation of third order neurons. However while this may 
hold true for features such as nausea, photophobia and phonophobia, it would not 
account for the premonitory phase, which can start up to 48 hours before the headache. 
Hence, if a peripheral sensitisation were the trigger event for a migraine attack, the 
process would also have to start severed days before the headache. This would raise 
some interesting questions, such as how would some of the trigger factors of migraine 
such as certain foods, stress, alteration in daily routine, initiate this process and what 
intracellular processes could account for such a long duration of action in the 
periphery?
The effect of factors such as stress that trigger migraine in susceptible individuals is 
extremely complex and not easily studied as the physiological response varies between
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individuals and is not fully understood. However, considerable efforts have been made 
to understand how and where the effects of substances, such as GTN, that can act as a 
trigger, occur. While the effects of GTN in generating migraine are delayed by 4 or 5 
hours following intravenous infusion, the time scale is not in agreement with a 
peripheral response generated over several days. Furthermore, GTN is likely to have 
widespread effects in both the peripheral and central nervous system, hence even if 
activation of a peripheral mechanism could be observed following GTN infusion, a 
central basis for the effects could not be excluded.
The effects of PGE2 on the response of second order neurons in the VBNC described 
in study 2 of this thesis, provide the greatest evidence that peripheral sensitisation of 
primary afferents innervating the dura mater can generate a neuronal effect that 
correlates well with the clinical features of migraine. However, the induction of 
endogenous PG synthesis is likely to occur only under conditions of inflammation, 
which could equally occur in response to a peripheral or central trigger.
If headache is on a sliding scale such that the underlying pathology of tension type 
headache and migraine is similar but of greater intensity in migraineurs, it is 
conceivable that trigger factors resulting in an activation of intracranial structures 
generate a meningeal inflammation that is also of graded intensity. Alternatively, the 
tendency of certain individuals to suffer recurrent migraineous episodes, may result 
from a greater genetically determined susceptibility of dural afferents to activation. 
However, neither scenario seems likely as they would not explain features such as the 
predominant unilateral localisation of migraine pain compared to the bilateral 
localisation of the head pain in tension type headache sufferers. Hence, while these
-238-
studies support the role of a peripheral inflammation in the development of migraine 
headache, evidence currently available suggests that the effect is secondary to a central 
dysfunction.
D o  t h e s e  s t u d i e s  p r o v i d e  e v i d e n c e  f o r  a  c e n t r a l  " g e n e r a t o r "  o f  m i g r a i n e ?
In support of a central dysfunction as the factor generating susceptibility to 
migraineous episodes is the data from the MO studies. In these studies application of 
the C-fibre activator outside the receptive field of the cell under study resulted in a 
significant facilitation of the response to MMA stimulation. This demonstrates that a 
peripheral sensitisation of cutaneous trigeminal afferents can result in central changes 
that are propagated throughout the VBNC causing a widespread hyperexcitability. 
Hence, it is also likely that excitatory input to the VBNC from other areas may result 
in a similar generalised increase in excitability. While this alone does not a indicate 
that a facilitation of excitatory descending pathways or an inhibition of descending 
inhibitory pathways generates a sensitisation of the VBNC, it does indicate that this 
type of effect would be sufficient to render the VBNC hypersensitive.
A dysfunction of supraspinal controls has previously been discussed in chapter 1 and 
may well result from genetic mutations manifesting as defective calcium channels 
present in structures such as the PAG or hypothalamus. However, it is also possible 
that no distinct "dysfunction" exists and the balance of descending inhibitory and 
excitatory controls is related to a threshold effect that varies between individuals. In 
either case normal activation of trigeminal afferents would be likely to result in a 
similar exaggerated response seen after peripheral sensitisation.
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It should also be remembered that while these studies have focused on abnormal 
activity of the trigeminal system, it is also possible that the pathology of migraine lies 
outside of the trigeminal system. The much greater incidence of migraine in females 
strongly suggests that the target organs of female sex hormones may play a crucial role 
in determining migraine susceptibility. Hence while current research does not 
adequately answer the "central versus peripheral debate", research directed towards 
understanding how only some individuals develop a tendency to suffer recurrent 
attacks may well point to the elusive "migraine generator".
F u t u r e  w o r k
Several areas where considerable improvements could be made to current preclinical 
migraine models are:
> Further characterisation of Vc electrophvsiology: The studies described in this 
thesis provide a preliminary report on the effect of various inflammatory mediators 
on electrophysiological recordings of second-order Vc neurons, however the list is 
by no means exhaustive and the effect of many other transmitters and peptides on 
trigeminal nociceptive activity, remain un-investigated. Of most interest for future 
investigation, is the elucidation of receptor mediated responses to substances that 
are likely to be produced endogenously during inflammation such as the PGs. 
Further value would also be added to these experiments by the sampling and 
analysis of blood neuropeptide content at various time points throughout a 
protocol.
Recently there has been a surge in interest in the role of spinal PGs in generating
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hyperalgesia and allodynia. There are a multitude of studies examining the 
involvement of PGs in centrally mediated responses following both experimental 
induction of peripheral sensitisation and direct application of PGs to the spinal 
cord (see table below for a summary of some of these findings). Experimentally, 
the induction of allodynia seems to be dependant on activation of EPi receptors 
and occurs over a time course of 5-50 minutes after application PGE2. Interestingly 
PGE2 induced allodynia appears to be modulated by glutamate receptor 
antagonists, morphine and NOS inhibitors (Taiwo & Levine 1988).
The characteristics of experimental hyperalgesia induced by intrathecal PGE2 are 
similar to those of allodynia with reliance on glutamate and NO for a functional 
response. However, knock out mouse studies have indicated that the hyperalgesic 
response is likely to be mediated through the EP2 and EP3 receptors (Minami et al., 
2001) rather than the EPi receptor. The EP2 and EP3 receptors have also been 
identified by Kumazawa et al., (1996) as mediating peripheral enhanced responses 
to bradykinin. These observations led to the suggestion that EP2 and EP3 mRNA, 
present in DRG's, may be transported to the periphery following peripheral insult, 
hence mediating both a central and peripheral effect of PGs (Ito et al., 2001). 
Hence it would also be of interest to look at the role of central PGs in trigeminal 
processing.
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In  Vivo E x p e r i m e n t s
L i g a n d T e s t D o s e E f f e c t R e f e r e n c e s
p g e 2
(EP3> e p4>
EP2> EPj>)
Paw pressure 2.5-10ng/rat hyperalgesia 
4 + hours
Ferreira & Lorenzetti, 
1996
Paw stroking 50pg-5pg kg'1 (it) allodynia
5-60minutes
Minami et a l 1996 
Minami et a l , 1994
Hot plate lpg-500ngkg* (it) hyperalgesia
15-60minutes
Nishihara et a l 1995 
Taiwo & Levine 1998
EAA& GABA 
release
2-7pg/rat (it) increase Juma et al., 1993
17-phenyl- 
trinor-PGE2 
(EPi ~EP3)
Vc
electrophysiolog
y
l-10nmol (icv) hypoalgesia Oka et al., 1997
Hot plate 500pg into VHM hypoalgesia Hosoi et a l, 1999
Hot plate 5pg-5ngkg'* (it) hyperalgesia Minami et al., 1994
Butaprost
(EP2)
Hot plate 50ng-5pgkg_1 (it) allodynia Minami et al., 1994
MB28767
(EP3)
Vc
electrophysiolog
y
1-lOOfinol
(icv)
hyperalgesia Oka et al., 1997
GR63799
(EP3)
Tail flick 20-300ng (icv) hyperalgesia and 
fever
Xin et al., 2000
Sulprostone
(EP3>EP,)
Hot plate 50pg-5ugkg‘ (it) allodynia Minami et al., 1994
In  Vitro E x p e r i m e n t s
L i g a n d T e s t C o n c e n t r a t i o n E f f e c t R e f e r e n c e s
p g e 2 Superficial dorsal 
horn neurone
-evoked EPSCs
-mEPSCs
lpM facilitation 10-40 
mins
Minami et al., 1999
DRG TTX-R INa lpM increase Gold et al., 1998
-capsaicin 
induced - 
Im
0.1-lpM increase -  15 
minutes
Lopshire & Nicol 1997
BK-
induced
[Ca2+]ic
lOOnM facilitation Stucky et al., 1996
firing lpM increase Cui& Nicol 1995
CGRP
release
O.I-lpM increase, 2-5 
minutes
Hingtgen et al., 1995
TG spontaneous 
firing
0.1 pM increase Baccaglini & Hogan 1983
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Table 13 Central action o f prostaglandins
Summary o f some o f the experimental findings using prostaglandins and their 
synthetic ligands in pain models. Adapted from Vanegas & Schaible (2001). 
(abbreviations: it- intrathecal; VHM-ventromedial hypothalamus; icv-
Intracerebroventricular injection; EAA-excitatory amino acids; TG-trigeminal 
ganglion; EPSC- excitatory post-synaptic current).
>  Development of recovery animal models: One of the major issues with current 
animal models is the generation of sensitisation per se., following surgery. Chronic 
implantation of stimulating devices or cannula, through which substances could be 
administered, would allow the testing of substances after surgical inflammation 
had subsided. Additionally it would also allow assessment of behavioural effects 
of stimulation which could later be assessed at the single cell level in anaesthetised 
preparations.
> Development of behavioural testing: While we can speculate that neuronal activity 
in the Vc is representative of pain experienced during a migraine, a behavioural 
read out that could be used in parallel with these type of experiments would be 
extremely useful. The features of migraine that could potentially be best utilised 
for behavioural testing are the sensitivity to light and sound. While it may also be 
possible to measure pain thresholds on facial skin in the same way as paw 
withdrawal thresholds are often assessed in neuropathic pain models, this would be 
complicated by the vibrissal innervation as even innocuous activation of a single 
vibrissae results in a withdrawal reflex.
Also of interest would be the use of in vitro techniques to develop migraine models. In 
particular, the use of molecular biological assays such as PCR to investigate the
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phenotypes of trigeminal primary afferents innervating dura mater and cutaneous 
tissue, may provide significant advances in understanding the differential effects of 
cutaneous and visceral stimulation. In vitro electrophysiological recordings would also 
be useful in examining the behaviour of Vc neurons in the absence of descending 
control systems, which to some extent has been assessed by recordings on slices of Vc. 
Further neuronal characterisation could further be obtained by looking at cultured 
neurons, so that local neuronal networks were also disturbed. This was explored in the 
developmental stages of this thesis and while at the time, investigation of the in vivo 
situation was considered more pressing, the generation of in vivo data over the last 
couple of years would now make the comparison with in vitro data extremely 
interesting. Additionally, use of tissue taken from in vivo migraine studies would 
further the understanding of molecular changes responsible for some of the effects 
seen in vivo.
S u m m a r y
The two main theories of migraine headache involve either a dysfunction of the cranial 
vessels and their trigeminal innervation or a central neural generation of symptoms. In 
either situation, sensitisation of VBNC neurons is a possible consequence. The studies 
described in this thesis show that sensitisation of VBNC neurons can be elicited by 
peripheral sensitisation of the dural receptive field and a cutaneous area innervated by 
the trigeminal nerve, that is in keeping with the time scale over which allodynia and 
hyperalgesia develop clinically. Further investigation of how the process of 
sensitisation is initiated is likely to provide breakthroughs in the understanding of 
migraine pathophysiology.
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7 Appendix
7.1 Appendix A-Drugs and dilutions
All doses refer to free base weight.
7,1.1 Anaesthetics
A l p h a - c h l o r a l o s e :  Alpha-Chloralose was obtained from Sigma (Sigma-Aldrich 
company, Dorset, England) (C-8091) and prepared by mixing with an equal weight of 
Borax (Sigma). It was then diluted in saline to a concentration of 80mg/ml
(dose=1.25ml/kg), warmed to 40 °C and stirred continually using a magnetic stirrer.
E u t h a n a l :  Euthanal (sodium pentobarbitone) was obtained from the distributor 
Genusxpress (Lancashire, UK) and manufactured by Merial (UK). It was used at the 
end of experiment for euthanasia and 0.5ml given iv, undiluted from stock (200mg ml"
')
I s o f l u r a n e :  Isoflurane was obtained from the distributor Genusxpress (Lancashire, 
UK) and manufactured by Merial (UK). For the induction of anaesthesia, animals were 
exposed to 5% in oxygen. For maintenance of anaesthesia, 3% in oxygen was used.
S a g i t t a l :  Sagittal (sodium pentobarbitone) was obtained from the distributor 
Genusxpress (Lancashire, UK) and manufactured by Rhone Merieux (UK). After 
discontinuation of isoflurane anaesthesia, 1ml of a 20mgmf1 solution was 
administered iv. Thereafter, a constant infusion of between 10 and SOmgkg^hr' 1 was 
given.
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U r e t h a n e :  Urethane was obtained from. Doses of up to 5gkg_1 ip were given. Due to 
adverse effects, the use of Urethane was governed by a risk assessment.
V e c u r o n i u m  b r o m i d e :  Vecuronium bromide was obtained as Norcuron from Sigma. 
Dilutions were made in saline.
7.1.2 Study 1 test compounds
C a p s a i c i n :  Capsaicin was obtained from Sigma. It was dissolved in 1 0 %  tween 8 0 ,  
1 0 %  ethanol and 8 0 %  saline.
C G R P :  Rat-aCGRP (Bachem, UK) was initially dissolved in distilled water and 
aliquots were frozen, subsequent dilutions were made in 0.9% saline.
G T N ,  i n t r a - a r t e r i a l  s t u d i e s :  Glyceryl trinitrate was obtained from Merck 
Pharmaceuticals as the commercially available product Nitronal and was infused 
undiluted from stock solution (lmgrnf1).
G T N ,  i n t r a - v e n o u s  s t u d i e s :  GTN was obtained as a 1 mg/ml solution in a non-light 
sensitive formulation (Schwarz Pharma Ltd, UK) and diluted in glucose saline.
L P S :  LPS (Lipopolysaccharide from E.coli, serotype 0111 :B4) was obtained from 
Sigma. It was diluted in saline and frozen as a 4mgml' 1 solution. Subsequent dilutions 
(20pg in 50pl) was also made in saline.
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N G F :  NGF (Nerve growth factor) was obtained from Sigma. Dilutions were made in 
saline and administered as 2.5pg in 50pl
S u m a t r i p t a n :  Sumatriptan (SKF-98515-K) was donated by GSK as the hydrogen 
succinate salt and diluted to a dose of 300pg/kg in 0.2ml.
7.1.3 Immunohistochemical reagents 
R a b b i t  s e r u m :  Rabbit serum was obtained from Vector Laboratories (Peterborough, 
UK) and diluted in 98% immunobuffer.
N o r m a l  G o a t  S e r u m :  Normal goat serum was obtained from Vector Laboratories 
(UK). 10% normal goat serum (NGS) was used for incubation and diluted in PBS + 
0.2% triton.
P r i m a r y  fos a n t i b o d y :  Primary fos antibody was obtained from Sigma Genosys. 
(Sheep anti-fos OA-11-824) and reconstituted with distilled water. Dilutions were 
made ini pi rabbit polyclonial antisera, 1ml NGS and 19ml PBS containing 0.2% triton 
to give a 1:20,000 dilution.
S e c o n d a r y  b i o t i n y l a t e d  r a b b i t  a n t i - s h e e p  a n t i b o d y :  Secondary biotinylated rabbit 
anti-sheep antibody was obtained from Vector Laboratories (UK) and diluted in 
immunobuffer. Final dilutions in 20ml PBS, 300pl normal goat serum, 66pi antibody 
to give 1:300 dilution were made before use
T r i z m a  B a s e :  Trizma base was obtained from Sigma. 6.06g trizma base was added to 
950ml distilled water, 4.5 ml of HC1 added and the pH set to 7.4.
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D A B  k i t :  DAB kit ( containing lOOpl buffer, 200jil DAB, 80pl hydrogen peroxide 
and 80pl nickel solution) was obtained from Vector laboratories (UK). 6 drops of 
buffer stock solution, 20 drops of DAB, and 10 drops of peroxide were added to 15ml 
of distilled water.
A B C :  ABC (actin-biotin complex) was obtained from Vector laboratories (UK). 2 
drops of actin and 2 drops of biotin were added to 5ml PBS and left to stand for 30 
mins before use, at room temperature.
P B S :  PBS (Phosphate buffered saline) consisted of 0.01M phosphate buffer, 0.0027M 
KC1, 0.137M NaCl and saline. pH was buffered at 7.4. All components were obtained 
from Sigma
I m m u n o b u f f e r :  Immunobuffer consisted of NaCl (7g), KC1 (0.37g), Na2HPC>4, 
(1.21g), NaH2PC>4 (1.80g), trizma base (1.2g), Thimersal (0.4g) and Triton X-100 
(3ml) in 1 litre of distilled water. pH was between 7.4 and 7.6 (adjusted with 
NaH2PC>4). All component were obtained from Sigma.
7.1.4 Study 2
B u t a p r o s t :  Butaprost was obtained from Sigma. It was dissolved in ethanol to a 
concentration of lOOpg/lOOpl, frozen as aliquots at ~70°C and further diluted in saline 
before use.
E P  a n t a g o n i s t s :  GW627368 and ZM325802, were a kind gift from Ged Giblin, GSK.
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Both compounds were dissolved in 66% PEG 200, 1% DMSO and 33%H20
N a r a t r i p t a n :  Naratriptan was donated by GSK. It was diluted in sterile saline, 
however to ensure adequate solvency, the solution was run under hot water.
PGE2: PGE2 was obtained from Sigma-Aldrich (UK), dissolved in ethanol and saline 
and frozen as 3mM aliquots. Subsequent dilutions were made in 0.9% saline to a final 
concentration of ImM in 1% ethanol and 99% saline.
7,1.5 Study 3
M O :  MO (Mustard Oil or Allyl isothiocyanate) was obtained from Sigma. Because of 
the hazards associated with it, use was dictated by a risk assessment form. For use it 
was diluted to 10% in mineral oil.
D M S O :  DMSO (Dimethyl sulfoxide) was obtained from Sigma.
G l u c o s e  s a l i n e :  Glucose saline (4% glucose by volume) was obtained from 
Aquapharm
M i n e r a l  O i l :  Mineral oil was obtained from Sigma.
PEG200: PEG (Polyethylene glycol) was obtained from Sigma.
S t e r i l e  s a l i n e :  Sterile saline was obtained from Phoenix Pharma Ltd Gloucester, UK
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S t e r i l e  w a t e r :  Sterile water was obtained from Arnolds Vetinary Products Ltd. UK
T w e e n  8 0 :  Tween 80 was obtained from Sigma
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7 .2  A p p e n d i x  B  A n a l y s i s  o f  E l e c t r o p h y s i o l o g i c a l  d a t a
7.2.1 Sequence files
To ensure accuracy and consistency of data collected during in vivo 
electrophysiological recordings, every effort was made to automate stimulus evoked 
recordings. This was done by using sequence files derived with spike 2 software to 
drive the stimulator, an example of a basic programme to drive trains of 50 electrical 
stimuli in cycles of 5 minutes is shown below
7.2.1.1 50 x1Hz
SET 5.00 1 0 This defines the clock rate, in this case 200
ticks =1 second
HALT Holds the running of the programme until it'
manually started via the PC
'y CALL4 start,0
START DAC2 5.0 Drives the 1401 to send a TTL signal to the
DELAY 10 > DAT and switch on recording
DAC2 0.0
DELAY 1000 Delays the programme by 5 seconds
CALL1 es,50 Defines the number of times the programme
cycles before pausing, in this case, 50 times
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ES: DACO 5.0
DACO 0.0
DELAY 200 
DBNZ1 es
DELAY 1000
DAC2 5.0 
DELAY 10 j 
DAC2 0.0
DELAY 50000
DBNZ4 start
’z HALT
Drives the 1401 to send a TTL signal 
to the stimulus isolator to generate 
electrical stimulation defined by the 
Neurolog.
Delay =1 second
Returns the cycle to CALL1 es,50 
and calculates how many cycles are 
left (i.e. 50-1)
Delay=5 seconds
Switchs DAT recording off
Delay=250 seconds 
Returns the programme to start 
Ends the programme
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7.2.2 On line analysis of neuronal responses
During recording of data it was essential to analyse neuronal responses to ensure 
reproducibility. In the first case this was done by the use of script files derived from 
spike 2 software, an example of which is shown below;
7.2.2.1 Script file
var t:=0; start of experiment
var g:=0; Defines which stimulation number within train
data is from
var b%; count (1, s, q)
var a%; count (1, u, 1)
var h%; Defines evoked activity
var p%; Defines spontaneous activity
var z%; Defines total activity
var y%; Defines the number of stimuli left in the train to
analyse after cycling
var w%; spontaneous events in 800ms
var w; Definition of where analysis ends
var 1; Defines the period of analysis after the
stimulation
var x; Definition of number of stimuli in trains
var v; Definition of where analysis starts
var u; Defines the period between stimulation
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and the start of analysis
var q; Defines where the period of pre-stimulus
analysis should end (this was at least 5ms before
the start of the stimulus in all script files)
var y; Definition of analysis period before stimulus
var s; Defines where the period of pre-stimulus
analysis should start
var m; Definition of the factor to average spontaneous
data
View (LogHandleQ). EditSelectAllQ; 1 Controls the output window where
PrintLog ("Train Spont Total Evoked\n\n"); Data titles
y:=Input ("Pre-stimulus duration", 0.05, 0,250); Allows definition of the
duration of analysis before 
the stimulus
v:=Input("Post-stimulus duration, from?", 0.00, 0, 10); Allows definition of
where the analysis starts 
from
w:=Input("Post-stimulus duration, to?", 0.05, 0, 10); Definition of
View (LogHandleQ)- EditClearQ; results are displayed
where analysis
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ends
x:=Input ("Number of stimuli per train?", 50, 1, 100); Defines number of
stimuli in a train
m:= (0.8/y); Defines the nearest real number to enable averaging of
calculated spontaneous events in a 800ms period for 
comparison with defined period of pre-stimulation
repeat
w%:=0;
z%:=0;
for y%:= x to 1 step -1 do
Start cycling between here and 
"next" command
Decreases the stimulus train number by 1 on 
each cycle until 0 then allow the programme to 
move on.
t:= NextTime(32, t); 
l:=t + w; 
u:=t + v; 
s:=t - 0.805;
j
q:=t - 0.005;
Definition of the bins to be counted
a%:-Count(l, u, 1); Counts events on channel 1 after the stimulus
defined by v and w
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b%:=Count(l, s, q); counts events on channel 1 in the 800ms
preceding the stimulus in the defined period of s and q (- 
5ms and -805ms)
w%:=w%+b%;
z%:=z%+a%;
next;
p%:=round (w%/m);
Calculates the corrected number of spontaneous events 
in the 800ms preceding the stimulus 
Calculates the number of events in the defined post­
stimulus time
Calculates the number of spontaneous events in the 
15ms by averaging the events in 800ms calculated above
g:=g+l; Adds data from next stimulation response
h%:=z%-p%; evoked activity = total activity minus spontaneous 
activity
PrintLog("%4d\t%4d\t%4d\t%4d\n", g, p%, z%, h%); formats the data into
columns defined by 
g, p%, z%, h%
until t=MaxTime(32); Moves the analysis programme on to the next
stimulation train
FrontView (LogHandleO); Displays the data in a window at the front of the view
FileSaveAs ("?.txt", 1); Option to save data
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7 .3  A p p e n d i x  C  M a n u f a c t u r e r s  a n d  s u p p l i e r s
All equipment not listed below was kindly made by the engineering department at 
GlaxoSmithKline.
Equipment
Stereotaxic frame 
CED 1401 plus
Rat ventilator
Micromanipulator (model FMC100)
Syringe driver
Headstage
Oscilloscope
Tungsten recording electrodes
Bipolar stimulating electrodes 
Homoeothermic blanket unit 
Neurolog components 
Dental drill 
Spike 2
Video capture card
Video dimension analyser system & 
Notocord data capture system
DAT recorder
Cannula
Supplier
Kopf, USA
Cambridge Electronic Design, 
Cambridge, UK
Harvard apparatus Ltd. Edenbridge, Kent
Newport Corporation, Irvine CA, USA
Harvard apparatus Ltd. Edenbridge, Kent
Digitimer, Herts, UK
Harvard apparatus Ltd. Edenbridge, Kent
World Precision Instruments, Stevenage, 
Herts, UK
Harvard apparatus Ltd. Edenbridge, Kent
Harvard apparatus Ltd. Edenbridge, Kent
Digitimer, Herts, UK
Foredom Electric Co., Bethel, USA
Cambridge Electronic Design, 
Cambridge, UK
Hauppage, U.K.
Living Systems Instrumentation, USA
Bio-logic science instruments, France 
Portex, UK
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Intravital Microscope Moritex Europe Ltd
Table 14 Manufacturers and Suppliers o f equipment used in these studies
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